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ABSTRACT 
 
ALARMING IMMUNITY: A WAKE UP CALL FOR CD8 T CELLS  
USING GENETIC ADJUVANTS 
(IL-33 AND ISG15) 
Daniel Villarreal 
David B Weiner 
 
There exists a paramount need for effective vaccines against cancer, TB, malaria, HIV, 
HCV, and other chronic infections. The hope for long-term control of these important 
diseases ultimately may depend upon development of potent T cell-based therapeutic 
vaccines. However, current, licensed vaccines or capable vaccine platforms have not 
made a substantial impact on treatment of these conditions, likely due in part to poor 
CD8 T cell immune induction. Thus, identification of novel adjuvants to be deployed to 
induce effective T responses is an important area of research in T cell based vaccines. 
While multiple adjuvants have been readily identified which impact CD4 T cells, it has 
been a challenging task to identify adjuvants that can amplify CD8 T cell responses. In 
this regard, Interleukin 33 (IL-33) and Interferon Stimulated Gene 15 (ISG15) have 
emerged as immunomodulatory molecules facilitating the generation of TH1-mediated T 
cell immunity; however, their ability to function as vaccine adjuvants to enhance CD8 T 
cell immunity was not previously explored. Here we used a DNA-vaccination approach to 
investigate the effect of IL-33 and/or ISG15 on vaccine-induced CD8 T cell immune 
responses. My studies showed that both IL-33 and ISG15 served as effective vaccine 
adjuvants to enhance the antigen-specific, polyfunctional, and cytolytic effector CD8 T 
cell responses in vivo. Importantly, I demonstrate for the first time the efficacy of both   
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IL-33 and ISG15 as DNA vaccine adjuvants in driving viral or tumor protective immunity. 
Consideration of our findings, combined with a further understanding of the functional 
roles of these molecular adjuvants in immune expansion, likely will aid in the 
development of therapies for augmenting T cell based responses against many 
infectious diseases and cancers.       
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CHAPTER 1 
 
GENERAL INTRODUCTION  
 
“If I have seen further it is by 
              Standing on the shoulders of giants.” 
—Isaac Newton 
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Vaccination is one of the greatest triumphs of modern medicine. Immunization 
eradicated smallpox in 1976 and has nearly eradicated polio from this world (1,2). In 
addition, the substantial reduction of the number of incidences of measles, mumps, 
diphtheria, and tetanus worldwide are examples of the incontrovertible success of 
vaccines in the prevention and protection against infectious pathogens (2). Many of the 
aforementioned vaccines are based on live attenuated or whole-killed organisms, as 
they mimic a live infection without causing disease. These traditional vaccines 
occasionally have well-known safety issues such as reversion, incomplete inactivation of 
virus and/or transmission of virus to immunocompromised individuals that deem them 
inappropriate for certain populations. Thus, alternative vaccine formulations, such as 
subunit, conjugate, toxoid and DNA vaccines, which contain only target proteins, are 
used to reduce the drawbacks concerning traditional vaccines. However, these 
alternative vaccine approaches are often poorly immunogenic as a result of its limited 
antigenic targets. Therefore, the addition of adjuvants has become a key method for 
enhancing the protective immunity generated by current vaccination.  
 
Adjuvants 
 Adjuvant is derived from the Latin word adjuvare which means to help. It was first 
termed by Ramon Gaston, a French veterinarian, who defined it as a substance that 
enhanced immune responses to an antigen (3). Subsequently, Gleeny and colleagues 
would be the first to report the critical role adjuvants played in the effectiveness of 
vaccines. Gleeny et al. demonstrated the adjuvant activities of aluminum compounds, 
observing a 1,000 fold increase in antibody production when using an alum precipitated 
diphtheria toxoid vaccine (4,5). Since then, aluminum based adjuvants (aluminum 
hydroxide, aluminum phosphate, aluminum sulfate (alum)) have been used successfully 
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in vaccines for over 80 years for promoting the enhancement of antibody responses. 
Today, alum adjuvants can be found in several vaccines, such as Gardasil (HPV), DTaP, 
HBV, Haemophilus influenza B (HIB) and pneumococcal vaccines (Table 1) (6). 
Adjuvants currently licensed to be used in human vaccines in the US and/or Europe 
include aluminum-based salts, oil-in-water emulsions (MF59, AS03) and AS04 
(monophosphoryl lipid A preparation (MPL) with aluminum salt) (Table 1.1). Due to the 
attractive property of adjuvants to promote and modulate vaccine immunogenicity they 
have become an increasingly important ingredient in novel vaccines being developed 
today. 
Adjuvants, in the context of vaccines, are defined as substances that enhance 
and/or shape antigen (Ag)-specific immune responses. For new vaccines in 
development, adjuvants are increasingly used to promote types of immunity not 
effectively generated by the nonadjuvanted antigens. A variety of compounds have been 
examined as adjuvants including mineral salts, emulsions, microparticles, saponins, 
microbial products, liposomes and cytokines (7,8). Based on their proposed mechanism 
of actions, adjuvants can be divided into two classes: delivery systems and 
immunostimulatory adjuvants (7,9). Delivery systems concentrate and present vaccine 
antigens to antigen presenting cells (APCs) and help colocalize antigens and immune 
potentiators to increase specific immune responses (7,10). Immunostimulants, such as 
cytokines or bacterial components, activate immunity directly or through pathogen 
recognition receptors (PRRs), respectively, to increase the immune responses to 
antigens (7). Despite the wide use of adjuvants in vaccines, the underlying mechanisms 
by which they potentiate immune responses are not well characterized. However, 
available evidence suggest that adjuvants induce immune responses by a combination 
of the following mechanisms: (i) activation, maturation and migration of APCs to the 
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draining lymph nodes, (ii) induction of cytokines ad chemokines; (iii) enhancement of 
cellular recruitment of important immune modulating cells at the site of injection; (iv) 
increase antigen uptake and presentation to APC; (v) activation of PRRs and 
inflammasomes (11). Both delivery systems and immune potentiators serve to augment 
vaccine-induced Ag-specific responses in vivo. Clearly, since adjuvants can affect the 
immune responses in different manners, inducing humoral vs cellular immunity, well-
informed and rational selection of adjuvants will contribute to development of effective 
new specific vaccine formulations.  
 
Major Benefits of Adjuvants 
Adjuvants can have a variety of other beneficial advantages besides the 
traditional role of being used to improve the immunogenicity of vaccine immune 
responses (Figure 1.1). First, adjuvants can enable the use of lower vaccines doses, 
greatly expanding the supply when large-scale vaccination is urgent in the case of a 
major pandemic outbreak of infection (12). Second, vaccines can benefit from suitable 
adjuvants by inducing a more rapid immune response and thus reducing the number of 
immunizations to achieve effectiveness (13-15). This approach would be beneficial for (i) 
vaccine delivery in parts of the world where compliance can be an issue and (ii) for the 
development of biodefense vaccines against potential bioterrorism weapons where a 
single-shot vaccine would be critical. A third advantage of adjuvants would be 
broadening the repertoire (breadth and/or specificity) of antibody responses, which could 
be crucial to the success of vaccines targeting pathogens that undergo antigenic drift or 
strain variation (16-18).  Finally, a major role for the inclusion of adjuvants would be to 
aid in the development of new effective therapeutic T cell inducing vaccines. These are 
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practical applications by which adjuvants can be specifically used to improve future 
vaccines for unmet needs.  
 
Importance for T Cell-Based Vaccine Adjuvants 
Although widespread use of vaccines with adjuvants has had an extraordinary 
impact on global health, there remain many infectious and other diseases for which 
vaccines are not available.  The difficult challenge remains in developing adjuvants that 
generate effective CD8+ T cell responses for chronic viral infections and for therapeutic 
treatment of cancers. Historically given that most vaccines confer protection through 
humoral immunity (19), it led to the development of adjuvants focused at inducing and/or 
enhancing antibody responses. As a consequence, a major limitation of the currently 
licensed vaccine adjuvants are ineffective at inducing CD4 T helper 1 (TH1), especially 
CD8 T cell immune responses (20,21), which are required for either controlling or 
preventing the onset of chronic infections and cancer. Therefore, they are not optimal for 
many of the challenges in vaccination today. And given that there are still no effective 
vaccines against Tuberculosis (TB), Malaria, HIV, or for cancer therapy, developing 
adjuvants that can generate potent and durable protective T cell immunity will have a 
profound clinical impact for a variety of diseases. This underscores the critical need to 
develop vaccines with appropriate adjuvants capable of evoking the desired potent and 
durable Ag-specific CD8 T cell immunity.  
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CD8 T cells  
The goal of successful vaccination is the induction of the potent CD8 memory T-
cell populations to rapidly control infection or disease. CD8 T cells are an important 
component of the immune response to infection and cancer (22-25). CD8 T cells (as 
known as cytotoxic T lymphocyte, CTL, cytolytic T cell, Tc, or killer T cells) mediate their 
effector functions through production of cytokine such IFNγ and TNFα and/or secretion 
of perforin or granzyme (23,26). After infection or immunization, Ag-specific CD8 T cells 
respond in 3 distinguishable phases: expansion, contraction and memory (23,27,28). 
When naïve CD8 T cells are primed they undergo clonal expansion when its TCR comes 
in contact with its cognate peptide-bound MHC class I molecule presented by APCs. 
After activation it culminates in a higher frequency of antigen-specific CD8 T cells that 
can enter the blood and migrate to the site infection inducing rapid effector function 
capable of killing infected cells. CD8 T cell activation is also dependent on a second 
signal, which is the engagement of the CD28 molecule on the T cell with the 
costimulatory molecule CD80 and CD86 expressed on APCs. In addition, simultaneous 
external influences, such as the presence of inflammation and cytokines (e.g. IL-2, IL-12, 
IL-7, IL-15) are also essential for T cells to undergo full T cell proliferation and 
differentiation into Ag-specific memory T cells (29-32) (Figure 1.2). After pathogen 
clearance, the Ag-specific CD8 T cells undergo contraction, where the bulk of the 
effecter T cells die. However, a small number of effector cells survive, leading to 
established long-loved CD8 memory T cell subsets, which are the basis for protective 
immunity against infection and diseases (33). Thus, given that CTLs can survive long 
term in the absence of antigen and provide protection against recurrent infections 
(26,34,35), enhancing the quantity and quality of memory CD8 T cells is the ultimate 
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goal for improving the efficacy of most vaccines.   
 
DNA Vaccines 
In recent years, improved DNA vaccines have now reemerged as a promising lead 
candidate for therapeutic intervention due to their ability to potently induce CD8 T cell 
immunity in humans (15,36-38).  
The DNA vaccine platform first came into the spotlight in the early 1990s, when it 
was reported that the delivery of plasmid DNA into the muscle induced an immune 
response against encoded viral antigens (39-41). In 1993, Wang et al. were the first to 
show immune responses against a chronic viral infection (40). Subsequently, Margaret 
Liu et al. (39) and Harriet Robinson et al. (41) both independently reported that injecting 
plasmid DNA encoding influenza A nucleoprotein intramuscularly generated both 
humoral and cellular immune responses against influenza virus antigens in mice. 
Subsequently, David Weiner and colleagues at the University of Pennsylvania would 
show that DNA plasmids carrying HIV antigens engendered the induction of both Ag-
specific antibodies and cytotoxic T lymphocytes (CTLs) (42). These findings introduced 
the potential of DNA as an immunization platform.  
DNA vaccination has been suggested as an ideal therapeutic strategy due to 
numerous advantages over competing platforms. For example, DNA vaccines are non-
live and non-replicating and thus unable to revert into virulent form, unlike live vaccines.  
Furthermore, DNA vaccines are highly customizable and hence, multiple antigens can 
be encoded within a single DNA plasmid.  This allows for a much greater breadth in the 
host immune response and better protection as different epitopes can elicit different 
types of immune responses (43). In addition, individuals receiving DNA vaccines are 
unlikely to harbor anti-plasmid vector immunity, as seen with adenovirus vectors. For this 
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reason, DNA therapeutic vaccinations can be delivered repeatedly without initiating an 
immune response against the DNA plasmid (44,45).  Moreover, DNA vaccines are 
simple and inexpensive to construct, can easily be produced in large quantities, are 
more temperature-stable than conventional vaccines, and can be easily stored and 
transported (45). Finally, DNA encoded antigens can be processed via both MHC class I 
and MHC class II pathways. Thus, DNA vaccines can drive the diverse induction of TH1, 
TH2 and CD8 T cell responses, unlike recombinant protein vaccines that mainly drive TH2 
skewed responses. These advantages may help contribute to the successful delivery 
and administration of therapeutic vaccines to infected individuals in developing nations. 
The success of DNA vaccines in preclinical studies quickly lead to clinical trials, 
and the idea of using DNA to immunize people immediately gained widespread 
recognition. The first DNA vaccine studies in humans were conducted over 15 years 
ago. The goals of the various studies were to evaluate and demonstrate the safety, 
tolerability and immune potency of the DNA vaccines. In the first Phase I clinical trial, a 
DNA vaccine for HIV-1 infection was evaluated for both therapeutic and prophylactic 
applications (46). Soon other DNA vaccine trials would follow, including trials that tested 
DNA-based vaccines against other HIV antigens, HBV, and malaria (47-49). These 
introductory studies established that DNA vaccines were tolerable in humans, and that 
they could enhance T cell proliferation and CTL activity (50,51), although the immune 
responses elicited were weaker than expected based on preclinical data. Although ‘first-
generation’ DNA vaccines failed to demonstrate a robust level of vaccine-specific 
immunity in humans, extensive research continued to develop new modifications and 
improvements to the technology to enhance DNA efficacy.  
To date, a plethora of approaches have been conducted to significantly improve 
the immunogenicity elicited by DNA vaccines, and as a result has sparked great 
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excitement and interest in the DNA platforms to be examined for therapeutic approaches 
and vaccines for unmet needs. These efforts have included optimization of the vaccine 
vectors (e.g. RNA/codon optimization) and antigens encoded by the plasmids (e.g. 
consensus sequences) to enhance antigen expression and cellular/humoral cross-
reactivity (45,52); and in vivo electroporation (EP), a promising delivery method that 
improves the expression and presentation of antigens expressed by DNA vectors (45). 
EP is a simple, direct approach that involves the application of short electrical pulses to 
the vaccine delivery site. This transiently increases cell membrane permeability allowing 
for increased plasmid uptake and increased expression in the target tissue of mice, pigs 
and rhesus macaques (45,53-56).  Although the mechanism for DNA delivery by EP is 
not fully understood,  the procedure has improved plasmid transfection efficacy by a 
factor of 100 fold or greater and as result, has increased immunogenicity of DNA 
vaccines  in both small (mice, guinea pigs, and rabbits) and large animal models (pigs, 
rhesus macaques, and chimpanzees) (56-64). DNA vaccination in combination with EP 
is a novel, safe, and effective strategy that elicits a strong, broad, and long-lasting 
humoral and cellular immune responses. EP is advantageous as a vaccine delivery 
approach because it can broadly activate CD8 cytotoxic T cells (CTL) that eliminate cells 
infected with intracellular pathogens. Thus, EP has been successfully used to enhance 
both cellular and humoral responses in small animal models and humans (55,56,65,66). 
More recently, Bagarazzi M.L., et al. (38), have published exciting data on EP 
administration with a DNA-HPV vaccine that opens many exciting new avenues for this 
combined technology approach to treat or prevent against many human pathogens. 
Bagarazzi and colleagues (38) reported that a therapeutic DNA vaccine co-administered 
with EP on its own in humans could produce long-lived CD8 T cells with cytolytic activity. 
The results also show that DNA delivered by EP is safe and tolerable (38). Finally, the 
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inclusion of molecular cytokine adjuvants to enhance, modulate and skew a desired 
immune response has become a promising way for significantly enhancing the efficacy 
of the DNA vaccine platform. 
 
Cytokines 
The human immune system is constantly in a perennial battle against infectious 
agents that cause disease and often, death. Therefore, to resolve such conflicts the 
immune system has developed countless strategies to effectively vanquish pathogenic 
intruders. One essential tactic is the release of chemical messengers known as 
cytokines. Cytokines are a group of proteins that promote copious biological functions 
that help regulate and generate the immune system (e.g. inducing maturation of APCs, 
differentiation of TH1 and TH2 cells, and inducing NK cells and CTLs) (67). Cytokine 
activity is highly pleiotropic as many cells can produce one to several cytokines therefore 
influencing many phenotypic traits of immune cells (68,69). They facilitate inflammatory 
and proliferative responses, differentiation, and crosstalk between immune cells; cells 
which perform the real-time fight against harmful pathogens that enter the body (68,70). 
Because of their crucial role in triggering the innate and adaptive immune responses for 
fighting off infections, certain cytokines, such as IL-2, TNFα, IL-15 and GM-CSF, have 
been used as vaccine adjuvants to increase memory response against some infectious 
diseases and cancer (68,71,72). Therefore, cytokines are promising vaccine adjuvants 
for boosting the immune responses for the prevention, control, and treatment against 
infectious pathogens and cancers.  
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DNA Co-delivery with Molecular Adjuvants 
One important approach with regard to increasing the potency of DNA based 
vaccines is the ability to manipulate the immune response through co-administration of 
cytokine genes. Genetic molecular adjuvants are normally administered as plasmids 
encoding a specific cytokine, chemokine, or costimulatory molecule. Indeed, the addition 
of immune modulatory adjuvants as part of a vaccine cocktail has been demonstrated to 
boost the adaptive immune response (73). A number of groups have shown that cell-
mediated responses can be modulated both quantitatively and qualitatively through co-
immunization with cytokine-expressing plasmids (Table 1.2). Specifically, it was 
demonstrated that co-immunization with TH1 type cytokines (e.g. IL-12, IL-18) can 
enhance cellular immunity and bias the immune response toward a TH1 type response, 
while TH2-type (e.g. IL-4) cytokines can boost antibodies responses and promote a TH2-
type bias immune response (74,75). In choosing an adjuvant that provides a TH1 or TH2 
biased response, it is important to consider which type of response may be more helpful 
in contributing to protection. For example, Tuberculosis (TB) and Leishmania major 
require a TH1-type response for effective immunity, while other parasitic and microbial 
infections require a TH2-type response (76-78). This ability to modulate or enhance the 
immune response in a defined manner has great promise to improve vaccine design and 
development.  
The exact mechanism by which DNA molecular adjuvants induces an immune 
response is not fully understood. However, it is assumed first that after injection of DNA 
plasmids encoding the antigen of interest and cytokine adjuvant, local APCs, myocytes, 
monocytes or keratinocytes are transfected (45). Once cells are transfected, the plasmid 
encoded antigens and cytokine genes are expressed. In the case of the antigen, it is 
processed, and peptides are presented in the context of Class I or Class II MHC 
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molecules by DCs, affording these cells to stimulate CD4 and CD8 T cells in the 
secondary lymphoid organs (Figure 1.3). Meanwhile, as the antigen presentation by 
DCs is perpetuating an immune response, the transfected cells are subsequently 
producing the selected cytokine to help shape and augment the desired immune 
responses (Figure 1.3).       
The inclusion of different cytokines is actively being studied as a way to induce 
and shape both innate and adaptive immune responses. For example, one of the most 
studied and tested cytokine adjuvants has been IL-12. IL-12 a cytokine produced by DCs 
supports the differentiation of Ag-specific CD4 T cells to produce TH1 cytokines as well 
as prompts the expansion of Ag-specific CD8 T cells to express cytotoxic molecules, 
such as granzyme B, perforin, and IFNγ (79).  Kim J.J. et al. were the first to investigate 
the role of co-delivery of IL-12 with DNA vaccines, observing an increase in specific CTL 
responses when mice where coimmunized with a HIV-1 DNA vaccine plus an IL-12 
plasmid (81). Moreover, IL-28, a cytokine that belongs to the Interferon III/lambda (IFNγ) 
family cytokines has also been shown to play a role in the adaptive immune response 
(82,83). Its inclusion as an immunoadjuvant during small animal and NHP vaccination 
led to augmented Ag-specific TH1-biased responses, as well as an increased cytotoxic 
potential in CD8 T cells (84-86). Finally, granulocyte macrophage colony-stimulating 
factor (GM-CSF), a cytokine secreted white blood cell growth factor has also been used 
a molecular adjuvant and has been shown to enhance both cellular and humoral 
responses in mice and non-human primates (87-90). This indicated that our search for 
improving effective vaccine-induced CD8 T cell responses for diseases where vaccines 
are still needed such as HIV, TB, malaria and even cancer, may lie in the discovery of 
novel molecular cytokine adjuvants.  
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While certain immunoadjuvants have been shown to enhance the potency of TH1 
vaccine-induced responses, it has been a challenge to find adjuvants that can enhance 
polyfunctional CD8 T cell responses. Every year new insights into the biological 
functions of cytokines or cytokine-like molecules are being discovered, with many still 
waiting to be discovered. However, recently, two novel immunomodulatory molecules, 
IL-33 and ISG15, have been demonstrated to drive Th1-type cell-mediated viral and/or 
tumor immunity (91-93). Therefore, this led us to explore the use of Interleukin 33 and 
Interferon stimulating gene 15 as effective vaccine adjuvants to boost a TH1 and CTL 
immune responses, a desired result for effective vaccination against cancer and chronic 
infections.  
 
Interleukin 33 (IL-33) 
Interleukin 33 (IL-33) was first described in 1999 by Onda H and colleagues who 
identified it as DVS27—a 30-kDa protein highly expressed in canine vasospastic 
cerebral cells (94). Six years later, through computational sequence comparison, 
Schmitz and colleagues revealed that the C-terminal end of IL-33 contained a β-sheet 
trefoil-fold structure characteristic of the Interleukin 1 (IL-1) family (95). IL-33 then 
became the 11th identified IL-1 family member. Subsequently, IL-33 was recognized as 
the functional ligand for the orphan IL-1 receptor ST2 (also called IL-1R-like-1) (95). ST2 
is selectively expressed on the cell surface of TH2 cells and not on TH1 cells (95). 
Therefore, IL-33 has been studied primarily for its role in the context of TH2 immunity and 
TH2-related diseases such as asthma, atopic dermatitis, and anaphylaxis (95,97,98). 
However, recent studies are beginning to show that IL-33 cytokine activities far exceed 
the realm of TH2 immunity by promoting TH1 immune responses and influencing the 
development of antiviral CD8 T cells (Figure 1.4) (91).  
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While historically isolated from keratinocytes, epithelial cells, and endothelial 
cells, IL-33 is now known to be released from a variety of tissue types as a pro-
inflammatory cytokine (97-99). Specifically, IL-33 functions as an alarmin by signaling 
tissue damage to local immune cells after exposure to pathogens, tissue damage, or 
death by necrosis (Figure 1.5) (99). IL-33 is predominantly expressed at the epithelial 
barrier as the first line of defense against pathogenic threats. Through its cognate 
receptor ST2, IL-33 activates a variety of cells: hematopoietic cells, mast cells, 
eosinophils, basophils, Natural Killer (NK) cells, Natural Killer T (NKT) cells, CD8 T cells, 
TH2 lymphocytes, and non-hematopoietic cells (99). In addition, IL-33 signaling can be 
negatively regulated by a soluble form of ST2 that lacks transmembrane domain, which 
behaves as a decoy receptor (97,98,103) (Figure 1.5). 
IL-33 exists in two biologically active isoforms: full-length IL-33 (proIL-33) and 
mature IL-33 (mtrIL-33). These two isoforms can operate in at least two spaces—nuclear 
and extracellular (100,101), highlighting IL-33 dual-function cytokine properties. The 
nuclear space is the exclusive domain of proIL-33 and it is able to concentrate there via 
its amino terminus that contains a non-classical nuclear-localization sequence and a 
short chromatin-binding motif (99). This is where IL-33 is usually found; however, when 
released by inflammation or stimulation, proIL-33 is often digested into mtrIL-33, a form 
with a lower molecular weight (18-kDa). Unlike proIL-33, mtrIL-33 is not capable of 
localizing into the nucleus because it lacks the N-terminal nuclear-localization sequence. 
Currently, the nuclear function of proIL-33 is unclear, but recent studies have suggested 
it may play a role in transcriptional repression and chromatin compaction (100,102).  
Extracellular proIL-33 and mtrIL-33, on the other hand, are known to bind to their 
cognate receptor ST2, activating the MyD88-signaling pathway which induces the 
production of various cytokines and chemokines or causes cell differentiation, 
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polarization, and activation, depending on the target cell (Figure 1.5) (103,104). While 
one might assume that they induce similar effects because they bind to the same ST2L, 
Luzina et al. demonstrated that proIL-33 can promote inflammation differently from 
mtrIL-33 in an ST2-independent fashion (Figure 1.5) (105). This study showed that 
compared to proIL-33, mtrIL-33 produced a strong TH2-skewing cytokine profile (105). 
However, the processing and release of IL-33 appears cell-type specific and how proIL-
33 is digested into mtrIL-33 is still a matter of debate (99). 
 
IL-33’s Role in Antiviral and Antibacterial Immunity 
Multiple groups have shown that IL-33 activity is primarily associated in driving 
TH2-immune responses, particularly in augmenting cytokine levels of IL-4, IL-5 and IL-13 
(98). However, it is now beginning to surface that IL-33 has functions that surpass TH2 
immunity as it can contribute to the development of TH1-type immune responses and 
promote CD8+ T cell responses (99). 
Given its ability to direct these TH1-type immune responses, it is reasonable to 
suggest IL-33 may also be essential in inducing protective immunity against viral 
infections. Some of the 1st studies to implicate IL-33’s pro-TH1 cytokine activities 
observed its biological target on NKT cells (106,107). These studies showed that 
exposure to IL-33 privileged the production of IFNγ by NKT cells in response to TCR 
engagement and in the presence of IL-12. More recently, several studies have shown 
that this activity was not restricted to NKT cells. Yang et al. showed that CD8+ T cells 
can also express ST2 and respond to IL-33 (108). They reconfirmed the notion that IL-33 
synergizes with TCR and/or IL-12 signaling to augment IFNγ production in effecter CD8 
T cells (108). Consistent with these findings, Bonilla et al. showed that following LCMV 
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infection in mice, roughly 20% of activated Ag-specific CD8 T cells expressed ST2 (91). 
Subsequently, Sesti-Costa et al, demonstrated in a Coxsackie virus infection model, that 
mice treated with recombinant IL-33 (rIL-33) increased IFNγ and TNFα secretion by CD8 
T cells and NK cells, which correlated with viral clearance of Coxsackie virus (109). 
These studies provide evidence that IL-33 can drive protective antiviral CD8 T cell 
responses in vitro and in vivo. 
 On the hand, studies on IL-33’s protective role against bacterial infections have 
been limited and are only beginning to be appreciated. Li et al showed in a mouse model 
of S. aureus skin infection, delivery of rIL-33 improved antibacterial defense by activation 
of nitric oxide in macrophages (110). Moreover, a recent study by Lee et al. reported a 
positive correlation between IL-33 and IFNγ levels in patients with TB pleurisy (111). 
Clearly, IL-33 likely has protective antibacterial properties, however, more studies are 
needed to understand its role during bacterial infections. Together, these studies give 
insight into IL-33’s new biological activity to direct TH1 and effector CD8 T cells and its 
essential role in driving protective immunity against viral and bacterial pathogens. 
 
IL-33’s Role in Antitumor Immunity 
There is a plethora of studies about the pleiotropic cytokine activities of IL-33 and 
its role in inflammation and its association with allergy and autoimmune diseases 
(97,98). However, its role in antitumor immunity and antitumor growth is only beginning 
to surface. Several recent studies have highlighted the important role of IL-33 in 
experimental mouse tumor models and have shown that IL-33 can drive antitumor CD8 
T cell responses. Gao et al. used B16 melanoma and Lewis lung carcinoma (LLC) 
metastatic models to show that transgenic expression of IL-33 inhibited tumor growth 
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and metastasis in mice (92). Transgenic expression of IL-33 and delivery of recombinant 
IL-33 increased the infiltration of CD8 T cells and NK cells into the tumor and also 
increased their cytotoxicity both in vitro and in vivo (92). This study provides further 
evidence that IL-33 promoted the proliferation and activation of CD8 T cells and NK cells 
by activating the intracellular molecule nuclear factor-κb (NF-κb) and suggests a 
mechanism by which IL-33 might promote CD8 and NK activation and expansion. In 
addition, Gao et. al. recently also reported that tumoral expression of IL-33 can inhibit 
tumor growth and modify the tumor microenvironment by promoting the function of CD8 
T and NK Cells (112). Interestingly, recent reports have reported that increase levels of 
IL-33 in human cancers may have a correlation with better diseases prognosis in HPV 
cervical cancer (113) or associated with hepatocellular carcinoma prolonged patient 
survival (114). Together, these studies demonstrate the notion that IL-33 increases the 
formation of Ag-specific CD8 T cells and reveals that IL-33 has immunotherapeutic 
implications in driving immune responses against cancer.  
 
Interferon Stimulated Gene 15 (ISG15) 
Interferon stimulated gene 15 (ISG15) was identified in 1984 by Ernest Knight Jr 
and colleagues as a 15kDa protein induced by type 1 interferons (IFNs) (115). Three 
years later, Haas and colleagues, showed a resemblance between ISG15 and ubiquitin 
(116). The crystal structure of ISG15 showed its similarity to ubiquitin by revealing that 
ISG15 consisted of two ubiquitin-like domains, located at its N-terminal and C-terminal 
ends of the protein (117). ISG15 is synthesized as a 17kDa precursor that is cleaved at 
its C-terminal domain to yield the mature form of ISG15 (118). Unlike ubiquitin which is 
highly conserved, ISG15 varies between species (119). However, similar to ubiquitin, the 
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mature form contains the ubiquitin-like C-terminal LRLRGG motif that is essential for 
covalently attaching itself to the lysine residues of target proteins by an E1-E2-E3 
enzyme process called ISGylation (Figure 1.6) (117). This enzymatic cascade that is 
similar to, yet distinct from that of ubiquitin conjugation has been studied in great detail 
and has been reviewed elsewhere (93,119-121). Several proteomic strategies have 
been conducted to catalogue ISGylated proteins, identifying more than 300 candidates 
(122). However, how ISGylation affects their cellular distribution and function remains to 
be elucidated (123). ISG15 is one of the most highly induced transcripts after type 1 
IFNs stimulation or other stimuli, such as exposure to viral infections, 
lipopolysaccharides, and TNFα stimulation (93). These types of stimuli activate 
transcription factors in IFNs signaling, mainly IRF3 and ISGF3 (119-123), which in turn 
upregulate expression of ISG15 (Figure 1.6). For instance, in Type I IFN receptor R1 
knockout mice, ISG15 production significantly decreases upon treatment with Gram-
negative bacteria lipopolysaccharide (LPS) or viral infections (93), suggesting that 
induction of Type I IFN secretion triggers ISG15 expression. Therefore, ISG15 is 
essential for the control of certain viral and bacterial infections.  
 
Antiviral and Antibacterial Activity of ISG15 
Frist, given that IFNs play an important role during viral infections, and second, 
that ISG15 and its ISGylation are strongly induced by Type 1 IFNs, many studies have 
explored their contribution to antiviral activities (93,125). Briefly, several in vitro 
challenges have shown that ISG15 can regulate viral growth or titers of Dengue, West 
Nile, HIV, Ebola, Japanese encephalitis and Influenza A virus (93). For instance, the 
delivery of small interfering RNA knockdown of ISG15 in wild-type murine cells or human 
airway epithelia cells were found to increase the titers of dengue virus and influenza A 
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viral titers, respectively (93). Moreover, increase lethality has been observed in ISG15-/- 
mice after infection with Influenza A and B viruses, herpes simplex virus type 1, Sindbis 
virus and Chikungunya (93). ISGylation does not usually cause substrate degradation 
like ubiquitin (119,123), but can function to regulate protein levels, signaling pathways, 
vesicular trafficking, and numerous other undefined regulative roles (119). While, it is 
known that ISG15 conjugates to hundreds of target proteins, how ISG15 conjugation 
mediates a broad range of protection still remains to be fully elucidated (93,126). 
Although a number of studies have shown ISG15 antiviral protective properties, no 
studies have evaluated ISG15’s biological role during bacterial infection or its protection 
in vivo. ISG15 mediated protection against bacterial infection is largely unknown and 
future studies are warranted.  
 
Antitumor Activity of ISG15 
ISG15 has also been implicated in host defense pathways that serve antitumor 
functions. To initiate the process of ISG15 conjugation (ISGylation), ISG15 must first 
utilize the E1 enzyme (UBE1L) (Figure 1.6) (93). Without this enzyme ISGylaton of 
specific target proteins cannot occur. UBE1L has been demonstrated not to be detected 
in all human lung cancer cells lines (122-124), implicating a tumor-suppressive role of 
ISGylation and suggesting the potential role of ISG15 in facilitating tumor control or 
immunity. Human leukemia cells have also been found to lack functional E1 enzymes 
and inducing ectopic expression of UBE1L restore ISGylation and enhanced IFN 
signaling (127). Moreover, ISG15 has also been reported to be induced during cancer 
chemotherapies, as studies have shown that ISG15 was upregulated following 
camptothecin treatment of colorectal and breast cancer cells (122-124). Collectively, 
these studies potentially demonstrate that reduced ISGylation may be linked to a 
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malignant phenotype, and enhanced ISGylation correlated with the therapeutic response 
to anticancer signals. In contrast, a few studies have also demonstrated that 
overexpression of ISG15 or ISGylation positively correlated with tumorgenesis (122-
124). This relationship is complex and a universal consensus on the relationships 
between ISG15 and tumor development is still missing. A similar yin and yang role in 
human cancers have also been reported for other cytokine mediators such as IL-2 and 
HGMB1 (128,129). A better understanding of the potential function of ISG15 in tumor 
immunity or in the tumor microenvironment requires future studies. Nevertheless, given 
ISG15’s ability to be induced by a diverse stress of stimuli, suggests that it may serve 
broader functions beyond the innate immune response. 
 
Free ISG15 Modulates Immune Responses 
In addition to its conjugated form, ISG15 can also exist in a free unconjugated 
form both intracellularly and extracellularly (Figure 1.6). Both forms of free ISG15 could 
influence cellular functions. For instance, intracellular free ISG15 has been shown to 
control the ability of Ebola VLPs to egress from cells in vitro (93,130). Over expression of 
ISG15, independent of the conjugation cascade, consequently decrease Ebola VP40 
VLP release (93,130). More interestingly, the secreted ISG15 form can act as cytokine 
and modulate the immune responses (125). ISG15 is synthesized in many cells and has 
been shown to be secreted by monocytes, lymphocytes and neutrophils in vitro (126). 
The underlying mechanism of how ISG15 is secreted from the cell remains unknown.  
The secretion of free ISG15 was first described in the early 90s by Ernest Knight Jr and 
Beverly Cordova demonstrating secretion of ISG15 from human lymphocytes and 
monocytes (131). Subsequently, Ernest Knight Jr and colleagues would report on its 
function to induce secretion of IFNγ from peripheral blood mononuclear cells (PBMCs) 
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(132). Five years later, in 1996, Ernest C. Borden and colleagues would confirm the 
immunoregulatory properties of ISG15 to induce IFNγ production from PBMCs (133). 
Although given these exciting results of ISG15 cytokine-like properties, no further studies 
on free ISG15 would be made for almost two decades. In 2012, Casanova and 
colleagues would reconfirm the cytokine-like role for ISG15 by demonstrating that 
ISG15-deficiency was associated with a loss of IFNγ, which in turn led to increased 
susceptibility to mycobacterial disease in both mice and humans (134). They 
reestablished that ISG15 can induce IFNγ production in PBMCs and also demonstrated 
that NK cells upregulate IFNγ production in respond to recombinant ISG15. These 
collected studies support the ability of free ISG15 to function as an immunomodulatory 
molecule to regulate IFNγ production and that ISG15 contributes to host protection 
against infectious disease through both conjugation-dependent and –independent 
modes of action. Therefore, given that ISG15 has been implicated in the regulation of 
IFNγ and NK cells, both which are important mediators of viral and tumor immunity, it is 
conceivable that ISG15 could be used as a vaccine adjuvant to help fight pathogenic 
infections or even cancer. The mechanism by which all three forms of ISG15 exert 
antiviral or antitumor effects is an important area of research that remains poorly 
understood.  
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Goals of this Thesis 
CD8 T cells play a crucial role in mediating protection against cancers and to a 
variety of chronic infections, including HIV, tuberculosis (TB) and malaria. An overall 
shortcoming of currently licensed vaccines, especially non-live vaccines, is their inability 
to generate effective CD8 T cell responses. One way to improve the quantity and quality 
of immune responses during vaccination is to incorporate adjuvants, which have been 
shown to help increase their immune potency. However, it has been a challenge to 
discover adjuvants that can amplify the induction of CD8 T cell responses. This 
highlights the need to develop new vaccine adjuvants capable of inducing potent and 
durable CD8 T cell immunity in human-kind.  
Different vaccine platforms have been studied, but the development of DNA-
based vaccines in conjunction with immunomodulatory ‘cytokine’ adjuvants has emerged 
as particularly promising for inducing Ag-specific CD8 T cell-mediated immune 
responses (15). Recently, two immunomodulatory molecules have been demonstrated to 
play a role in inducing TH1-type cell-mediated immunity: cytokine IL-33 and cytokine-like 
molecule ISG15 (91-93). Therefore, in this thesis, I tested the hypothesis that both IL-33 
and ISG15 delivered as molecular adjuvants can increase the CD8 T cell potency of 
DNA vaccines. Specifically, I proposed that IL-33 and ISG15 can act as vaccine 
adjuvants to enhance the CD8 T cell immunity against intracellular chronic pathogens 
and tumors. I used different disease models to study the efficacy of IL-33 and ISG15 as 
DNA vaccine adjuvants. Additionally, this thesis aims to give further insight into the 
biological function of IL-33 and ISG15 to modulate the cell-mediated immune responses. 
Overall, I believe that identifying new molecular adjuvants that elicit effective vaccine-
induced CD8 T cell immunity may be critical for the elimination of many challenging 
diseases including TB, HIV, malaria and cancers.  
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Table 1.1. Licensed adjuvants in humans 
Ab, antibodies; MPL, monophosphoryl lipid A; Th1, CD4 T helper 1; Th2, CD4 T helper 2 
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Figure 1.1. Major benefits of adjuvants. These are all factors by which idea adjuvants 
can be used to improve future vaccines against many challenging diseases where no 
effective vaccines still exist.  
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Figure 1.2. CD8 T cell priming and activation. When innate cells interact with 
pathogen-associated molecular patterns (PAMPs), damage-associated molecular 
patterns (DAMPs) or some inducible signal, the immune system is initiated (Signal 0). 
Dendritic cells uptake protein antigen, process it into smaller peptide fragments and load 
them onto MHC Class I or II molecules. These mature DCs with highly upregulated 
costimulatory molecules due signal 0, then migrate to the draining lymph nodes where 
their MHC-peptide complex can be recognized by the T cells expressing the matching 
cognate T cell receptor (TCR) (Signal 1). For proper activation of CD8 T cells they 
require a second signal, provided by binding to costimulatory molecules CD80 and CD86 
on APC by CD28 (Signal 2). As a result, CD8 T cells secrete effector cytokines and 
cytotoxins, which can directly kill pathogen infected cells or tumor cells. In addition, 
proinflammatory and cytokines are also essential for proper activation, differentiation and 
expansion of memory CD8 T cell subsets or can further amplify costimulatory molecules 
(Signal 3).      
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Figure 1.3. Proposed mechanism of DNA vaccination with molecular adjuvants. (1) Vaccine 
formulation containing two separate DNA plasmids, one that contains the antigen target and the other that 
contains the immune adjuvant gene, is administered in the muscle followed with electroporation. After 
immunization, myocytes (2a), resident antigen presenting cells (APCs) (2b), and other cells (e.g. 
keratinocytes, monocytes) (2c), are transfected with the plasmids, leading to protein and cytokine 
production. The protein processed and/or released by transfected cells are presented in the context of MHC 
class II (3a) or MHC class I (2b) molecules which stimulate CD4 and CD8 T cells, respectively. Peptides can 
also be presented on MHC class I by cross-presentation due to APCs engulfing apoptotic or necrotic bodies 
(4). Meanwhile, the transfected cells are simultaneously secreting the gene (e.g. cytokines or chemokines) 
adjuvant which in turn facilitates the recruitment of many various immune cells to the site. All these events 
lead more effective maturation and activation of immune cells. Mature antigen-loaded APCs then migrate to 
the draining lymph nodes (5) to interact with antigen-specific B and T cells (6) to activate both B (antibody 
secreting) and T cell (effector CD8) responses (7). These activated lymphocytes can now migrate to the 
inflammatory sites to provide protection against infectious diseases (8). At the infection site these activated 
lymphocytes could be restimulated and further expanded at the site of immunization by transfected cells 
(2c). In addition, the secretion of the selected adjuvant by transfected cell at site can lead to further 
enhancement of immunological parameters, perpetuating proper expansion and differentiation of memory T 
cells, thus leading to the proper establishment of immunological memory. Therefore, upon reinfection the 
established surveillance memory system could rapidly and effectively respond.    
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Figure 1.4. Interleukin 33 effects on innate and adaptive immune cells. Interleukin 
33 (IL-33) can be secreted by neutrophils, macrophages, DCs, fibroblasts, but it is 
mainly secreted by epithelial and endothelial cells and is released in response to 
external stimuli or passively secreted due to tissue damage or cell neurosis. IL-33 has 
pleiotropic activities that act on a variety of innate and adaptive immune cells. The key 
effects they have on some of these cell types are indicated. DC, dendritic cell; IFNγ, 
interferon-gamma; NKT, natural killer T; TH2, T helper 2; TH1, T helper 1 
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Figure 1.5. The basic biology of interleukin 33. In its normal state interleukin 33 (IL-
33) resides in the nucleus of cells. Tissue damage or some inducible signal leads to the 
release of IL-33 from cells such as fibroblasts, epithelial cells, endothelial cells, and 
smooth muscle cells. IL-33 can be released or secreted as two biological active forms: 
full-length IL-33 (proIL-33) and/or as processed proIL-33 into mature IL-33 (mtrIL-33). As 
a cytokine-alarmin, IL-33 signals through a heterodimer complex which consists of ST2 
and IL-1 receptor accessory protein (IL-1RAcP). The binding of IL-33 to its cognate 
receptor results in recruitment of MyD88 and TRAF6, which then leads to the activation 
of the transcription factor nuclear factor-kB (NK-kB) and mitogen-activated protein 
kinase (MAPK) pathways. This signaling perpetuates an immune response, inducing 
gene expression which leads to cytokine and chemokine synthesis. Through a poorly 
defined mechanism proIL-33 can induce immune responses independent of its ST2 
receptor. In addition, ProIL-33 not only acts as a secreted cytokine, but can also act as a 
nuclear binding factor. ProIL-33, which contains a nuclear localization and chromatin 
binding motif at its N-terminus, can migrate into the nucleus, and bind to acidic residues 
of dimeric histones (H2A-H2B). However, proIL-33’s role in the nucleus is still not fully 
understood. Moreover, soluble ST2 can act as a decoy receptor to negatively regulate 
IL-33 signaling.   
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Figure 1.6. The ISGylation machinery and schematic roles of ISG15. ISG15 is 
strongly induced by type I interferons (IFNs), which initiates several initial signaling 
pathways to induce expression of ISG15. The first step, ISG15 is activated by UBE1L 
enzyme (E1) in an ATP-dependent manner. ISG15 is then transferred to UbcH8 (E2) 
and subsequently conjugates to target substrate proteins through the aid of E3 ligases 
(HERC5, EFP, HHAR1).  The isopeptidase USP18 (deconjugating enzyme) reverses the 
coupling by removing ISG15 from target proteins. The ISGylation pathway can therefore 
be recycled. However, ISG15 can also exist as free intracellular ISG15 or as secreted 
extracellular free ISG15. The biological role of free intracellular ISG15 remains unknown. 
Secreted free ISG15 is known to have immunomodulatory properties, however, how it is 
secreted or how cells may respond to ISG15 (may bind to unknown receptors) remains 
to be determined. IFN, interferon; ISG, IFN-stimulated gene. Figure was adapted from 
Joen YJ, et al 2010. 
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CHAPTER 2 
 
ALARMIN INTERLEUKIN 33 ACTS AS A VACCINE ADJUVANT INDUCING POTENT 
ANTIGEN-SPECIFIC TUMOR IMMUNITY 
 
This section was adapted from a published journal article 
 
Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. 
Cancer Res. 2014. Mar;74(6):1789-800. 
 
 
“Two roads diverged in a wood, and I— 
I took the one less traveled by, 
And that has made all the difference” 
-Robert Frost 
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ABSTRACT 
Interleukin 33 (IL-33) has emerged as a cytokine that can exhibit pleiotropic properties. 
Here we examine IL-33 for its immunoadjuvant effects in an HPV-associated cancer 
immune therapy model in which cell-mediated immunity is critical for protection. It is 
known that two biologically active forms of IL-33 exist: full-length IL-33 and mature IL-33. 
The potential ability of both isoforms to influence the adaptive immune responses and 
act as a vaccine adjuvant has not been well defined. We show that both isoforms of IL-
33 are capable of enhancing potent antigen specific effector and memory T cell immunity 
in vivo in a DNA vaccine setting. We also show that while both forms of IL-33 drove 
robust IFNγ responses, neither form drove high secretion of IL-4 or any elevation of IgE 
levels. Further, both isoforms augmented vaccine-induced polyfunctional CD4 and CD8 
T cell responses, with a large proportion of CD8 T cells undergoing cytolytic 
plurifunctional degranulation. Therapeutic studies indicated that vaccination either IL-33 
isoform in conjunction with an HPV DNA vaccine caused rapid and complete regression 
of established tumors in vivo. Moreover, we show that IL-33 can significantly expand the 
magnitude of antigen-specific CD8 T cell responses and elicit effector-memory CD8 T 
cells. Overall, our results support the development of these two IL-33 isoforms as 
immunoadjuvant candidates in future vaccination against pathogens and in the context 
of anti-tumor immune-based therapy. 
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INTRODUCTION 
Adjuvants are critical components of most clinical vaccines and are used to 
enhance adaptive immune responses to antigen (1). Adjuvants can help shape the 
quantity and quality of immune responses (1). However, currently available FDA-
licensed adjuvants are poor inducers of CD4+ T helper 1 (TH1) and even worse at 
treating CD8 T cell responses (2,3). It is important to identify a new generation of potent 
vaccine adjuvant(s) that can drive and specifically direct these desired responses. Thus, 
the inclusion of different molecular adjuvants, such as cytokines, is actively being 
studied as a way to increase the efficacy of vaccines. Different vaccine platforms have 
been studied, but the development of DNA-based vaccines in conjunction with cytokine 
adjuvants, has emerged as a particularly promising for inducing anti-viral and anti-tumor 
cell-mediated immune responses (4,5). Indeed, the potency of DNA-based vaccines co-
administered with molecular cytokine adjuvants as part of a vaccine cocktail has been 
demonstrated to boost the adaptive immune response (5). Recently IL-12 as a vaccine 
molecular adjuvant has been shown to augment the T cell immunity induced by a DNA 
vaccine in humans (4). IL-12 was particularly effective in expanding CD4 and CD8 
immunity but less effective, in driving strong B cell immunity.  Building on this important 
recent success is an area of great importance. We therefore employed a DNA 
vaccination approach to investigate the inclusion of Interleukin 33 (IL-33) to further 
enhance, both arms of the adaptive immune responses.  
IL-33 is a member of the IL-1 family of cytokines that is constitutively expressed 
in the nucleus of epithelial and endothelial cells (6,7). IL-33 is classified as an alarmin-
like molecule, whose release during cell injury signals tissue damage to local immune 
cells (7). Alarmin IL-33 has been shown to have pleiotropic cytokine activities such as 
mediating diverse pro-inflammatory responses (9,10), activation and recruitment of 
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antigen-presenting cells (11), enhancing adaptive immunity (12,13), and wound healing 
(14). To date, IL-33 has been studied primarily in the context of T helper type 2 (TH2) 
immune responses associated with modulating inflammatory disorders such as asthma 
and atopic dermatitis (6,15,16-18). More recently though, IL-33 has been reported to 
activate CD8 T cells and influence the development of protective anti-viral CD8 T cells 
against infections in mice (12). However, the role of IL-33 in the induction of vaccine-
induced, antigen-specific TH1 and CD8 T cell immunity remains to be determined. Two 
different biologically active forms of IL-33 exist: full-length IL-33 (proIL-33) and mature 
IL-33 (mtrIL-33) (18). ProIL-33 is thought to be the most biologically active form 
promoting inflammation, while the function of mtrIL-33 in modulating immune responses 
remains more elusive (7,15,18). Therefore, we investigated whether the two isoforms of 
IL-33 (proIL-33 and mtrIL-33) can function as vaccine adjuvants to augment adaptive 
immune responses (both TH1 and CD8 T cell responses) and induce anti-tumor immunity 
using a murine model for HPV-associated cancer.  
In this study, we demonstrate that IL-33 can act as a potent cell-mediated 
adjuvant using the DNA vaccine platform. Its adjuvant activity skews towards the TH1 
axis, and not to the TH2 axis. We show that IL-33 can be effective as an adjuvant in 
either form – its uncleaved “pro” form or its “mature” state, a shorter form that results 
from cleavage by cellular enzymes (10,17,19). Both IL-33 isoforms when combined with 
an HPV16 E6/E7-encoded DNA vaccine enhance the adaptive effector and memory 
immune responses, but pro IL-33 was more potent at also expanding the humoral 
immune response. We show that both immunoadjuvant IL-33 isoforms induce potent 
anti-tumor immunity and regression of established TC-1 tumor-bearing mice. Using the 
P14 LCMV DbGP33 transgenic mouse model, we show that immunoadjuvant IL-33 can 
significantly expand the magnitude of Ag-specific CD8 T cell responses and elicit potent 
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effector-memory CD8 T cells.  Our findings reveal that IL-33 can be an effective adjuvant 
to drive CD4 immunity, humoral immunity and to generate effective CD8 mediated 
protective immunity against cancer and potentially have application in treatment of 
chronic viral infections. 
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METHODS 
Plasmid Construction 
The GenBank sequence NM_001164724.1 (accession no: Q8BVZ5.1) for mouse IL-33 
was used to synthesize full-length (proIL-33) and mature IL-33 (mtrIL-33) (aa 109-266) 
plasmid DNA constructs.  Each construct had highly efficient immunoglobulin E (IgE) 
leader sequence inserted at the 5’end of the gene. The constructs were commercially 
synthesized and optimized as described previously (20). Plasmid expressing HPV 16 
ConE6E7 was prepared as previously described (21). The GP33 construct was provided 
by Dr. Rafi Ahmed of Emory University, Atlanta GA, USA and used as described (22). 
 
Transfection and Expression of Plasmids 
ProIL-33 and mtrIL-33 construct expression was confirmed by Western Blot and 
Immunofluorescence microscopy in Human Rhabdomyosarcoma (RD) cells. RD cells 
were cultured in 6-well plates and transfected with the constructs (pVAX as control) 
using LipofectamineTM2000 (Invitrogen) following the manufacturer’s protocol. Forty-
eight hours later cells were lysed using modified RIPA cell lysis buffer and cell lysate 
was collected. Western blot analysis was performed with an anti-IL33 monoclonal 
antibody (R&D systems) and visualized with horseradish peroxidase (HRP)-conjugated 
anti-rat IgG (Cell Signaling) using an ECL western blot analysis systems (GE 
Amersham). In addition, supernatants were also collected at 48 hours after transfection 
and cytokine secretion was examined by mouse/rat IL-33 Quantikine ELISA kit (R&D 
Systems) according to manufacturer’s protocol. An indirect immunofluorescence 
microscopy assay was also utilized to confirm expression of both IL-33 isoforms. Briefly, 
RD cells were plated on two-well chamber slides (BD Biosciences) and grown to 70% 
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confluence overnight in a 37 incubator with 5% CO2. The cells were transfected with 1ug 
of IL-33 constructs and the control plasmid pVAX (1 ug/well) using TurboFectinTM8.0 
Transfection Reagent (OriGene) according to the manufacturer’s instructions. Forty-eight 
hours later the cells were fixed on slides using ice cold methanol for 10 min. The cells 
were stained with anti-IL-33 mouse monoclonal antibody (R&D Systems, Minneapolis, 
MN) and subsequently incubated with Alexa 555-conjugated anti-rat secondary antibody 
(Cell Signaling). Slides were mounted using Fluoromount G with Dapi (Southern 
Biotechnology). Images were analyzed by florescence microscopy (Leica DM4000B, 
Leica Microsystems Inc, USA) and quantification was conducted using SPOT Advanced 
software program (SPOTTM Diagnostic Instruments, Inc).  
 
Animals 
Female 8-week-old C57BL/6 mice were purchased from Jackson Laboratory (Bar 
Harbor, ME, USA). The P14 mice bearing the DbGP33-specific T-cell receptor were a 
kind gift from Dr. John Wherry of the University of Pennsylvania. To generate the “P14 
chimera” mice, 1.6x105 naïve T-cell receptor transgenic T cells were adoptively 
transferred into naïve B6 mice. All animals were conducted and maintained in 
accordance with the National Institutes of Health and the University of Pennsylvania 
IACUC guidelines.  
 
Immunization/EP of mice  
Mice were immunized three times at three-week intervals in the tibialis anterior muscle. 
In vivo Electroporation (EP) was delivered, with the CELLECTRA adaptive constant 
current EP device (Inovio Pharmaceuticals, Blue Bell, PA), at the same site immediately 
46 
 
following vaccination as described (20). The mice (n=4-5) were immunized with either 
5µg pVAX1 or 5µg ConE6E7 alone or with various amounts of proIL-33 and mtrIL-33 
constructs, depending on the experiment. The GP33 construct was administered at 5µg. 
All studies were repeated twice.  
 
ELISpot assays  
Spleens were harvested 8 days following the final immunization as previously described 
(20). After spleens were harvested and processed both IFNγ and IL-4 ELISpot assays 
were performed to determine antigen-specific cytokine secretion from immunized mice 
as described previously (20,21,22). A set of peptides (15 amino acid residues 
overlapping by 8 amino acids) representing the entire consensus E6/E7 fusion protein 
sequence of HPV16 was synthesized from GenScript. This set of peptides was 
combined into two pools, spanning the length of the E6 and E7 antigens as previously 
described (21). Concavalin A (Sigma-Aldrich, St. Louis, MO) at 5µg/ml was used as 
positive control and complete culture medium was used as negative control. Spots were 
enumerated using an automated ELISPOT reader (Cellular Technology, Shaker Heights, 
OH). 
 
Flow Cytometry 
Lymphocytes were isolated and processed from the spleen and peripheral blood as 
previously described (20, 23, 24). Splenocytes were added to a 96-well plate 
(1x106/well) and were stimulated with pooled HPV-16 E6/E7 pooled peptide for 5-6 
hours at 37C/5% CO2 in the presence of Protein Transport Inhibitor Cocktail (Brefeldin A 
and Monensin) (eBioscience) according to the manufacturer’s instructions. The Cell 
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Stimulation Cocktail (plus protein transport inhibitors) (phorbol 12-myristate 13-acetate 
(PMA), ionomycin, brefeldin A and monensin) (eBioscience) was used as a positive 
control and R10 media as negative control. In cultures being used to measure 
degranulation, anti-CD107a (FITC; clone 1D4B; Biolegend) was added. All cells were 
then stained for surface and intracellular proteins as described previously (20). Briefly, 
the cells were washed in FACS buffer (PBS containing 0.1% sodium azide and 1% FCS) 
before surface staining with flourochrome-conjugated antibodies. Cells were washed 
with FACS buffer, fixed and permeabilized using the BD Cytofix/Ctyoperm TM (BD, San 
Diego, CA, USA) according to the manufacturer’s protocol followed by intracellular 
staining. The following antibodies were used for surface staining: LIVE/DEAD Fixable 
Violet Dead Cell stain kit (Invitrogen), CD19 (V450; clone 1D3; BD Biosciences) CD4 
(FITC; clone RM4-5; Ebioscience), CD8 (APC-Cy7; clone 53-6.7; BD Biosciences), 
CD44 (A700; clone IM7; Biolegend); KLRG1 (FITC; clone 2F1; eBioscience). Major 
histocompatibility complex class I peptide tetramer to LCMV-GP33 was used as 
described previously (4,5). For intracellular staining the following antibodies were used: 
IFNγ (APC; clone XMG1.2; Biolegend), TNFα (PE; clone MP6-XT22; ebioscience), CD3 
(PerCP/Cy5.5; clone 145-2C11; Biolegend). All data was collected using a LSRII flow 
cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, 
OR) and SPICE v5.2 (free available from http://exon.niaid.nih.gov/spice/). Boolean 
gating was performed using FlowJo software to examine the polyfunctionality of the T 
cells from vaccinated animals. Dead cells were removed by gating on a LIVE/DEAD 
fixable violet dead cell stain kit (Invitrogen) versus forward scatter (FSC-A) 
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Antigen-specific Antibody Determination  
The measurement of IgG antibodies specific for viral genes E6 and E7 was performed 
by ELISA (enzyme linked immunosorbent assay) in both immunized and controlled mice. 
The plates were coated with 1ug/ml of each protein (ProteinX Lab) and incubated 
overnight at 4 degrees. After washing, plates were blocked with 10% fetal bovine serum 
(FBS) in 1x phosphate-buffered saline (PBS) for 1 hour at room temperature.  Plates 
were then washed again and serum was added at a 1:25 dilution in 1% FBS + PBS + 
0.05% Tween-20 and incubated at room temperature for 1 hour. After another wash, 
goat anti-mouse IgG HRP (Santa Cruz) at a 1:5000 dilution was added to each well and 
incubated for 1 hour at room temperature. Following a final wash, the reaction was 
developed with the substrate 3,3’,5,5’-tetramethylbenzidine (Sigma-Aldrich) and stopped 
with 100ul of 2N sulfuric acid/well. Plates were read at 450nm on Glomax Multi-
Detection System (Promega). All serum samples were tested in duplicate. The amount 
of antigen specific IgE was also determined using a similar ELISA protocol using the 
secondary rat anti-mouse IgE HRP antibody (Southern Biotech).  Total IgE was 
determined using GenWay’s mouse IgE kit. The manufacturer’s protocol was followed 
with serum dilutions at 1:50. All serum samples were tested in duplicate. 
 
Tumor Cell line 
TC-1 cells were purchased from ATCC and cultured as previously described (26). The 
TC-1 cell line was a graciously given gift from Dr. Yvonne Paterson of the University of 
Pennsylvania, Philadelphia, PA, USA. The TC-1 cell line is well characterized, 
constitutively expresses E6 and E7, and is highly tumorigenic (26, 27). TC-1 cells were 
prepared and mixed with Matrigel (BD Bioscience) for subcutaneous (s.c.) tumor 
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implantation. 
 
In vivo tumor treatment (regression) study 
Female B6 mice were separated into four groups of 10 mice each and 5 x 104 TC-1 cells 
were s.c. implanted into the flanks of each wild-type female B6 mice. On days 4, (after 
tumor implantation and when tumors reached 3mm), each group of mice was immunized 
i.m./EP with pVAX, ConE6E7, ConE6E7 proIL-33 and ConE6E7 mtrIL-33, respectively 
and boosted on day 11 and 18. Mice were monitored twice a week for tumor growth and 
were measured as described previously (21,27).  
 
Statistical analysis 
Student’s t-test was applied for comparison of the quantitative data of the cellular 
immune response and tumor diameters. In this study, p < 0.05 were regarded as 
statistically significant. 
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RESULTS 
Construction and expression of IL-33 isoforms 
Two IL-33 adjuvants constructs (pro-IL33 and mtrIL-33) were designed and 
generated to test our working hypothesis (Figure 2.1A). To determine the expression of 
both IL-33 isoforms, human rhabdomyosarcoma (RD) cells were transfected separately 
with each construct, and expression was assessed by Western immunoblotting. A 
~20kDA protein was observed for mtrIL-33 and a ~30kDA and ~20kDA protein size was 
observed for proIL-33, in cell lysates harvested 48 hours after transfection using an anti-
IL33 monoclonal antibody (mAb) for detection (Figure 2.1B). For a comparative control, 
no protein band could be detected in the negative pVAX control. To examine the 
cytokine secretion of both isoforms, cell supernatants were obtained 48 hours after 
transfection in RD cells and the detection of cytokine secretion into the extracellular 
environment were carried out by enzyme-linked immunosorbent assays (ELISAs). As 
shown in Figure 2.1C, supernatants from mtrIL-33 and proIL-33 transfected RD cells 
contained mtrIL-33 and proIL-33 at concentrations of roughly 20,000 pg/ml and 600 
pg/ml, respectively. Finally, the expression for both IL-33 isoforms was further confirmed 
using immunoflourescent staining using an anti-IL33 mAb. ProIL-33 can act both as a 
secreted cytokine and as a nuclear binding factor (19). ProIL-33 nuclear localization is 
mediated by the nuclear localization signal in its N-terminus, which also contains a 
chromatin-binding motif (Figure 2.1A). However, the cleavage of proIL-33 into mtrIL-33 
yields a truncated IL-33 that lacks the nuclear localization signal found in proIL-33. As 
projected, high nuclear expression with some cytoplasmic expression was observed in 
the proIL-33 transfected cells (Figure 2.1D, bottom). This is an important observation 
which supports previous findings showing that proIL-33 cytokine can also be expressed 
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and found in the cytoplasm (27). In contrast, only high cytoplasmic expression was 
visualized in the mtrIL-33 transfected cells shown in Figure 2.1D, middle.  
 
IL-33 adjuvant isoforms enhance potent HPV-specific cellular immune responses 
following vaccination  
A quantitative ELISpot assay was used to determine the number of antigen-
specific IFNγ secreting cells in response to stimulation with the E6 and E7 peptide pool. 
As we have reported, electroporation (EP) improves the immunogenicity or potency of 
DNA vaccines by increasing antigen expression (28,29), thus we performed 
ConE6E7/EP intramuscular (i.m.) vaccination in C57BL/6 (B6) mice (n=5) with a dosage 
of 5µg alone or in combination with either mtrIL-33 or proIL-33 at various doses followed 
by EP. One week after final immunization we monitored the degree of immune 
responses by isolating splenocytes for further analysis (Figure 2.2A). As shown in 
Figure 2.2B, the critical role of IL-33 to drive TH1-polarized immune responses is clearly 
demonstrated. Co-immunization with both adjuvant cytokine-encoding plasmids induced 
higher numbers of E6- and E7-specific IFNγ secreting T cells at all doses when 
compared with ConE6E7 alone-vaccinated mice (~500 SFU per million splenocytes). As 
noted in Figure 2.2B, the optimal dose of either the mtrIL-33 or proIL-33 (7µg) resulted 
in a total 4 and 3.5-fold increases in IFNγ responses, respectively.  Due to earlier reports 
suggesting that IL-33 was a key cytokine in the induction and support of a TH2 response 
(6,15,16), we assessed whether IL-33 induced the prototypical TH2 cytokine, Interleukin-
4 (IL-4) via IL-4 ELISpot. Our data reveals that neither form of IL-33 drove a robust 
secretion of IL-4 (Figure 2.2C). Instead, IL-33 as an adjuvant skewed towards the TH1 
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biased axis, and not the TH1 cytokine associated immune responses as originally 
described (18).  
 
IL-33 enhances HPV antigen-specific CD4 and CD8 T cell immunity 
We next characterized the antigen (Ag)-specific phenotype and cytokine 
production profile of memory T cells generated, using the 7µg dose that induced the 
optimal adjuvant affect as shown in Figure 2.2B. Given the importance of multifunctional 
CD4 and CD8 T cell immunity in the elimination of HPV16-infected cells (5, 30-33), we 
measured the ability of vaccine-induced Ag-specific T cell populations to secrete IFNγ 
and TNFα, in response to ex vivo E6/E7 pooled peptide stimulation in the spleens. Our 
gating strategy for intracellular cytokine flow-cytometry analysis is depicted in Figure 
2.3A. Compared with ConE6E7 vaccination alone, the ConE6E7 co-administered with 
mtrIL-33 and proIL-33 elicited higher frequency of HPV-specific CD4 T cells producing 
either total IFNγ (mtrIL-33: 0.21%; proIL-33: 0.25%), total TNFα (mtrIL-33: 0.25%; proIL-
33: 0.39%) and dual IFNγ/TNFα (mtrIL-33: 0.12%; proIL-33: 0.15%) (Figure 2.3B-E). In 
terms of CD8 T cells, we observed that vaccination with both IL-33 isoforms elicited 
substantially higher frequencies of HPV-specific CD8 T cells producing total IFNγ (mtrIL-
33: 3.68%; proIL-33: 3.50%), total TNFα (mtrIL-33: 3.11%; proIL-33: 3.13%) and dual 
IFNγ/TNFα (mtrIL-33: 2.83%; proIL-33: 2.75%) (Figure 2.4A-C). The same trend was 
seen with the frequency of Ag-specific CD8+ T cells secreting IFNγ alone and TNFα 
alone (Figure 2.4D). Overall, both immunoadjuvant IL-33 isoforms produced similar 
amounts of Ag-specific CD4 and CD8 T cell responses, with cytokine production 
mediated mainly by CD8 T cells. The high frequencies of effector cells secreting anti-
viral cytokines are indicative of the adjuvant effects of IL-33 to enhance vaccine potency. 
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Given the importance of cytotoxic CD8 T lymphocytes (CTLs) functionality as 
critical components in protection (34), we characterized the cytotoxic potential of vaccine 
induced CD8 T cells undergoing degranulation. CD8 T cells isolated from mice 
vaccinated with adjuvant showed a higher frequency of the degranulation marker, 
CD107a (mtrIL-33: 4.4%; proIL-33: 4.9%), compared to mice that received the ConE6E7 
constructs alone (Figure 2.4E). More interestingly, the HPV-adjuvanted vaccines elicited 
substantially higher frequencies of plurifunctional effector CD8 T cells co-expressing 
CD107a/IFNγ/TNFα (mtrIL-33: 2.5%; proIL-33: 2.5%), compared to the ConE6E7 
construct alone (Figure 2.4F). These results indicate the adjuvant potential of IL-33 to 
induce functional effector cytotoxic CTLs, which have a phenotype suggesting the cells 
ability to clear HPV16 infected cells.  
 
IL-33 role in the induction of humoral responses 
Identifying potent adjuvants that not only mediate protective cell-mediated 
immune responses, but can also induce humoral immune responses, will be ideal for 
enhancing effective prophylactic and therapeutic vaccines against a variety of microbial 
infections. Thus, to determine whether mtrIL-33 and proIL-33 influence the level of 
circulating HPV E6- & E7-specific antibodies, we analyzed humoral responses by ELISA 
using collected sera obtained one-week post final vaccination. As shown in Figure 2.5A, 
only co-immunization with proIL-33 significantly induced E7-specific total IgG compared 
to other immunized groups. No E6-specific antibodies were induced or detected (data 
not shown). In addition, because reports have indicated that IL-33 plays a role in allergic 
responses we examined E7-specific IgE and total IgE responses in the sera. As 
illustrated in Figure 2.5B and 2.5C, the adjuvant effects of mtrIL-33 and proIL-33 did not 
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drive enhanced levels of IgE responses compared to control vaccinated groups. This is 
consistent with the low induction of IL-4 responses shown in Figure 2.2C, as IL-4 is 
known to drive IgE class-switch (35). These results supported that IL-33 adjuvant effects 
in a DNA vaccination setting do not induce TH2-associated responses. Interesting, only 
the combination of HPV and proIL-33 increased Ag-specific IgG humoral responses, 
indicating its role as an effective adjuvant to enhance both Ag-specific cell-mediated and 
humoral responses.  
 
IL-33 immunoadjuvants induce potent anti-tumor immunity and regression of 
established TC-1 tumor-bearing mice  
A strong frequency of anti-HPV CD4 TH1 and CD8 T cell immunity has been 
considered a critical characteristic of an effective therapeutic T cell-based vaccine 
designed to control and eliminate established pre-existing HPV infections and 
associated lesions (32,36). Given the results that IL-33 acts as a cell-mediated adjuvant 
eliciting potent HPV Ag-specific TH1-and CD8-biased T cell immune responses, we 
performed an in vivo tumor therapy study to determine the therapeutic efficacy of IL-33 
immunoadjuvants in TC-1 tumor bearing mice. HPV16 E6/E7-expressing TC-1 tumors 
(5x104) cells were implanted in naïve B6 recipient mice. Four days after TC-1 cell 
implantation, tumors were measured (tumors had reached an average size of 3 mm) and 
groups of mice (n=10) were immunized with pVAX, ConE6E7 (5µg) alone, or ConE6E7 
co-administered with 7µg of mtrIL-33 or proIL-33, followed with two boosts at one week 
intervals as outlined in Figure 2.6A. As shown in Figure 2.6B, tumor growth was 
substantially rejected in the mtrIL-33 and proIL-33-adjuvanted groups compared with 
controls. The IL-33 groups remained tumor free until day 42, with the exception of one 
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mouse in the mtrIL-33-adjuvant group. Meanwhile, only 6 mice in the ConE6E7-
vaccinated group were tumor free after 42 days and in the control group all mice had 
died by day 28. Furthermore, as shown in Figure 2.7, both IL-33 isoforms can maintain 
and elicit anti-tumor memory responses similar to ConE6E7. Clearly, ConE6E7 can 
easily prevent E6/E7 tumor growth, but have difficulties curing in a tumor therapy study, 
however the inclusion of IL-33 makes a substantial difference (Figure 2.6B). Thus, our 
data illustrates that HPV-specific T cell immunity induced by both immunoadjuvants 
provides substantial protective anti-tumor immunity by further delaying or rapidly 
inducing complete regression of established TC-1 tumors.  
 
IL-33 adjuvant expands Ag-specific CD8 T cell responses and elicits potent 
CD62L-KLRG1+ effector-memory CD8 T cell responses after vaccination 
Given the increase of Ag-specific CD8 T cell responses and the remarkable 
display of complete tumor regression elicited by immunoadjuvant proIL-33, we examined 
whether the 100% protective efficacy of proIL-33 was due to its ability to rapidly expand 
the effector memory CD8 Ag-specific T cell responses. To achieve this goal, we took 
advantage of the P14 (DbGP33-specific T cell receptor (TCR)) mouse model, which is a 
great model for tracking populations of T cell subsets. Therefore, to investigate CD8 T 
cell expansion during vaccination with proIL-33, we transferred ~150,000 Ly5.1+ naïve 
P14 TCR transgenic CD8 T cells into (n=4/group) naïve wild type recipients to make 
“P14 chimeric mice” that were subsequently vaccinated with GP33 alone and GP33 
coimmunized with proIL-33. The frequency of the Ag-specific CD8+ T cells responses 
was monitored in the blood during the course of a prime and boost DNA vaccination with 
or without proIL-33 adjuvant (Figure 2.8). As shown in Figure 2.8A and Figure 2.8B, 
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the GP33-proIL-33 adjuvanted group dramatically increased the frequency of P14 
CD8+Ly5.1+ T cells in the blood, compared to the non-adjuvanted group. This 
significantly increased frequency (~5-fold) of Ly5.1+ CD8+ T cells peaked at ~14 dpv 
(days post vaccination) compared to the GP33 immunized group which reached its peak 
at ~21 dpv. Furthermore, seven days after homologous boosting (48 days after initial 
vaccination), proIL-33 immunoadjuvant markedly increased the frequency of Ag-specific 
CD8+ T cells compared to control group (Figure 2.8B).  
Several studies have suggested that effector CD8 T cells are the optimal subset 
for protective immunity and pathogen control (37-39). It has been proposed that a 
predominant CD62L-KLRG1+ effector-memory T cell response may be a vital prognostic 
for the efficacy of therapeutic cancer vaccines (40). Thus, starting at 14 dpv we 
examined the phenotype of the effector CD8 T cells within the vaccine-induced P14-
specific CD8 T cell population based on the cell surface expression markers: Ly5.1, 
CD62L and KLRG1 (Figure 2.8C).  As shown in Figure 2.8C, the percentages of 
CD62L-KLRG1+ effector memory cells were significantly higher in the proIL-33 adjuvant 
group compared to the GP33-only vaccinated group. Secondary memory cells showed a 
greatly expanded population of KLRG1+ T cells in both groups after homologous DNA 
boosting, 48 days after initial immunization. The effector-memory responses remained 
significantly higher in the proIL-33-adjuvanted group compared to GP33-alone group. 
Together, these results support the notion that IL-33 increases the formation of Ag-
specific CD8 T cells and that IL-33 can enhance clonal expansion of the effector memory 
pool (12). 
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FIGURES 
 
Figure 2.1. Expression and secretion of mtrIL-33 and proIL-33 DNA vaccine 
constructs. (A) Schematic representation of IL-33 protein and the IL-33 adjuvant 
constructs encompassing the proIL-33 and mtrIL-33 under the CMV promoter. All 
constructs contain an IgE leader sequence. The N-terminus domain of IL-33 contains a 
chromatin-binding motif (CBM) and nuclear localization signal (NLS). (B) Expression of 
mtrIL-33 and proIL-33 constructs in RD cells as examined by Western blot analysis. 
Labeled lanes show proteins detected by anti-IL33 mAb. Smaller band represents mtrIL-
33, while the larger band represents proIL-33. (C) Secretion of IL-33 from transfected 
RD cells was confirmed via ELISA. Data shows the means with standard error of the 
means (SEM) for two replicate assays. (D) Detection of expression of mtrIL-33 and 
proIL-33 via Immunofluorescence microscopy 
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Figure 2.2. Immunoadjuvants IL-33 isoforms enhance strong HPV16 E6- and E7-
specific IFN-γ immune responses, but no IL-4 responses. (A) DNA vaccine 
immunization schedule for adjuvant study. C57BL/6 (B6) mice (n=5 per group) were 
immunized at weeks 0, 3, and 6 with HPV16 consensus E6/E7 (ConE6E7) construct with 
or without adjuvant via intramuscular/EP and spleens were harvested one week post 
final immunization to assess the cellular immune responses. (B) The induction of a Th1 
response is shown by the frequency of HPV16 E6 and E7-specific IFNγ spot-forming 
units (SFU) per million splenocytes determined by IFNγ ELISpot assay. (C) Antigen-
specific IL-4 responses measured by IL-4 ELISpot assay. Experiments were performed 
independently at least two times with similar results.  
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Figure 2.3. Cytokine frequencies of specific CD4 T cells induced by 
immunoadjuvants mtrIL-33 and proIL-33. (A) Depicted is the gating strategy used for 
identifying Ag-specific T cell populations. (B) Column graphs depicting E6/E7-specific 
CD4+ T cells releasing the cytokines IFNγ (C) TNFα and (D) double-positive producing 
cells (and pVAX control). (E) Column graph shows plurifunctional subpopulations of 
single- and double-positive CD4 T cells releasing the cytokine IFNγ  and TNFα. Pie 
charts show the relative proportion of each cytokine subpopulation to Ag-specific 
stimulation. Experiments were performed independently at least two times with similar 
results with five mice per group. 
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Figure 2.4. Cytokine frequencies of specific CD8 T cells induced by 
immunoadjuvants mtrIL-33 and proIL-33. (A) Column graphs depicting E6/E7-specific 
CD8+ T cells releasing the cytokines IFNγ (B) TNFα and (C) double-positive producing 
cells (and pVAX control). (D) Column graph shows plurifunctional subpopulations of 
single- and double-positive CD8 T cells releasing the cytokine IFNγ and TNFα. Pie 
charts show the relative proportion of each cytokine subpopulation to Ag-specific 
stimulation. Dot plots, representative of four mice is also shown in (D), depicting double 
positive cytokine expressing CD8 cells after stimulation with pooled E6/E7 peptide. (E) 
Antigen-specific cytolytic degranulation T cells were measured by degranulation marker 
expression, CD107a. (F) Cytokine profile of the cytolytic phenotype. Experiments were 
performed independently at least two times with similar results with five mice per group. 
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Figure 2.5. Humoral responses of ConE6E7 with and without mtrIL-33 and proIL-33 
adjuvants. Blood collected from control (pVAX) and immunized mice (n=4) was 
analyzed  for humoral responses via ELISA one week after last immunization. (A) 
Specific total IgG antibodies against HPV16 E7 (B) Specific IgE antibodies against 
HPV16 E7. (C) Total IgE antibodies detected in the serum. Experiments were repeated 
two times with similar results. 
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Figure 2.6. Vaccination with IL-33 adjuvants induces regression of established TC-
1 tumors. (A) Schematic illustration of the time line of therapeutic study regimen. (B) 
Groups of B6 mice (10 mice/group) were s.c. challenged with 5x104 TC-1 tumor cells. 
Tumors were measured twice a week in two dimensions with electronic calipers and 
data are presented with the average of these values over time for each individual 
mouse. Mice were sacrificed when tumor diameter reached approximately 2.0 cm. 
Tumor measurements for each time point are shown only for surviving mice. pVAX 
immunized mice served as negative control.  
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Figure 2.7. Protective efficacy maintained by mtrIL-33- and proIL-33-adjuvanted 
ConE6E7. In a prophylactic study, groups of B6 (10 mice/group) were immunized (three 
times at three week intervals) with ConE6E7 with or without 7µg of mtrIL-33 or proIL-33 
and challenged with 5x104 TC-1 cells one week after last immunization to assess the 
anti-tumor effects. All vaccination groups prevented tumor growth upon TC-1 
implantation. 
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Figure 2.8. Immunoadjuvant IL-33 expands the frequency and effector memory 
phenotype of the Ag-specific CD8 T cells.  P14 chimera mice (n=4) were vaccinated 
twice (on day 0 and day 41) containing GP33 with or without proIL-33. (A) Displayed are 
representative fluorescent intensity plots of GP33/Ly5.1-specific CD8 T cells responses 
in the blood of vaccinated mice at days 14, 21 and 31 after first vaccination and day 48 
(day 7 after second immunization). Numbers indicate the percentage of Ag-specific 
CD8+ T Cells within the total CD8+ T cell populations. (B) Kinetics of Ly5.1+ expression 
on P14-specific CD8 T cells in PBMC following DNA vaccination with a prime at day 0 
and a boost at day 41. (C) Distribution of effector memory CD8+ T cell from immunized 
mice at day 14, 21, 31  after first vaccination and day 48 (day 7 after second 
vaccination). Data are representative of two independent experiments with four mice per 
group.  
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DISCUSSION 
In this study, we provide insight on the TH1-and CD8-biased adjuvant activity of 
two isoforms of IL-33-encoding plasmids in a DNA vaccine setting. We demonstrate that 
IL-33 elicits bonafide Ag-specific TH1cell-mediated immune responses to a consensus 
HPV16 E6/E7 antigen, but neither IL-4, nor any elevation of IgE levels as previously 
described. Clearly both isoforms elicited strong HPV16 Ag-specific polyfunctional CD4 
and CD8+ T cells secreting both anti-viral IFNγ and/or TNFα cytokines, and also induced 
an increase in the Ag-specific cytolytic effector CD8 T cells undergoing plurifunctional 
degranulation. More importantly, both IL-33 isoforms were shown to be strong adjuvants 
when used in conjunction with a therapeutic HPV DNA vaccine to generate robust anti-
tumor immunity, facilitating successful tumor regression in established TC-1 tumor-
bearing mice.  
The major significant difference between proIL-33 and mtrIL-33 was that proIL-33 
was able to increase E7-antigen specific IgG levels. However, because mtrIL-33 induced 
90% tumor regression, it suggested that T cells mediated the anti-tumor protection, not 
B-cell responses.  Full length IL-33’s dual function property, to act not only as a cytokine, 
but also as a nuclear transcription factor, may explain the increase in antibody 
responses by proIL-33.  Its nuclear localization may have additive effects on modulating 
the humoral immune responses. However, the specific transcriptional targets of nuclear 
IL-33 are still unclear. We are currently pursuing understanding its precise role in the 
nucleus and its association with modulation of immunogenicity. Although the importance 
of this finding is not yet clear, the data suggests that proIL-33 could also be useful in 
vaccine strategies aiming to achieve enhanced antibody responses and cellular 
immunity. This is an area of further investigation. 
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The specific roles in the protective responses against HPV infection and 
associated cancers have been attributed to CD8 T cell immune responses, and 
therefore, are the focus for achieving effective immunity by therapeutic treatments 
against tumors (5,21, 28, 32). Our results reveal that the cytokine secreting T cell 
responses induced by IL-33 were mainly mediated by eliciting a high frequency of Ag-
specific CD8+ T cells co-expressing CD107a/IFNγ/TNFα. While Bonilla et al. similarly 
demonstrated that IL-33 can drive plurifunctional CD8 T cell responses in a viral infection 
model (12), we further demonstrated that the delivery of IL-33 as an immunoadjuvant 
can indeed enhance plurifunctional CD8 T cell responses, further expanding the pool of 
information we now know about IL-33. Consistent with this enhanced polyfunctional anti-
HPV effector CD8 and CD4 T cell immunity, mice vaccinated with IL-33 demonstrated 
remarkable ability to induce anti-tumor immunity and tumor regression in established 
TC-1 tumor bearing mice (Figure 2.6B). The significantly improved vaccine efficacy 
offered by IL-33 suggests its potential utility as a vaccine adjuvant. Recently, Luzina et 
al. demonstrated that mtrIL-33 induced TH2 responses in vivo via a mouse model of 
pulmonary infection (18). In contrast, we show in vivo that not only proIL-33, but also 
mtrIL-33, a cleaved form of proIL-33 has pleiotropic properties, and can modulate the 
immune responses towards a TH1 and CD8 T cell response. It seems that IL-33 may not 
be a classical TH2 cytokine as originally suggested, but under certain conditions can 
promote TH1 and CD8 type immunity. It is likely that other immune cells may have 
accounted for the observed enhancement in TH1 immunity and tumor regression. For 
instance, IL-33 has been shown to activate Natural Killer (NK) cells (6,41). However, it is 
unlikely that NK cells could have accounted for the observed enhancement in CD8 T cell 
immunity or tumor regression. The HPV E6-E7 vaccine encodes a nuclear antigen that is 
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not lipid based and not targetable by Fc-Receptor bound antibodies directing NK 
immunity and can only be a target of CD8 T cells.  Furthermore, much prior work in the 
TC-1 tumor challenge model, including work conducted by our lab, has established that 
this model is CD8+ T cell dependent for protection (26,32,42-44). Nevertheless, further 
studies will be needed to elucidate under what conditions IL-33 promotes TH1 and CD8 T 
cell immunity, and the IL-33 regulatory networks connecting the innate with the adaptive 
immune response. 
It is known that IL-33 exhibits pleiotropic properties and could promote responses 
other than TH1, such as activating CD8 T cells (12,13,27). Thus, to investigate the ability 
of IL-33 to modulate the CD8 T cells we used the P14 mouse model to monitor the 
expansion of LCMV DbGP33/Ly5.1+ cells in the P14 chimeras after immunizing mice with 
a cognate viral Ag. We show in vivo that IL-33 can modulate the expansion of CD8 T 
cells in a vaccine setting and observed that inclusion of the IL-33 adjuvant significantly 
expanded the magnitude of Gp33/Ly5.1+-specific CD8 T cell responses in the blood 
(Figure 2.8). These data demonstrate the overall superiority of immunoadjuvant IL-33 in 
enhancing the Ag-specific CD8 T cells in a DNA vaccine. In addition to implying that IL-
33 plays an important role in the expansion of CD8 T cells, it also suggests that IL-33 
mediated antitumor immunity and tumor regression in the TC-1 tumor therapy study was 
probably CD8 T cell related (Figure 2.6).  Moreover, as shown in Figure 2.8, the peak of 
CD8 expansion (14 dpv) seemed to correlate with the complete tumor regression 
mediated by prolL-33, which was 17 days post first vaccination (Figure 2.6B). From the 
increased expansion of CD8 effector T cells elicited by the effects of IL-33 adjuvant 
properties, we can postulate their important role in providing tumor protection as shown 
in Figure 6B. Subsequently, we also demonstrate that a boost vaccination can further 
expand the formation of Ag-specific CD8 T cells after a prime vaccination suggesting the 
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potential recall of the established memory CD8 T cell pool (Figure 2.8B). The reasons 
behind the ability of IL-33 to expand the frequency of CD8 T cells are not yet entirely 
clear (12,13,41,45). However, further studies are needed to elucidate these 
mechanisms.  
From a therapeutic point of view, the goal of successful vaccination is the 
induction of the most potent subsets of CD8 memory T cell populations to rapidly control 
infection. Recently, reports have begun to show that the effector-memory KLRG1+CD8+ 
T cell population can mediate potent protective immunity against certain pathogens (37-
39) and might be optimal for immediate regression of established subcutaneous (s.c.) 
tumors (40). Mice immunized with IL-33 demonstrated robust expansion of activated 
effector memory CD8+ T cells in the periphery (Figure 2.8C), suggesting trafficking of 
activated CD8+ T cells to the site of Ag stimulation. Our findings support the concept that 
vaccine-induced effector-memory CD8 T cell responses might be important memory 
CD8+ T cell subsets for an effective therapeutic vaccine against tumors (40). The high 
frequency of Ag-specific effector-memory cells in the periphery is consistent with the 
observation that effector-memory T cells can migrate to the site of infection and initiate 
immediate effector function (46). Furthermore, these results are in agreement with 
Bonilla et al., reporting IL-33 is important for primary effector CD8 T cell responses (12). 
However, they show that IL-33 may not play a role in memory responses, while our 
findings suggest that in certain cases it may play an important role. The reasons for the 
differences between the two studies are currently unknown, but may be due to 
differences in model systems. We also demonstrate that secondary memory cells after 
boost showed a greater formation of CD62L-KLRG1+ cells in the periphery (Figure 
2.8C). Together, these results indicate that the increase in the frequency and phenotype 
of the IL-33-adjuvanted vaccine-induced Ag-specific P14 CD8 T cells after a prime and 
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boost vaccination may be a prediction of the protective correlates of immunity behind the 
therapeutic efficacy of immunoadjuvant IL-33 against the established TC-1 tumors 
(Figure 2.6B). We are currently investigating the ability of IL-33 to generate central 
memory immunity, since central memory T cells are important subsets of memory CD8 T 
cells that also mediate optimal protective immunity against pathogens (47,48). Overall, 
understanding the mechanism of action by which IL-33 influences the expansion and 
development of heterogeneous CD8 T cell populations in vaccines is an important area 
for further investigation.  Altogether, these results support evidence that IL-33 acts as a 
potent adjuvant capable of inducing and modulating potent Ag-specific cell-mediated 
immunity in a variety of pathogens. 
In summary, we provide insight into the biological function of proIL-33 and mtrIL-
33 and its effects on modulating the adaptive immune responses in vivo, inducing potent 
Ag-specific anti-viral and anti-tumor TH1 and CD8 T cell immunity, which resulted in 
effective tumor regression. This study provides evidence that immunoadjuvant IL-33 
elicits its affects by enhancing the formation of the Ag-specific effector CD8 T cells and 
markedly amplifying the effector-memory CD8 T cells responses. These findings, we 
believe, establish the validity of IL-33 as a new adjuvant for consideration in the context 
of immune-therapies, in particular, for cancer vaccine therapies. 
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CHAPTER 3 
 
MOLECULAR ADJUVANT IL-33 ENHANCES THE POTENCY OF A DNA VACCINE IN 
A LETHAL CHALLENGE MODEL 
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ABSTRACT 
Identifying new molecular adjuvants that elicit effective vaccine-induced CD8 T cell 
immunity may be critical for the elimination of many challenging diseases including 
Tuberculosis, HIV and cancer.  Here, we report that co-administration of molecular 
adjuvant IL-33 during vaccination enhanced the magnitude and function of antigen (Ag)-
specific CD8 T cells against a model Ag, LCMV NP target protein.  These enhanced 
responses were characterized by higher frequencies of Ag-specific, polyfunctional CD8 
T cells exhibiting cytotoxic characteristics.  Importantly, these cells were capable of 
robust expansion upon Ag-specific restimulation in vivo and conferred remarkable 
protection against a high dose lethal LCMV challenge.  In addition, we demonstrate the 
ability of IL-33 to amplifying the frequency of Ag-specific KLRG1+ effector CD8 T 
cells.  These data show that IL-33 is a promising immunoadjuvant at improving T cell 
immunity in a vaccine setting and suggest further development and understanding of this 
molecular adjuvant for strategies against many obstinate infectious diseases and cancer. 
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INTRODUCTION 
There is still a great need for effective vaccines against many chronic infectious 
including HIV, HCV, Tuberculosis and malaria. For these pathogens, it is known that T 
cell-mediated immunity is critical in either controlling, preventing or delaying the onset of 
disease (1). Thus, a crucial step in vaccine development for these infections requires 
producing cytotoxic TH1 versus humoral TH2 responses. Currently, licensed vaccines 
such as inactivated and recombinant protein or non-live vaccines predominately drive 
humoral immune responses (2). An overall shortcoming of these vaccines, especially 
non-live vaccines, is their inability to generate both effective TH1 and CD8 T cell 
immunity, thus hindering their beneficial role in limiting or preventing diseases that 
require adaptive cellular immune responses (2,3). One way to improve the quality of 
immune responses during vaccination is to incorporate immunoadjuvants, which have 
been shown to help increase their TH1 immune potency (2). However, it has been a 
challenge to discover immunoadjuvants that can amplify the induction of CD8+ T cell 
responses. Notably, IL-33 has emerged as a proinflammtory cytokine capable of 
promoting both potent TH1 and cytotoxic CD8 T cell immunity (4,5,6). Therefore, IL-33 
has great potential to act as a potent molecular adjuvant in vaccines designed to boost 
CD8+ T cell immune responses.  
 IL-33 is a member of the IL-1 cytokine family, which is released by necrotic cells 
or activated innate immune cells during trauma or infection (6,7). Therefore, it is 
considered to serve as the first line of defense against pathogens, by providing an 
endogenous “danger signal” that triggers inflammation and promotes cell-mediated 
immune response. Originally studied in the context of TH2 immunity associated with 
inflammatory disorders (6,7), evidence has begun to unveil IL-33’s unappreciated ability 
to induce TH1 and CD8 T cell-mediated immunity (4-6). We have recently reported that 
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IL-33 can act as novel immunoadjuvant to induce both potent TH1 and effective CD8 T 
cell responses in an anti-tumor DNA vaccine (5). Here we expanded the scope of these 
initial studies to evaluate the capacity of IL-33 to serve as a vaccine adjuvant to enhance 
and modulate cell-mediated responses against various models of infection that require 
CD8 T responses.  
In the present study, we use the well-studied lymphocytic choriomeningitis virus 
(LCMV) model to investigate IL-33’s ability to facilitate the induction of antiviral and 
protective immunity and further elucidate its biological function on memory CD8 T cell 
expansion and differentiation in a vaccine setting. We hypothesize that IL-33 would have 
the capacity to improve the efficacy of DNA vaccines against a viral challenge, providing 
optimal effector function and protection. Here we show that the administration of IL-33 
coadministered with a DNA vaccine against LCMV induces robust antigen-specific IFNγ 
responses, enhances antigen (Ag)-specific polyfunctional CD8+ T cell immune 
responses, increases the cytotoxic phenotype of the CD8 T cells, and provides 
substantial protective immunity against a high-dose lethal LCMV challenge. We also that 
inclusion of IL-33 can significantly amplify and expand the Ag-specific effector memory 
CD8 T cell responses. Furthermore, we provide evidence of IL-33’s ability to also 
enhance cell-mediated immune responses when co-delivered with an HIV DNA vaccine. 
These findings significantly highlight the important role of IL-33 as a potential future 
vaccine adjuvant with applicability in the treatment of a variety of chronic viral diseases 
that require potent TH1-type immunity for their prevention or control. 
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METHODS 
Constructs 
The DNA constructs encoding mature IL-33 (mtrIL-33), HIV (ConC) and LCMV-GP 
construct has been described (5-10). All constructs had highly efficient immunoglobulin 
E (IgE) leader sequence inserted at the 5′end of the gene. The constructs were 
commercially synthesized and optimized as described previously (10).  
 
Animals 
All animals were conducted and maintained in accordance with the NIH and the 
University of Pennsylvania Institutional Animal Care and Use Committee guidelines. 
Female C57BL/6 (H-2b) 8-week-old mice were purchased from Jackson Laboratory (Bar 
Harbor, ME).  
 
Animal immunizations 
Mice were immunized once intramuscularly (i.m.) in the tibialis anterior muscle. In vivo 
electroporation (EP) was delivered, with the CELLECTRA adaptive constant current EP 
device (Inovio Pharmaceuticals), at the same site immediately following vaccination as 
previously described (5,10). The mice were immunized with either 10 μg pVAX1 or 10 μg 
pLCMV-NP with or without 11 μg of mtrIL-33 construct. Three weeks after initial 
immunization, mice were sacrificed and splenocytes were harvested to measure immune 
responses. The LCMV-GP (GP) construct was administered at 10 μg. For the HIV 
immunizations, mice were immunized three times at two-week intervals with 10 μg of 
each construct (ConC) with or without 11 μg of mtrIL-33. One week after immunization, 
the mice were sacrificed and splenocytes were harvested to monitor immune responses. 
All studies were repeated at least two times.  
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LCMV Viral Challenge 
For lethal challenge studies, immunized mice were challenged intracranial (i.c.) 21 days 
after initial vaccination with either 20xLD50 or 40xLD50 of LCMV Armstrong as previously 
described (11) in 30 μl of virus diluent (PBS with 20% FBS and 1X Anti-Anti (Invitrogen, 
Carlsbad,CA)). All mice LCMV challenged were housed in a BSL-2 facility and were 
observed daily for 21 days.  
 
ELISPOT assay 
For mice vaccinated with DNA all spleens were processed and IFNγ ELISpot assays 
were performed to determine the antigen-specific cytokine secretion. Spleens were 
collected in RPMI 1640 medium (supplemented with 10% FBS, 1X Antibiotic-
Antimycotic, and 1X β-ME) and splenocytes were isolated by mechanical disruption of 
the spleen using a Stomacher machine (Seward Laboratory Systems, Bohemia, NY). 
The resulting mashed spleens were filtered using a 40µm cell strainer, treated with ACK 
lysis buffer for 5 minutes to lyse the RBCs, washed in PBS and then resuspended in 
RPMI medium for use in ELISpot or Flow Cytometry assay. The IFNγ ELISPOT assays 
were conducted as previously described in detail (5,10,11). The measurement of LCMV-
specific T cell responses were assessed by stimulating splenocytes with 
immunodominant LCMV epitope from the H-2b background (DbNP396-404 (NP396)) or 
(DbGP33-41 (GP33)) (Invitrogen). The HIV-specific T cell responses were measured by 
using pooled peptides (15-mers overlapping by 9 amino acids; 2.5 µg/ml final 
concentration). All peptides were synthesized from GenScript. Concavalin A (Sigma-
Aldrich, St. Louis, MO) was used as positive control and complete culture medium was 
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used as negative control. Spots were enumerated using an automated ELISPOT reader 
(Cellular Technology, Shaker Heights, OH).  
 
Flow cytometry 
Lymphocytes were isolated and processed from the peripheral blood as previously 
described (5). Cells were stained with CD8, CD44, CD62L, KLRG1, and MHC class I 
peptide tetramer to LCMV-GP33 (KAVYNFATC) (Beckman Coulter) as described 
previously (5). Intracellular cytokine staining was performed after 5 hr of ex vivo 
stimulation with either LCMV epitope DbNP396-404 or DbGP33-41 peptide, HIV and Ag85B 
pooled peptides depending on the study as described (5,10). The following antibodies 
were used for surface staining: LIVE/DEAD Fixable Violet Dead Cell stain kit 
(Invitrogen), CD4 (FITC; clone RM4-5; ebioscience), CD8 (APC-Cy7; clone 53-6.7; BD 
Biosciences); CD44 (A700; clone IM7; Biolegend). For intracellular staining the following 
antibodies were used: IFNγ (APC; clone XMG1.2; Biolegend), TNFα (PE; clone MP6-
XT22; ebioscience), CD3 (PerCP/Cy5.5; clone 145-2C11; Biolegend); IL-2 (PeCy7; 
clone JES6-SH4; ebioscience). All data was collected using a LSRII flow cytometer (BD 
Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, OR) and SPICE 
v5.2 (free available from http://exon.niaid.nih.gov/spice/). Boolean gating was performed 
using FlowJo software to examine the polyfunctionality of the T cells from vaccinated 
animals.  
 
Bone Marrow Dendritic Cell Maturation 
Bone marrow was harvested from femurs and tibias of female C57BL/6 mice age 6-8 
weeks.  Following RBC lysis, bone marrow cells were cultured in 40 ng/mL recombinant 
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murine GM-CSF and incubated at 37° C, 5% CO2. Media was refreshed on days 3 and 
6. On day 8, immature BMDCs were harvested by pipetting floating and loosely adherent 
cells.  BMDCs were subsequently treated for 24 hours with 100 ng/mL recombinant IL-
33 or vehicle-sham (PBS) control.  Following treatment, BMDCs were harvested by 
scraping and analyzed by flow cytometry against CD40, CD80, CD86, or isotype-
matched control antibodies. 
 
Luminex 
Cytokines and chemokines were quantified in supernatant collected from BMDC treated 
with or without 100ng/ml of rIL-33 (R&D Systems) at 24 hours, using a custom Millipore 
cytokine assay (Millipore, Billerica, MA) according to manufacturer’s instructions. The 
panel of cytokines and chemokines included: IL-1a, IL-1b, IL-2, IL-6, IL-12, TNFa, IP-10, 
MIG and RANTES. Samples were read on a Bio-Plex 200 system with Bio-Plex Manager 
Software (Bio-Rad). 
 
T cell proliferation assay 
Splenocytes isolated from immunized B6 mice 21 days after initial immunization were 
labeled with Cell Tracer violet Violet (Molecular Probes) and pulsed with 10 μM peptide 
for 5 days. CD8 T cell proliferation was determined using flow cytometry to assess Cell 
Trace Violet dilution. 
 
Statistical Analysis 
Group analyses were completed by matched, two-tailed, unpaired t-test and survival 
curves were analyzed by log-rank Mantel-Cox test. For non-equally distributed samples 
nonparametric Mann-Whitney test was performed (Figures 3.2E and 3.2F).  All values 
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are mean ± SEM and statistical analyses were performed by GraphPad Prism (La Jolla, 
CA). 
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RESULTS 
IL-33 elicits protection against a lethal LCMV challenge 
The LCMV infection model has been extensively used to understand the role of 
virus-specific CD8+ T cell responses in the context of vaccine-elicited protection (12-14). 
Considering our recent novel finding that IL-33 can act as an immunoadjuvant to induce 
both anti-viral and anti-tumor CD8 T cell immunity (5), we used the intracranial (i.c.) 
LCMV challenge model to further study the protective efficacy of IL-33. Three groups of 
C57BL/6 mice (B6) (n = 10) were vaccinated by electroporation (EP) one time with 10 µg 
of pLCMV-NP (NP) construct with or without 11 µg of mature IL-33 (mtrIL-33) construct. 
The empty vector pVAX was used as a negative control. The LCMV NP structural 
protein is recognized as a critical component and target for protective LCMV immunity 
since it is not a target for neutralizing antibodies (11). All animals were challenged 21 
days post-vaccination (dpv) with a lethal 20xLD50 dose of LCMV Armstrong (Figure 3.1a) 
(11,14-16). Vaccinated animals with NP plus mtrIL-33 showed complete protection while 
the NP alone group achieved only 60% protection (Figure 3.1b). On the other hand, all 
control pVAX vaccinated animals succumbed to infection. After showing that mice 
immunized using mtrIL-33 as an adjuvant exhibited 100% survival rate, we next sought 
to determine whether vaccinated mice with adjuvant could confer protection against an 
even higher lethal dose of LCMV challenge. Therefore, mice where challenged with a 
40xLD50 dose of LCMV Armstrong (11), 21 days post-single vaccination (Figure 3.1c). 
Notably, animals receiving one immunization of NP plus mtrIL-33 yielded a significant 
80% protection, while the NP alone group only conferred 10% protection against this 
highly lethal dose of LCMV (Figure 3.1c). These data show that IL-33 elicits protection 
against a lethal LCMV challenge. 
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IL-33 significantly increases LCMV-specific CD8 T cell responses 
Considering that CD8 T cell responses are essential for facilitating control 
against LCMV (11-16), we hypothesized that the IL-33 adjuvanted vaccine induced CD8 
T cells mediated antiviral protection. Thus, to better characterize the protective immune 
correlates driven by mtrIL-33, groups of mice (n = 4-5) were immunized once with NP 
either with or without mtrIL-33. The magnitude of NP-specific immune responses was 
measured 21 dpv in response to peptide re-stimulation (2.5 µg/ml) using the 
immunodominant epitope in the H-2b background: DbNP396-40 (NP396) (11). Compared to 
NP alone-vaccinated mice, we found that co-immunization with mtrIL-33-encoding 
plasmid elicited stronger NP-specific T cell responses by greater than 2.5 fold (Figure 
3.2a); IFN-γ ELISPOT counts were ~2,500 spot-forming cells [SFCs] per 106 splenocytes 
in the IL-33 vaccinated mice versus ~980 SFC/106 splenocytes for the NP alone group. 
Next, we assessed the phenotypic and functional profile of vaccine-induced CD8+ T cells 
in response to NP396 peptide re-stimulation (2.5 µg/ml final peptide concentration). 
Twenty-one days after vaccination there was a significant difference among vaccine 
groups in the frequency of CD8 T cells producing effector cytokines (Figures 3.2b,c). 
The NP vaccine coadministered with mtrIL-33 elicited a higher percentage of Ag-specific 
CD8 T cells producing all three cytokines (Figure 3.2b), and a significant number of the 
CD8 T cells were polyfunctional (Figure 3.2c). Compared with the NP alone vaccinated 
group, the NP+mtrIL-33 vaccinated group elicited substantially higher frequencies of NP-
specific CD8 T cells producing either IFNγ alone (NP, 1.3%; NP+mtrIL-33, 2.3%), dual 
IFNγ+TNFα+ (NP, 0.76%; NP+mtrIL-33, 1.63%), or triple-positive IFNγ+TNFα+IL-2+ (NP, 
0.20%; NP+mtrIL-33, 0.43%) in the spleens 21 dpv (Figure 3.2c). Collectively, the 
enhanced Ag-specific CD8+ T cell response induced by IL-33 is indicative of IL-33’s 
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ability to provide substantial protection against LCMV challenge. We next characterized 
the cytotoxic potential of vaccine-induced CD8 T cells. CD8 T cells isolated from mice 
vaccinated with IL-33 showed a significantly higher frequency of antigen-specific 
(IFNγ+CD107a+: 2.5%) degranulation compared to NP alone-vaccinated mice 
(IFNγ+CD107a+: 1.2%) (Figure 3.2d). We next evaluated the proliferative capacity of the 
CD8 T cells by monitoring Cell Trace Violet dilution in splenocytes isolated from mice 21 
dpv rechallenged in vitro with NP396 peptide re-stimulation. Figure 3.2e shows that 
mtrIL-33 vaccinated mice underwent significantly higher Ag-specific proliferation of CD8 
T cells, being ~2 fold greater than NP control group. Notably, there was an enrichment of 
effector memory CD8 T cells (CD44+CD62L-) in the adjuvant-vaccinated group (Figure 
3.2f). There was no significant difference in the central memory CD8 T cell 
(CD44+CD62L+) population (data not shown). Taken together, the inclusion of IL-33 
elicits robust levels of NP-specific T cell immunity, especially enhancing CD8 T cell 
immune responses.  
To better understand the biological function of IL-33 on the induction of Ag-
specific CD8+ T cells during the course of vaccination, we further characterized IL-33’s 
ability to expand the Ag-specific effector memory CD8 T cell population. To achieve this 
goal, we took advantage of the well-studied DbGP33-41 MHC class I tetramer to follow Ag-
specific CD8 T cells as they develop after initial priming. Mice were vaccinated once with 
a LCMV glycoprotein LCMV-GP (GP) DNA vaccine and the frequency of DbGP33-
specific CD8+ T cells was monitored in the peripheral blood during the course of 
vaccination either with or without mtrIL-33 (Figure 3.4a). Delivery of IL-33 expanded the 
number of DbGP33 tetramer-specific CD8 T cells in the peripheral blood (Figure 3.3a). 
In peripheral blood lymphocytes (PBLs), the frequency of GP33-specific CD8 T cell was 
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significantly 2-fold higher at 18 and 21 dpv compared with the nonadjuvanted group 
(Figure 3.3a). Similarly, the inclusion of IL-33 also increased the number of GP33-
specific CD8+ T cells in the spleen 21 dpv (Figure 3.3b) and the Ag-specific CD8 T cells 
secreting IFNγ, undergoing degranulation, and expressing the transcription factor T-bet 
(Figures 3.3c-f). Additionally, all mice were boosted with the GP construct alone (21 
days after initial immunization) to quantify the Ag-specific recall responses. Compared to 
control group, the IL-33 vaccinated group significantly increased the Ag-specific CD8+ T 
cells. Notably, the IL-33 immunized group GP33 tetramer-specific T cells were ~3-fold 
higher starting 3 days post-boost vaccination (d24) compared to the NP-vaccinated 
group (Figure 3.3a). The significant difference in the amplification of the GP33-specific 
CD8 T cells was still observed 10 days after DNA boost (d31). Consistent with figure 
3.2, the current data further confirms IL-33’s ability to induce the quality of Ag-specific 
CD8 T cells which seemed to correlate with IL-33’s adjuvant effect to mediate its antiviral 
protection as shown in Figure 3.1. Finally, since it has been demonstrated that effector-
phenotype memory CD8 T cells (Teff) can mediate clearance of blood-borne pathogens 
(17-22), we next evaluated the ability of IL-33 to induce the differentiation of Teff cells 
based on expression markers: CD44 and KLRG1 (Figure 3.4b). The administration of 
mtrIL-33 resulted in a significant expansion in the percentages of CD8+KLRG1+ Teff cells 
in the PBLs, compared with the GP-only vaccinated group (Figure 3.4c). We also 
evaluated the recall response of DbGP33 tetramer-specific CD8+KLRG1+ T cells after 
DNA-GP boosting, 21 days after initial immunization and observed marked expansion of 
GP33-specific memory CD8+KLRG1+ T cells in both groups after boosting; however, the 
proportion of CD8+KLRG1+ T cells remained significantly higher in the mtrIL-33 adjuvant 
group (Figure 3.4c). In summary, IL-33 significantly increased LCMV-specific CD8 T cell 
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immunity against two separate viral proteins and enhanced effector-memory 
CD8+KLRG1+ T cell subset differentiation. 
 
IL-33 promotes DC maturation in vitro 
It is well known that antigen presented by activated DCs and the type of 
production of polarizing cytokines they secrete can promote different fates on T cell 
development (23). We next investigated whether IL-33 could induce DC maturation by 
assessing the up-regulation of certain surface expression markers and their induction of 
proinflammatory cytokines, all of which may influence adaptive immunity. Mouse bone 
marrow-derived dendritic cells (BMDC) incubated with 100 ng/ml of recombinant IL-33 
(rIL-33) for 24 hours up-regulated the expression of co-stimulatory CD80 and CD86 and 
CD83 (marker for DC maturation) molecules (Figure 3.5a). Moreover, to characterize 
the cytokines induced by the effect of IL-33, we employed a multiplex cytokine array 
consisting of a panel of TH1 cytokines (IL-12), TH2 cytokines (IL-4), anti-inflammatory 
cytokines (IL-10), and pro-inflammatory cytokines (IL-1a, IL-1b, IL-6, TNF-α). In addition, 
we included cytokines and chemokines associated with activation and chemoattraction 
of T cells: RANTES (CCL5), IP-10 (CXCL10) and MIG (CXCL9). As shown in figure 
3.5b, rIL-33 stimulated DC production of a variety of proinflammatory cytokines and 
chemokines. Additionally, DCs incubated with rIL-33 showed no detectable production 
anti-inflammatory suppressive cytokine IL-10 and of the prototypical TH2 cytokine IL-4 
(data not shown). Therefore, the biological function of IL-33 exhibits the capacity to 
induce phenotypic maturation of DCs, which have the potential to drive proinflammatory 
cytokines and chemokines that may facilitate a polarized TH1/CD8+ T cell protective 
response.  
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IL-33 augments HIV-specific T cell-mediated responses 
To determine whether mtrIL-33 adjuvant can enhance the vaccine potency for 
other pathogens requiring both TH1 and CD8 T cell responses, we assessed the Ag-
specific T cell-mediated responses of mtrIL-33 co-delivered with a HIV DNA vaccine 
antigen (Figure 6.6). B6 mice (n = 5) were vaccinated three times i.m. at two week 
intervals with 10 µg HIV Consensus clade C (ConC) alone or in combination with 11 µg 
of mtrIL-33 followed by EP. One week after final immunization Ag-specific immune 
responses were measured using cells derived from the spleen. Consistent with findings 
in the LCMV model (Figures 3.2a-c), the inclusion of mtrIL-33 enhanced the numbers of 
HIV-specific IFNγ secreting T cells (ConC, ~3,800 SFC) when compared with non-
adjuvanted groups (ConC, ~2,300 SFC) (Figure 3.6a). Furthermore, we characterized 
the cytokine-producing phenotype of the T cell population after immunization with the 
HIV DNA (Figures 3.5b,c). In mice, the Ag-specific TH1 response after HIV vaccination 
with mtrIL-33, consisted of significantly high frequency of polyfunctional double-positive 
(IFNγ+TNFα+) and TNFα- and IFNγ-single-positive CD8 T cells in the spleen (Figure 
3.6B). Regarding CD4 T cells, the Ag-specific TH1 response after HIV plus IL-33 
vaccination, consisted of high frequency of polyfunctional triple-positive (IFNγ+TNFα+IL-
2+), double-positive (IFNγ+TNFα+) and IFN-γ single-positive CD4 T cells in the spleen 
(Figure 3.6C). Overall, these findings significantly highlight the important role of IL-33 as 
an effective immunoadjuvant to be incorporated into future vaccines targeting an array of 
microbial infections. 
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FIGURES 
 
Figure 3.1. IL-33-elicited protection against lethal LCMV challenge. (a) Mice (n = 
10/group) were immunized one time i.m. using EP with 10 µg of empty vector control 
plasmid (pVAX) or 10 µg of LCMV-NP with or without 11 µg of mtrIL-33. At day 21 post-
vaccination, mice were either challenged intracranial (i.c.) with (b) 20xLD50 armstrong 
LCMV or (c) 40xLD50 armstrong LCMV and animal survival was monitored for 21 days 
post challenge. Experiments were performed at least two times in independent 
experiments and data are representative of the result. *, P < 0.05; **, P < 0.01. 
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Figure 3.2.  IL-33 induces potent antigen-specific effector CD8 T cells. C57BL/6 
mice (n = 4-5) were immunized once by i.m. followed by EP with 10 µg of NP with or 
without 11 µg of mtrIL-33. Splenocytes were harvested 21 days post vaccination to 
assess the cellular immune responses. ELISpot and ICS assays were stimulated for 18 
hours and 5 hours, respectively, with a final concentration of 2.5 µg/ml   Mice that 
received 10 µg pVAX only served as a negative control. (A) The ability of T cells to 
produce IFNγ in response to DbNP396 epitope (CD8) was determined by IFNγ ELISpot 
assay. (B) Flow cytometry was used to determine the total cytokine (IFNγ, TNFα and IL-
2) frequencies of the DbNP396-specific CD8 T cells induced by mtrIL-33. (C) Column 
graph shows multifunctional subpopulations of single-, double- and triple-positive CD8 T 
cells releasing the cytokines IFNγ, TNFα and IL-2. (D) The antigen-specific cytolytic 
degranulation T cells induced by mtrIL-33 adjuvant were measured by degranulation 
marker expression, CD107a and producing IFNγ. Dot plots show representative 
examples of each mouse group. (E) Splenocytes from mice were labeled with cell tracer 
violet and stimulated with DbNP396 peptide. Cell tracer signals on CD8 T cell population 
were detected by flow cytometry to measure proliferation. (F) After proliferation the % of 
effector CD8 T cells upon stimulation with NPDb396-specific peptide (2.5 µg/ml) was 
assessed. Dot plots show representative figure of CD62L-CD44+ CD8 T cells after 
stimulation. Data shows the SEM of two independent experiments repeated at least two 
to three times. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with NP. 
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Figure 3.3. IL-33 amplifies the percentage of antigen-specific CD8 T cells. C57BL/6 
mice (n = 4-8) were immunized once with 10 µg LCMV-GP (GP) construct with or 
without mtrIL-33 and the Ag-specific CD8 T cell population was monitored during the 
course of vaccination. (A) Kinetics DbGp33(Tet+)-specific CD8 T cells in the blood 
following DNA vaccination with a prime at day 0 and boost with GP alone (red arrow) on 
day 21 post vaccination (dpv). The cells are gated on live CD8+CD44+ T cells. (B-F) At 
day 21, spleens (n =4 per group) were harvested and antigen-specific responses were 
monitored ex vivo with GP33 peptide. (B) Frequency of DbGP33 CD8+ T cells at 21 dpv. 
(C) IFN-γ ELISpot assay used to measure the GP-specific T cells producing IFN-γ on 21 
dpv. (D) Frequency of GP-specific IFN-γ+CD8+, (E) CD107a+CD8+, and (F) T-bet+CD8+ T 
cells at 21 dpv. Data shows the SEM of two independent experiments repeated at least 
two times. *, P < 0.05; **, P < 0.01; no statistical difference in Fig 3 B, C, E. 
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Figure 3.4. IL-33 enhances the expansion of CD8+KLRG1+ effector-memory T cells. 
(A) Vaccine immunization schedule in mice.  B6 mice (n = 4-8) were immunized once 
with 10 µg of GP plasmid with or without 11 µg of mtrIL-33 construct and boosted with 
only GP (red arrow) at 21 days after initial vaccination. Ag-specific responses in the 
blood were monitored as indicated. (B) Gating strategy used to identify the 
DbGp33+CD44+KLRG1+CD8+ T cell population in the blood following vaccination (C) 
Kinetics of the CD8+KLRG1+ T cell population after DNA vaccination. Experiments were 
repeated two times. Population were gated on DbGp33+CD8+CD44+KLRG1+  *, P < 0.05; 
**, P < 0.01; ***, P < 0.001. 
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Figure 3.5. IL-33 promotes phenotypic and functional maturation of DCs. (A) 
Mouse bone marrow dendritic cells (BMDCs) were incubated in medium in the absence 
(sham-PBS) or presence of 100 ng/ml recombinant IL-33 (rIL-33) for 24 hours before 
measurement of the indicated DC surface marker expression by flow cytometery (red, 
isotype-matched control). The data shown represent the results of one experiment 
repeated twice. (B) Supernatants were obtained after BMDCs were incubated in the 
absence or presence of 100 ng/ml for the measurements of the indicated cytokines. 
Shown is the SEM of duplicate wells of one experiment representative of two. *, P < 
0.05; **, P < 0.01; ***, P < 0.001 
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Figure 3.6. IL-33 enhances potent HIV-specific cell-mediated immune responses. 
B6 mice (n = 5/group) where immunized three times i.m. at two week intervals with 10 
µg of HIV Consensus Clade C (ConC) alone or in combination with 11 µg of mtrIL-33. 
One week after last immunization mice were sacrificed and spleens were processed to 
monitor the vaccine induced immune responses. (A) IFNγ ELISpot was performed to 
detect antigen specific cells secreting IFNγ after vaccination. (B &C) Multiparameter flow 
cytometry was used to determine the percentages of both the polyfunctional CD8 and 
CD4 T cell cytokine profiles. The column chart shows the percentage of HIV-specific T 
cells displayed as triple, double and single positive secreting cytokines. Pie charts show 
the relative proportion of each cytokine subpopulation. Experiments were performed at 
least two times with similar results. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared 
with ConC group. 
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DISCUSSION 
Interleukin 33 is a pleiotropic cytokine whose properties extend beyond TH2 
responses. We show here that IL-33 is capable of inducing and modulating TH1 
responses (6). However, the biological role of IL-33 as an adjuvant in vaccines remains 
to be further elucidated. The mature form of IL-33 delivered as an adjuvant remarkably 
augments LCMV-specific cell-mediated antiviral immunity and provides substantial 
protection against a high-dose lethal LCMV challenge.  
The LCMV model of infection is well established with great applicability to 
investigations regarding vaccine-induced immunity. In a previous study, we showed that 
mice immunized once with a LCMV-NP DNA vaccine yielded 67% protection after a 
20xLD50 lethal dose of LCMV challenge (11). Therefore, we sought to investigate 
whether the inclusion of IL-33 after one immunization would increase its protective 
efficacy since a high frequency of LCMV-specific CD8+ T cells is considered a critical 
characteristic against an LCMV infection (12-16). Here, the coadministration of IL-33 not 
only increased the magnitude of IFNγ spot-forming NP396-specific CD8 T cells, but also 
improved their polyfunctionality, increased the cytolytic phenotype of the CD8 T cells, 
and their effector memory differentiation. As measured by IFNγ ELISpot for the specific 
CD8 T cell epitope DbNP396-40, the inclusion of IL-33 induced a 2.5-fold greater response 
compared to NP-alone immunization. IL-33 also induced greater responses compared 
with our previous LCMV-NP DNA vaccine study, where 25 μg of pLCMV-NP 
administered i.m. twice at two week intervals only elicited ~1400 SCFs per 106 
splenocytes (11). Nevertheless, although our IL-33 adjuvant approach matched the 
immunogenicity of the 35 μg of LCMV-NP dose that elicited 100% protection eventually 
after three immunizations (11), our IL-33-assisted DNA vaccination conferred 100% 
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protection only after one immunization (Figure 3.1). Furthermore, we show that IL-33 
enhanced the polyfunctional CD8+ T cell populations secreting IFNγ+TNFα+IL2+, 
IFNγ+TNFα+ and IFNγ+ and elicited a greater Ag-specific CD8 cytolytic degranulation 
(Figure 3.2). We find this data in accordance with our previous findings that IL-33 can 
increase the Ag-specific cell-mediated immune response when coadministered with a 
DNA vaccine (5) and with others (4,6). The reasons behind the role of IL-33 to enhance 
the frequency of CD8 T cells are not entirely clear. Nevertheless, recently Luzina et al. 
have shown in a vaccine delivery approach that mature IL-33 (the same isoform used in 
our vaccine) effect is ST2-dependent (24). Moreover, substantial research has shown 
the ST2 is important for IL-33 action as mice deficient in ST2 are entirely unresponsive 
to IL-33 (25). Therefore, the ability of CD8 T cells to respond to IL-33 is a possible 
explanation for the augmentation, as activated differentiated CD8 T cells can upregulate 
their cognate binding receptor ST2 (4,26) and therefore lead to more memory cells 
capable of responding to rechallenge. More importantly, consistent with the markedly 
enhanced cytotoxic CD8 T cell activity and the higher levels of NP396-specific effector 
memory CD8 T cells, the challenge studies using two different lethal doses of LCMV 
(Figure 3.1) validate IL-33’s potent adjuvant properties, ultimately to improving antiviral 
vaccine efficacy (4,5).  
 The inclusion of adjuvants in vaccine formulations has long been a method of 
improving vaccine efficacy, but how adjuvants alter the phenotype and differentiation of 
T cells still remain unknown. Current studies have shown that the characteristic profiles 
of Ag-specific T cell responses can be correlated with superior disease protection 
(18,19,27-29). Therefore, to examine the biological function of mtrIL-33 to expand and 
differentiate the CD8 T cells, we coadministered mtrIL-33 with an LCMV-GP DNA 
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vaccine to monitor the DbGP33 tetramer-specific T cells after immunization. In 
accordance with our previous data (5), we show that mtrIL-33, similar to full-length IL-33, 
can significantly amplify GP33+CD8+ T cell responses in the peripheral blood in a 
vaccine setting. Nevertheless, although not significant, a similar trend was observed 
whereby the frequency of GP33+CD8+ T cells in the spleen was higher in the IL-33 
vaccinated group (Figure 3.3B). These results substantiated IL-33’s cytokine property to 
mediate the expansion of CD8 T cells. In addition, we show that IL-33 also induced 
significant expansion of Ag-specific CD8+KLRG1+ T cells in the periphery (Figure 3.4c), 
as previously reported (4,5). These results can be explained by the ability of IL-33 to 
induce the trafficking of effector–memory T cells out of the spleen and into the periphery 
(Figure 3.4c), migrating to the site of infection to initiate immediate effector function (30-
32) and protective immunity as illustrated in figure 3.1. Moreover, the significant higher 
recall responses of the Ag-specific CD8 T cells 8 days after boosting (Figures 3.3a and 
3.4c) was due to higher basal levels of responses which likely correlated with IL-33’s 
adjuvant effect. We find these results in accordance with Olson et al demonstrating that 
this population can expand after boosting (18). These findings further support the notion 
that effector-memory CD8 T cell responses can mediate potent protective immunity 
against certain pathogens (18,19). CD8+KLRG1+ T cells are usually considered as short-
lived effector cells (22), and together, with recent reports demonstrating vaccines 
eliciting persistent effector-memory CD8 T cells may be essential for developing 
effective viral and cancer vaccines (27-29), suggest IL-33 as a suitable adjuvant for 
therapeutic vaccines. However, IL-33’s role as a suitable adjuvant for preventative 
vaccines cannot be negated. On the contrary, new reports have suggested that KLRG1 
expressing CD8 T cells may be capable of surviving long-term (18,19,30). And given that 
in this study IL-33 was administered in a prophylactic setting may also qualify IL-33’s 
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utility as a preventative vaccine adjuvant. Nevertheless, because preventive vaccines 
should induce long-lasting Ag-specific responses, we are currently pursuing the role of 
IL-33 to induce central memory CD8 T cells.  
One molecular mechanism behind IL-33’s potential to drive the formation and 
differentiation of effector memory CD8 T cells is likely due to its ability to significantly 
increase T-bet expression in CD8 T cells in vivo (Figure 3.3f). Joshi and colleagues 
have shown that overexpression of T-bet is enough to induce the formation of KLRG1+ 
effector cells and that CD8 T cells lacking T-bet are impaired in forming these cytolytic 
effector cells (32). Therefore, our data further support the notion that an increase in T-
bet is associated with effector CD8 T cell differentiation and their ability to have CTL 
phenotype. This finding also supports previous data showing that in vitro IL-33 can 
increase T-bet expression (26). Binfeng Lu and colleagues also reported that IL-33 
promoted the effector CD8 T cells synergistically with TCR and IL-12 signaling (26). 
Therefore, given that the expression of T-bet in T cells is known to be induced by a 
combination of T-cell receptor and IFNγ signaling, could explain one underlining 
molecular mechanism by which IL-33 promotes effector-memory CD8 T cells (22,32,33). 
Nevertheless, further studies are needed to further elucidate these mechanisms and 
how IL-33 alters the transcriptional programs to induce memory T cell differentiation. 
Interestingly, IL-33 was also associated with inducing the chemokines, CXCL9 
(MIG) and CXCL10 (IP-10). These two chemokines have been reported to play a critical 
role in (1) recruiting T cells into the inflammatory sites, (2) vaccine-induced T-cell 
infiltration into the tumor, and (3) driving effective TH1/CD8 T cell responses (34-43). To 
the best of our knowledge, this is the first time these two cytokines have been reported 
to be associated with IL-33. This provide further insight to one of the many potential 
99 
 
roles behind IL-33’s ability to elicit robust effector T cell generation and trafficking in the 
periphery that may have correlated with IL-33’s protective role in viral immunity as 
established in this study. Furthermore, this provides further insight to our previous 
finding on how IL-33’s may have induced complete tumor regression in a therapeutic 
HPV-tumor model (5). In fact, MIG and IP-10 have been shown to inhibit tumor growth 
by recruiting effector T cells to tumors (44-46). Therefore, these cytokines critical roles 
for attracting T-cells to the site of infection, may explain IL-33’s functional role on the 
impact of CD8 T cells observed in our study, recruiting the right type of immune cell 
infiltration necessary to facilitate viral immunity. We are currently investigating IL-33 
roles on DC maturation and function during vaccination in vivo. Indeed, this data 
prompts further questions about how IL-33 acts on innate and adaptive immunity and 
how it bridges both arms of the immune system in vivo. 
The goal of incorporating immunoadjuvants in vaccines is to regulate, modulate, 
and enhance the desired adaptive responses to prevent disease acquisition and/or 
progression. Therefore, understanding the biological functions and immunological 
mechanisms of immunoadjuvants can allow us to better understand correlates of 
vaccine immunogenicity, ultimately resulting in the design of better vaccines. Here we 
demonstrate that the administration of IL-33 serves as potent adjuvant improving 
vaccine efficacy by augmenting the frequencies of effective Ag-specific CD8 T cells, 
ultimately leading to significant antiviral protection in a widely used challenge model. 
This report also reveals new critical insight into the biological properties of IL-33 to 
perpetuate the differentiation of Ag-specific memory CD8 T cells during vaccination. 
Consideration of these findings may facilitate the development of better vaccine as well 
as to improve immune responses against cancer.  
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ALARMIN IL-33 ELICITS POTENT TB-SPECIFIC CELL-MEDIATED RESPONSES 
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ABSTRACT 
Tuberculosis (TB) still remains a major public health issue despite the current available 
vaccine for TB, Bacille Calmette Guerin (BCG). An effective vaccine against TB remains 
a top priority in the fight against this pandemic bacterial infection. Adequate protection 
against TB is associated with the development of TH1-type and CD8 T cell responses. 
One alarmin cytokine, interleukin 33 (IL-33), has now been implicated in the 
development of both CD4 TH1 and CD8 T cell immunity. In this study, we determined 
whether the administration of IL-33 as an adjuvant, encoded in a DNA plasmid, could 
enhance the immunogenicity of a TB DNA vaccine. We report that the co-immunization 
of IL-33 with a DNA vaccine expressing the Mycobacterium Tuberculosis (Mtb) antigen 
85B (Ag85B) induced robust Ag85B-specific IFNγ responses by ELISpot compared to 
Ag85B alone. Furthermore, these enhanced responses were characterized by higher 
frequencies of Ag85B-specific, multifunctional CD4 and CD8 T cells. Vaccination with IL-
33 also increased the ability of the Ag85B-specific CD8 T cells to undergo degranulation 
and to secrete IFNγ and TNFα cytokines. These finding highlights IL-33 as a promising 
adjuvant to significantly improve the immunogenicity of TB DNA vaccines and support 
further study of this effective vaccine strategy against TB.  
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INTRODUCTION 
Tuberculosis (TB) continues to be one of the most devastating infectious 
diseases existing worldwide and a major threat to global health. The causative agent of 
TB, Mycobacterium tuberculosis (Mtb), infects as many as 8.8 million new individuals per 
year with active TB and is responsible for over 1.4 million deaths annually (1). Against 
this threat, the BCG vaccine remains the only currently licensed TB vaccine approved for 
human use. While BCG has shown to have adequate efficacy against pediatric forms of 
TB, a major drawback has been its inability to protect against adult pulmonary TB (2,3). 
The current lack of an effective vaccine necessitates the urgent development of novel 
vaccine strategies against TB.  
Recently, DNA-based vaccines have shown promise as a therapeutic platform for 
treating established HPV infections, because of their ability to evoke both humoral and 
cell-mediated immunity (4). Furthermore, the delivery of DNA vaccines, along with 
molecular cytokine adjuvants, by electroporation has greatly improved the effectiveness 
of DNA vaccines (5). Together these features make DNA vaccines an ideal approach for 
the development of an efficacious TB vaccine. In the past several decades only a few 
adjuvants have been approved for human use; however, these adjuvants mainly induce 
humoral immunity and CD4 T cell responses with relatively little CD8 T cell responses 
(6,7). Given the trending evidence that an important feature for an effective vaccine 
against Mtb will require both CD4 TH1 and CD8 T cell responses (8-10), it will be 
imperative that new vaccine adjuvants tested induce optimal activation of both CD4 and 
CD8 T cells. 
  Alarmins are a unique group of endogenous molecules that initiate host defenses 
by inducing inflammation, activating wound healing, and perpetuating immune 
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responses (11-13). Alarmins comprise a multitude of molecules, many of which have yet 
to be described.  However, there are several identified alarmin cytokines, which are 
known to differentially induce specific types of immune responses. For instance, both IL-
1a and HGMB1 cytokines have been associated with promoting the generation of TH1 
immune responses (14,15). Specific to this paper, Interleukin 33 (IL-33), a relatively new 
member of the IL-1 pro-inflammatory cytokine family, has been associated with TH2-
driven responses (16,17). Although earlier studies have shown that IL-33 plays a role in 
TH2 immune responses, new confounding evidence also characterizes IL-33 as a potent 
TH1-polarizing alarmin (18-21). Current studies show that IL-33 can contribute to the 
development of TH1-like CD4 and CD8 T cell immunity against infectious diseases and 
cancer (20,21). We, ourselves, recently demonstrated that IL-33 could serve as an 
immunostimulatory molecule to generate effective immune responses by inducing potent 
CD4 TH1 and CD8 antiviral and antitumor immunity in a DNA HPV16 vaccine setting 
(21). Moreover, a recent study by Lee et al. reported a positive correlation between IL-33 
and IFNγ levels in patients with TB pleurisy (22). Here, we investigated whether 
administration of IL-33 expressed as a DNA vaccine construct could increase the 
immunogenicity of an anti-TB DNA vaccine. We found that the co-immunization of IL-33 
with a TB antigen 85B (Ag85B) DNA vaccine enhanced the potency of the Ag85B-
specific CD4 TH1 and CD8 T cell responses. This data encourages further studies 
investigating the potential use of IL-33 as an effective immunoadjuvant for future TB 
DNA vaccine studies and for protection in preclinical challenge models.  
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METHODS 
DNA Construct Designs 
The DNA constructs encoding mature IL-33 (mtrIL-33) and the TB Ag85B construct was 
designed as previously described (21,23). All constructs had highly efficient 
immunoglobulin E (IgE) leader sequences inserted at the 5′ end of the gene. The 
constructs were commercially synthesized and optimized as described previously 
(21,23). 
 
Animals 
All animals were conducted and maintained in accordance with the NIH and the 
University of Pennsylvania Institutional Animal Care and Use Committee guidelines. 
Female C57BL/6 8-week-old mice were purchased from Jackson Laboratory (Bar 
Harbor, ME).  
 
Animal Immunizations 
C57BL/6 mice (n = 4 per group) were immunized twice, two weeks apart,   
intramuscularly (i.m.) in the tibialis anterior muscle. In vivo electroporation (EP) was 
delivered, with the CELLECTRA adaptive constant current EP device (Inovio 
Pharmaceuticals), at the same site immediately following vaccination as previously 
described (21,23). The mice were immunized with either 10 μg pVAX1 or 10 μg Ag85B 
with or without 11 μg of mtrIL-33 construct. One week after final immunization, mice 
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were sacrificed and splenocytes were harvested to measure immune responses. All 
studies were repeated at least twice.  
 
ELISPOT Assay 
All spleens were processed and IFNγ ELISpot assays were performed to determine 
antigen-specific cytokine secretion. Briefly, spleens were collected in RPMI 1640 
medium (supplemented with 10% FBS, 1X Antibiotic-Antimycotic, and 1X β-ME) and 
splenocytes were isolated by mechanical disruption of the spleen using a Stomacher 
machine (Seward Laboratory Systems, Bohemia, NY). The resulting mashed spleens 
were filtered using a 40µm cell strainer, treated with ACK lysis buffer for 5 minutes to 
lyse RBCs, washed in PBS and then re-suspended in RPMI medium for use in ELISpot 
or Flow Cytometry assay. The IFNγ ELISPOT assays were conducted as previously 
described in detail (21,23). Ag85B-specific T cell responses were measured by 
stimulating splenocytes with pooled peptides (11-mers overlapping by 8 amino acids; 2.5 
µg/ml final) spanning the entire TB Ag85B antigen (Invitrogen). All peptides were 
synthesized from GenScript. Concavalin A (Sigma-Aldrich, St. Louis, MO) was used as 
positive control and complete culture medium was used as negative control. Background 
staining from cells stimulated with medium alone has been subtracted. Spots were 
enumerated using an automated ELISPOT reader (Cellular Technology, Shaker Heights, 
OH).  
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Intracellular Cytokine Staining Flow Cytometry 
Intracellular cytokine staining was performed after 5 hours of ex vivo stimulation with 
Ag85B pooled peptides as described (21-24). In cultures being used to measure 
degranulation, anti-CD107a (FITC; clone 1D4B; Biolegend) was added during time of 
stimulation to capture the degranulation induced by exposure to antigen stimulation by 
Ag-specific cells. The cells were then fixed and stained as described elsewhere (21-24). 
The following antibodies were used for surface staining: LIVE/DEAD Fixable Violet Dead 
Cell stain kit (Invitrogen), CD4 (V500; clone RM4-5; BD Biosciences), CD8 (APC-Cy7; 
clone 53-6.7; BD Biosciences). For intracellular staining the following antibodies were 
used: IFNγ (APC; clone XMG1.2; Biolegend), TNFα (PE; clone MP6-XT22; ebioscience), 
CD3 (PerCP/Cy5.5; clone 145-2C11; Biolegend), and IL-2 (PeCy7; clone JES6-SH4; 
ebioscience). All data was collected using a LSRII flow cytometer (BD Biosciences) and 
analyzed using FlowJo software (Tree Star, Ashland, OR) with SPICE v5.3 (free 
available from http://exon.niaid.nih.gov/spice/). Boolean gating was performed using 
FlowJo software to examine the polyfunctionality of the T cells from vaccinated animals. 
For flow cytometry, cells were gated on singlets using SSC-H by SSC-A followed by 
gating on LIVE-DEAD, CD3+CD4+CD8- T and CD3+CD8+CD4- T cells to examine the 
CD4 and CD8 T-cell populations. 
Statistical Analysis 
Group analyses were completed by matched, two-tailed, unpaired student’s t-tests to 
analyze statistical significance of all quantitative data produced in this study. A P<0.05 
was considered statistically significant. All values are mean ± SEM and statistical 
analyses were performed using GraphPad Prism (La Jolla, CA). 
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RESULTS 
IL-33 enhances TB Ag85B-specific IFNγ responses after in vivo vaccination 
We have previously shown that IL-33 delivered as an immunoadjuvant can 
induce TH1 responses in a DNA vaccine setting (21). Therefore we examined whether 
IL-33 could increase vaccine potency when co-administered with a DNA vaccine 
encoding the TB antigen 85B (Ag85B). To this end, C57BL/6 mice were immunized 
intramuscularly with 10μg of Ag85B with or without 11μg of IL-33, immediately followed 
by electroporation (EP) (Figure 4.1A). One week after final immunization the magnitude 
of Ag85B-specific IFNγ production was measured by IFNγ ELISpot assay. As shown in 
figure 4.1B, the addition of IL-33 increased the Ag85B-specific IFNγ T cell-secreting 
responses. Compared to the Ag85B alone-immunized group (~333 SFC per million 
splenocytes), the IL-33 vaccinated group resulted in a 3-fold increase (~1062 SFC per 
million splenocytes) in the frequency of Ag85B-specific responses (Figure 4.1B). These 
results suggest that IL-33 functions as an effective adjuvant to augment the TB antigen-
specific responses during DNA vaccination. 
 
IL-33 significantly increases TB Ag85B-specific CD4 and CD8 splenic T cell 
responses 
Next we were interested in whether IL-33 could enhance both the CD4 and CD8 
T cell responses to Ag85B, so we carefully characterized the phenotype and cytokine 
profile of the 85B-specific T cells generated. To that end, one week after last 
immunization (Figure 4.1A), splenocytes were stimulated ex vivo with Ag85B pooled 
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peptides and the production of IFNγ, TNFα, and IL-2 by CD4 and CD8 T cells was 
analyzed by intracellular cytokine staining (ICS). Compared to Ag85B vaccination alone, 
the IL-33 adjuvant group induced significantly higher percentages of Ag85B-specific CD4 
T cells, many of which were multifunctional (Figure 4.2D). These T cells were described 
by total IFNγ (Ag85B: 0.8%; mtrIL-33: 1.6%), TNFα (Ag85B: 0.9%; mtrIL-33: 1.6%), and 
IL-2 cytokine production (Ag85B: 0.30%; mtrIL-33: 0.51%) (Figures 4.2A-C). As shown 
in figure 4.2D, vaccination with Ag85B co-administered with IL-33 elicited substantially 
higher frequencies of TB-specific CD4 T cells producing dual IFNγ+TNFα+ (Ag85B: 
0.43%; mtrIL-33: 0.95%) or triple-positive IFNγ+TNFα+IL-2+ (Ag85B: 0.24%; mtrIL-33: 
0.47%) in the spleens (Figure 4.2D). In terms of CD8 T cells, we saw a similar trend with 
the vaccinated IL-33 group, which induced higher percentages of TB-specific CD8 T 
cells producing total IFNγ (Ag85B: 0.19%; mtrIL-33: 1.12%), total TNFα (Ag85B: 0.29%; 
mtrIL-33: 1.1%), and total IL-2 cytokine responses, although IL-2 responses were not 
significant (Figures 4.3A-C). However, we found that  immunization with IL-33 
predominately elicited higher frequencies of TB-specific CD8 T cells producing dual 
IFNγ+TNFα+ (Ag85B: 0.12%; mtrIL-33: 0.92%)(Figure 4.3D). The administration of IL-33 
produced similar amounts of Ag-specific CD4 and CD8 T cell responses with the 
majority of T cell subsets simultaneously secreted both IFNγ and TNFα.  Subsequently, 
we analyzed the cytotoxic ability of the vaccine-induced CD8 T cells to undergo 
degranulation, which was measured by staining with antibody to CD107a, a marker for 
degranulation. Compared to Ag85B alone-vaccinated mice (IFNγ+CD107a+: 0.2%), the 
CD8 T cells isolated from mice vaccinated with IL-33 showed significantly higher 
percentages of Ag-specific CD8+CD107a+ T cells secreting IFNγ (IFNγ+CD107a+: 1%)  
(Figure 4.4A). The IL-33 immunized mice also elicited substantially higher polyfunctional 
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CD8 T cells co-expressing CD107+IFNγ+TNFα+ (Ag85B: 0.11%; mtrIL-33: 0.91%), 
compared with the control groups (Figure 4.4B). Altogether, the inclusion of IL-33 can 
elicit robust levels of TB-specific TH1 driven cell-mediated immune responses. 
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FIGURES 
 
Figure 4.1. IL-33 enhances TB-specific IFNγ cellular immune responses in 
immunized mice. (A) Immunization schedule in mice. C57BL/6 mice (n = 4) were 
immunized twice, with a two-week interval between immunizations, with 10 µg Ag85B 
construct with or without 11 µg of IL-33 construct. (B) The total magnitude of IFNγ 
responses induced by isolated mice splenocytes (n = 4) stimulated ex vivo with Ag85B 
pooled peptides for 24 hours and measured by IFNγ ELISpot assay. The Data shows the 
SEM of one experiment repeated at least two times. **, P < 0.01 
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Figure 4.2. IL-33 augments cytokine production by Ag85B-specific CD4 T cells 
following DNA immunization. Cytokine-recall responses to TB Ag85B antigen were 
measured one week after last immunization by ICS and flow cytometry. A-C, column 
graphs depict the total TB-specific CD4 T cells expressing IFNγ (A), TNFα (B) and IL-2 
(C). (D) Polyfunctional flow cytometry was used to determine the percentages of 
multifunctional CD4 T cell cytokine profiles. The bar chart shows the percentage of 
Ag85B-specific CD3+CD4+ T cells displaying triple, double, or single release of the 
cytokines IFNγ, TNFα, and/or IL-2+. Pie charts show the proportion of each cytokine 
subpopulation to Ag-specific stimulation. Experiments were performed independently at 
least twice and data represent the mean ± SEM of four mice per group. *, P < 0.05 
compared with Ag85B non-adjuvanted group. 
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Figure 4.3. Induction of enhanced cytokine production of Ag85B-specific CD8 T 
cells following DNA immunization with IL-33. Cytokine-recall responses to TB Ag85B 
antigen were measured one week after last immunization by ICS and flow cytometry. A-
C, column graphs depict the total TB-specific CD8 T cells expressing total IFNγ (A), 
TNFα (B) and IL-2 (C). (D) Polyfunctional flow cytometry was used to determine the 
percentages of multifunctional CD8 T cell cytokine profiles. The bar chart shows the 
percentage of Ag85B-specific CD3+CD8+ T cells displaying triple, double, or single 
release of the cytokines IFNγ, TNFα, and/or IL-2. Pie charts show the proportion of each 
cytokine subpopulation to Ag-specific stimulation. Experiments were performed 
independently at least twice and data represent the mean ± SEM of four mice per group. 
***, P < 0.001; **, P < 0.01; *, P < 0.05 compared with Ag85B non-adjuvanted group. 
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Figure 4.4. IL-33 promotes Ag85B-specific cytotoxic degranulating CD8 T co-
expressing IFNγ and TNFα. (A) Ag85B-specific, cytolytic-degranulation CD8 T cells 
were measured by degranulation marker expression, CD107a and IFNγ. Figure (B) 
shows the frequency of polyfunctional CD8 T cells co-expressing CD107a. Data 
represent the SEM of 4 mice per group. The experiment was repeated twice with similar 
outcome. **P < 0.01, *P < 0.05 using Student’s t-test. 
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DISCUSSION 
It has been established that the development of an acquired cellular immune 
response (both TH1-type CD4 and CD8 T cells) is paramount for the control of Mtb 
infection. These T cell populations secrete essential cytokines (IFNγ+ and TNFα+), which 
stimulate infected macrophages to kill intracellular bacteria (25-27). Additionally it has 
been shown that knockout mice that have been genetically altered to eliminate IFNγ+ or 
TNFα+ production are more susceptible to mycobacterial infection (25-27). Therefore, 
the development of new molecular adjuvants to drive these preferable anti-TB immune 
responses may potentially lead to a more effective vaccine against TB.  
 The data presented here demonstrates that IL-33 delivered as a molecular 
adjuvant can evoke significant Ag85B-specific cell-mediated immune responses in a TB 
DNA vaccine setting. We show that co-administration of IL-33 with Ag85B DNA EP 
immunization markedly increases the magnitude of Ag-specific IFNγ responses by 
ELISpot. The inclusion of IL-33 induced a ~3-fold greater response compared with to 
Ag85B-alone immunization (Figure 4.1B). We find this in accordance with previous data 
showing that administration of IL-33 along with vaccine antigen can increase the 
vaccine-induced TH1 responses (20,21).  Furthermore, we show that IL-33 can increase 
the total splenic CD4 T cells and CD8 T cells secreting IFNγ and TNFα after Ag85B 
peptide pool stimulation (Figures 4.2-4.3). Given the importance of multifunctional 
vaccine-induced anti-TB protective CD4 T cell responses to prevent disease after 
exposure and to control Mtb in a latent state (28,29), we assessed the polyfunctionality 
of the CD4 T cells (Figure 4.2). The Ag85B vaccine co-administered with IL-33 elicited a 
significant enhancement of the polyfunctional CD4 T cell population simultaneously 
secreting both IFNγ+TNFα+ and IFNγ+TNFα+IL-2+ cytokines (Figure 4.2D). The triple 
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positive IFNγ+TNFα+IL-2+ and double positive IFNγ+TNFα+ T cell phenotypes normally 
represent effector memory and central memory T cells (30), indicating the induction of 
memory CD4 T cell immune responses. Within the cytokine-producing CD8 T cells, the 
proportional distribution of polyfunctional T cell subsets followed the order of IFNγ+TNFα+ 
being greater than IFNγ+ (Figure 4.3D). IL-33 not only improved the polyfunctionality of 
the CD8 T cells, but also increased their antigen-specific cytolytic phenotype activity as 
demonstrated by the co-expression of CD107a+IFNγ+TNFα+ (Figure 4.4B). Moreover, IL-
33 significantly enhanced the vaccine-induced total CD4 T cells secreting IL-2 responses 
(Figure 4.2C), a cytokine that is secreted predominately by Ag-stimulated CD4+ T cells 
(31-33). IL-2 also plays a crucial role in driving CD8 T cell differentiation, proliferation, 
and activation and therefore enhancing the Ag-specific CD8 effector functions (Figure 
4.3 & 4.4), such as cytolytic activity and cytokine production (8,9). Altogether, the data 
highlight adjuvant effects of IL-33 to augment vaccine potency of both CD4 and CD8 T 
cells, which would be indispensable for protective immunity against TB (8-10).  
These results are in agreement with our previously published data that 
demonstrated that IL-33 could enhance both CD4 TH1 and CD8 T cell responses with 
cytolytic properties (21). Furthermore, this finding is consistent with the recent reports 
that IL-33’s role extends beyond TH2 immunity; IL-33 can promote TH1 and CD8 type 
cell-mediated immunity given the appropriate cytokine milieu and microenvironment (16-
21). Recent reports suggest that IL-33 can be a potent inducer of CD8+ T cells, as only 
activated effector CD8 T cells can up-regulate the IL-33 cognate receptor, ST2, and in 
synergy with IL-12 can selectively enhance the expression of IFNγ responses (20). The 
mechanism by which IL-33 promotes TH1 CD4 and CD8 T cell differentiation is still 
unknown.  In our study, it is possible that the co-induction of type 1 cytokine IFNγ could 
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be related to our selected antigen, Ag85B, which is a potent TH1 antigen (34,35). 
Therefore, the favored TH1 cytokine milieu perpetuated by our selected TB antigen may 
have induced a favorable immune environment that allowed IL-33 to foster a greater TH1 
cell-mediated immune response. Further studies are needed to understand exactly how 
IL-33 induces type-1 TH1 IFNγ+ responses in the context of an in vivo immune setting. In 
addition, studies are needed to understand how IL-33 bridges the innate with the 
adaptive immune response to evoke a pro-TH1 cell-mediated response. 
Overall, in this study we further validate IL-33 as a future potent TH1- and CD8-
mediated immunoadjuvant in a DNA vaccine setting. IL-33 may be an effective strategy 
for increasing the efficacy of future DNA vaccines against Mtb. Since Mtb infection 
targets the lungs, current studies are evaluating the ability of IL-33 to induce 
polyfunctional antigen-specific T cells in the lungs. Furthermore, although IL-33 can elicit 
desired cell-mediated responses, it can also be detrimental to subjects at risk for HIV. 
The immune activation induced by IL-33 could pave the road for more efficient 
acquisition of HIV infection. Thus, challenge studies will be important to confirm the 
protective nature of IL-33 as a vaccine adjuvant in a relevant challenge system. 
Experiments are currently under way to test the protective efficacy of IL-33 against Mtb 
both as a standalone and as a prime-boost immunization regimen in combination with 
BCG. 
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CHAPTER 5 
 
UBIQUITIN-LIKE MOLECULE ISG15 ACTS AS AN IMMUNE ADJUVANT TO 
ENHANCE ANTIGEN-SPECIFIC CD8 T CELL TUMOR IMMUNITY 
 
 
“This day is full of glorious victory, 
Echoes of conquest whisper from afar 
In every wave of the remembering sea.”  
 -H. Begbie 
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Abstract  
ISG15 is an ubiquitin-like protein induced by type I interferon associated with antiviral 
activity. ISG15 is also secreted and known to function as an immunomodulatory 
molecule. However, ISG15’s role in influencing the adaptive CD8 T cell responses has 
not been studied. Here, we demonstrate the efficacy of ISG15 as a vaccine adjuvant, 
inducing HPV E7-specific IFNγ responses as well as the percentage of effector-like 
memory, polyfunctional, and cytolytic CD8 T cell responses. Vaccination with ISG15 
conferred remarkable control and/or regression of established HPV-associated tumor-
bearing mice. T cell depletion coupled with adoptive transfer experiments revealed that 
ISG15 protective efficacy was CD8 T cell-mediated. Importantly, we demonstrate that 
ISG15 vaccine-induced responses could be generated independent of ISGylation, 
suggesting that responses were mostly influenced by free ISG15. Our results provide 
more insight into the immunomodulatory properties of ISG15 and its potential to serve as 
an effective immune adjuvant in a therapeutic tumor or infectious disease setting.  
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Introduction  
The induction of cytotoxic CD8 T cells is believed to be essential in tumor control, and, 
thus, a necessary goal for any therapeutic cancer vaccine. Nevertheless, insufficient 
generation of CD8 effector T cells has led to the failure of several therapeutic cancer 
vaccines to produce clinical regression of solid tumors (1-3). For such vaccines, the 
incorporation of adjuvants can assist in generating potent and durable tumor immunity 
(4,5), but most of the effects of adjuvants have been limited to TH1 CD4 expansion with 
poor CD8 T cell killing function induced. Thus identifying adjuvants capable of amplifying 
CD8 T cell antitumor immunity is very important for therapeutic antitumor vaccines.  
 Interferon-stimulating gene 15 (ISG15) is one of the first and most abundant 
proteins induced by type I interferon stimulation (6). ISG15 is an ubiquitin-like protein, 
which plays a major role in antiviral defense (6). Its ubiquitin-like C-terminal (LRLRGG) 
motif is necessary for its conjugation to a variety of intracellular proteins in a process 
known as ISGylation (6) producing “conjugated” ISG15. When not in its conjugated form, 
free or “unconjugated” ISG15 can exist intracellularly or extracellularly. For decades, free 
ISG15 has been implicated in the production of IFNγ (7-9).  Recently, a new study 
confirmed this cytokine-like role for ISG15 by demonstrating that ISG15- deficiency was 
associated with a loss of IFNγ, which in turn led to increased susceptibility to 
mycobacterial disease in both mice and humans (10). Although these studies have 
established the ability of ISG15 to function as an immunomodulatory molecule, its ability 
to influence CD8 T cell immune responses and act as a vaccine adjuvant remains 
unknown. Here we sought to investigate the role of ISG15 as an adjuvant to enhance 
tumor-specific CD8 T cell immunity using a human papilloma virus (HPV)-associated 
tumor murine therapeutic model.  
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Here we report that ISG15 can act as an effective CD8 T cell-mediated adjuvant 
when co-delivered with a HPV16 DNA vaccine via in vivo electroporation (EP). The 
inclusion of ISG15 substantially increased E7-specific IFNγ responses as well as the 
percentage of effector-like memory, polyfunctional, and cytolytic CD8 T cells. 
Importantly, we report that the augmentation of ISG15’s functional CD8-mediated tumor 
immunity achieved control and/or regression of tumors in established HPV-associated 
tumor-bearing mice. We also show that the therapeutic efficacy of ISG15 correlates with 
the increase in magnitude and phenotype of tetramer-specific, effector-memory CD8 T 
cells. Finally, we demonstrate that ISG15 delivered as an immunoadjuvant generates 
responses independent of conjugation as an LRLRGG-mutant ISG15 also induced 
potent CD8 T cell responses. We conclude that ISG15 may be a valuable tool to improve 
the immunogenicity of vaccines against cancer as well as to treat persistent infections.  
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METHODS 
DNA construction and expression 
The GenBank accession no. Q64339 for mouse ISG15 was used to synthesize the DNA 
construct encoding wild-type ISG15 (wtISG15).  Mutated ISG15 (mutISG15) is a variant 
of wtISG15 with point mutations at its C-terminal conjugation site (LRLRGG to 
AAAAGG). All constructs contained highly efficient immunoglobulin E (IgE) leader 
sequence inserted at the 5’ end of the gene. The constructs were commercially 
synthesized and optimized as described previously (5,11). HPV16 plasmid containing 
the E6 and E7 antigens was prepared as previously described (15). In vitro expression 
of both ISG15 constructs was confirmed by Western Blot (WB) analysis using. Human 
rhabdomyosarcoma (RD) cells were maintained in Dulbecco’s modified Eagle’s medium 
(Life Technologies, Grand Island NY USA) and supplemented with 10% heat-inactivated 
fetal calf serum as well as penicillin and streptomycin. After plating 3.0 x105 cells per 
well, transfection was performed using Neofectin (NeoBiolab Cambridge MA) following 
the manufacture’s protocol. Cells were transfected with 2ug of each DNA construct 
including pVAX1 empty vector backbone as a negative control. Following 48 hour 
incubation, cell supernatants were collected and cells were washed with cold PBS. After 
centrifugation, cells were lysed using cell lysing buffer (Cell Signaling Technology 
Danvers, MA) and EDTA free protease inhibitor cocktail (Sigma-Aldrich St. Louis, MO). 
Cell lysate was run on a 10% Tris-Acetate gel with MES buffer (Life Technologies Grand 
Island NY USA) and transferred onto a PVDF membrane (Millipore, Darmstadt, 
Germany). The membrane was block using Odyssey blocking buffer (Licor, Lincoln, 
Nebraska) for three hours at room temperature followed by probing with rabbit anti-
mouse ISG15 (Cell Signaling Technology Danvers, MA) and mouse anti-human β-actin 
(Sigma-Aldrich St. Louis, MO) as a loading control at 4 degrees overnight. After washing 
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with PBS-Tween, secondary goat anti-mouse IRDye 680RD and goat anti-rabbit IRDye 
800 CW (Li-cor, Lincoln, Nebraska) were added for 1 hour at room temperature. The 
membrane was then washed and imaged on the Odyssey CLX (Licor, Lincoln, 
Nebraska). In addition, supernatants were also collected at 48 hours after transfection 
and cytokine secretion was examined by using a CircuLex mouse ISG15 ELISA kit (MBL 
International), according to manufacturer’s protocol. Optical density was measured at 
450nm using a Bioteck EL312e Bio-Kinetics reader (Biotek US, Winooski, VT). All 
supernatants were tested in duplicate with two separate supernatant sample per a 
plasmid. 
 
Animals 
All animals were conducted and maintained in accordance with the NIH and the 
University of Pennsylvania Institutional Animal Care and Use Committee guidelines. 
Female C57BL/6 (H-2b) 8-week-old mice and H2b B6.129S7-Rag1tm1Mom/J mice (Rag1 
KO) were purchased from Jackson Laboratory.  
 
Animal immunizations  
All mice were immunized intramuscularly (i.m.) in the tibialis anterior muscle. In vivo 
electroporation (EP) was delivered, with the CELLECTRA adaptive constant current 
electroporation device (Inovio Pharmaceuticals), at the same site immediately following 
immunization as previously described (11). The mice were immunized with either 5μg 
pVAX1 or 5μg of HPV16 construct with or without 11μg of wtISG15 and mutISG15.  All 
studies were performed at least twice.  
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ELISPOT assay 
Spleens were harvested and processed 7 days following the final immunization as 
previously described (5,11). After spleens were harvested and processed, an IFNγ 
ELISpot assay was performed to determine antigen-specific cytokine secretion from 
immunized mice as described previously in detail (5,11-12). HPV16 Ag-specific T cell 
responses were measured by stimulating splenocytes with E6 or E7 pooled overlapping 
peptides (2.5 µg/ml final concentration of peptide). The E7 overlapping pooled peptides 
contained the CD8 T cell immunodominant HPV16 DbE749-57 epitope (RAHYNIVTF).  
 
Flow cytometry 
Lymphocytes were isolated and processed from the spleen and peripheral blood as 
previously described (5,11,13). Lymphocytes were stained with CD8, KLRG1, and MHC 
class I peptide tetramer to HPV16 H-2DbE749-57 (RAHYNIVTF) (MBL International) as 
described previously (5,14). Intracellular cytokine staining was performed after 5 hrs of 
ex vivo stimulation with the HPV16 E7 peptide DbE7 (RAHYNIVTF) (2.5 µg/ml final 
concentration of peptide) or E7 pooled overlapping peptides to assess CD4 T responses 
(12). In cultures being used to measure degranulation, anti-CD107a (FITC; clone 1D4B; 
Biolegend) was added during time of stimulation to capture the degranulation induced by 
exposure to stimulation by Ag-specific cells (5). The cells were then fixed and stained as 
described elsewhere (5,15). The following antibodies were used for surface staining: 
LIVE/DEAD Fixable Violet Dead Cell stain kit (Invitrogen), CD4 (FITC; clone RM4-5; 
ebioscience), CD8 (APC-Cy7; clone 53-6.7; BD Biosciences), NK1.1 (FITC; clone 
PK136; biolegend); CD49b (FITC; clone DX5; ebioscience). For intracellular staining the 
following antibodies were used: IFNγ (APC; clone XMG1.2; Biolegend), TNFα (PE; clone 
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MP6-XT22; ebioscience), CD3 (PerCP/Cy5.5; clone 145-2C11; Biolegend); IL-2 (PeCy7; 
clone JES6-SH4; ebioscience). All data was collected using a LSRII flow cytometer (BD 
Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, OR) and SPICE 
v5.3 (free available from http://exon.niaid.nih.gov/spice/). Boolean gating was performed 
using FlowJo software to examine the polyfunctionality of the T cells from vaccinated 
animals.  
 
Tumor cell line 
The TC-1 cell line was a graciously given gift from Dr. Yvonne Paterson of the University 
of Pennsylvania, Philadelphia, PA. TC-1 cell line is a well-characterized lung epithelial 
immortalized cell line, constitutively expresses E6 and E7, and is highly tumorigenic 
(16,17). The TC-1 cells were purchased from American Type Culture Collection and 
cultured as previously described (5). 
 
In vivo therapeutic study  
B6 mice were separated into four groups of 10 mice each and 5x104 TC-1 cells were 
subcutaneously implanted into the right flank of each mouse. On day 4, after tumor 
implantation, each group of mice was immunized by intramuscular electroporation with 
pVAX1, HPV16, HPV16/wtISG15 or HPV16/mutISG15 and boosted on days 11, 18, and 
25. Tumor size was measured twice a week using electronic calipers and tumor volume 
calculated as described previously [½(length x width2)]. Mice were monitored twice a 
week for tumor growth and were measured as described previously (5,12). Under Penn 
Institutional Animal Care guidelines, mice were sacrificed when tumor size reached 18-
20mm. 
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In vivo CD8 T cell depletion study 
During therapeutic vaccination, B6 mice were injected intraperitoneal with 200 µg of anti-
CD8 (53-6.72, Bio X cell) one day before tumor inoculation and repeated every three 
days thereafter. Successful T cell depletion was confirmed by flow cytometric analysis of 
peripheral blood mononuclear cells. 
 
T-cell purification and adoptive transfer  
CD8 T cells were isolated from splenocytes of vaccinated B6 mice 1 week after final 
immunization in non-bearing tumor mice (Fig 2A). CD8+ T cells were purified from 
splenocytes using negative selection to deplete CD4+ T cells, B cells, and myeloid cells. 
Briefly, following RBC lysis, splenocytes were incubated with rat IgG anti-CD4 (GK1.5), 
anti-B220 (RA3), anti-CD11b (M170.13), anti-MHC-II (M5/114), and anti-CD16/32 
(2.4G2). Antibody-bound cells were removed using anti-rat IgG magnetic beads (18). For 
adoptive transfer, ~4 x 106 CD8 T cells in 200 µl PBS were injected intravenously via tail 
vein into each H2b B6.129S7-Rag1tm1Mom/J mouse.     
 
Statistical Analysis 
Group analyses were completed by matched, two-tailed, unpaired student’s t-tests to 
analyze statistical significance of all quantitative data produced in this study. A P-value 
<0.05 was considered statistically significant. Error bars indicate SEM and all tests were 
performed using the Prism Software (*, P < 0.05; **, P < 0.01; ***, P < 0.001 compared 
with HPV16 immunization). 
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RESULTS 
Design and expression of ISG15 constructs  
The wild-type ISG15 (wtISG15) adjuvant construct was generated using the 
mouse ISG15 sequence retrieved from GenBank (accession number: Q64339) with 
several modifications (Figure 5.1A). ISG15 contains a C-terminal LRLRGG motif that is 
necessary for its conjugation to a variety of target proteins in a process referred to as 
ISGylation (19-21). In order to determine if conjugation was necessary for ISG15-
mediated immunomodulation, the ISG15 conjugation sequence site was mutated 
(LRLRGG to AAAAGG) to generate the mutant ISG15 (mutISG15), incapable of 
conjugation (Figure 5.1A). Both ISG15 constructs were genetically optimized and 
subcloned into a modified pVAX1 mammalian expression vector (Figure 5.1B). To verify 
the expression of both ISG15 encoding constructs, human rhabdomyosarcoma (RD) 
cells were transfected separately with each vector and examined by WB. As shown in 
Figure 5.1C, an ~15kDa free ISG15 was observed for each in cell lysates harvested 48 
hours after transfection using anti-ISG15 monoclonal antibody (mAb) for detection. 
ISG15 expression was not detected in the negative control pVAX1 group. Next, via an 
enzyme-linked immunosorbent assay (ELISA) the secretion of free ISG15 was 
monitored from the cell supernatants that were obtained 48 hours after transfection of 
RD cells. As projected, supernatants from mutISG15 transfected RD cells had a higher 
concentration of detectable secreted free ISG15 (7.2 ng/ml), compared to wtISG15 (4.4 
ng/ml) (Figure 5.1D). This supported our notion that by mutating ISG15’s conjugation 
motif, more unconjugated ISG15 would be available and secreted to the extracellular 
environment.  
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Immunization with ISG15 adjuvant induced strong HPV E7-specific CD8 T cell 
immune responses.  
To assess the immunogenic properties of ISG15, an IFNγ ELISpot assay was 
performed to determine the number of vaccine-induced E7-specific IFNγ secreting cells 
in response to E7 pooled peptides containing the immunodominant CTL epitope H-2-
DbE749-57 (E7). The immunization regimen is shown in Figure 5.2A. Briefly, groups of B6 
mice (n = 4-5/group) were vaccinated twice at two-week intervals as follows: (i) HPV16 
DNA/EP; (ii) HPV16/wtISG15 DNA/EP; (iii) HPV16/mutISG15 DNA/EP; and (iv) 
pVAX1/EP. The co-administration of HPV16 with wtISG15 resulted in a 3.5-fold increase 
in E7-specific IFNγ responses (~230 SFC/million splenocytes) compared with HPV16 
alone-immunized group (~66 SFC/million splenocytes). ISG15 is an ubiquitin-like protein 
that conjugates to target proteins and is critical for control of certain viral and bacterial 
infections (6). In addition to the conjugated form of ISG15, it is known, that ISG15 is 
present in an unconjugated form (free ISG15) and can also play an important role in 
immunomodulation or during infection (6). Thus, in the same experiment, we examined if 
vaccine-induced responses were independent of conjugation by immunizing mice with a 
mutated form of ISG15 lacking a functional C-terminal LRLRGG conjugating motif. 
Interestingly, similar to wtISG15, the mutISG15 vaccinated group demonstrated an 
increase (~4-fold) in total E7-specific cells compared with HPV16-only group, suggesting 
ISG15 can induce its effects independent of conjugation. We did not find relatively higher 
induced levels of E6-specific vaccine-induced responses (data not shown). Together, 
these data suggest the ubiquitin-like molecule ISG15 can act as an adjuvant to enhance 
and stimulate E7-specific TH1-mediated CD8 T cell responses. Moreover, this data 
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demonstrated that the elevated antigen (Ag)-specific responses were most likely 
attributed to free ISG15.  
 
ISG15-mediated augmentation of polyfunctional HPV E7-specific cell-mediated 
responses 
Considering that CD8+ T cell immune responses are essential in prevention of 
tumorigenesis and elimination of tumors (1,22-25), we further examined the functional 
profile of E7-specific CD8 T cell populations from vaccinated mice to secrete IFNγ, TNFα 
and IL-2 in response to DbE749-57 peptide stimulation. Our gating strategy for intracellular 
cytokine multiparametric flow cytometry analysis is shown in Figure 5.3A. One week 
after final vaccination all tested vaccination regimens induced detectable CD8 T cell 
responses producing all three effector cytokines (Figure 5.3). Compared to the antigen 
alone group, both ISG15 vaccine regimens induced significant E7-specific CD8 T cells 
producing total IFNγ (wtISG15, 0.68%; mutISG15, 0.92%) (Figure 5.3B) and total TNFα 
(wtISG15, 0.42%; mutISG15, 0.54%) (Figure 5.3C). However, ISG15 only induced a 
minor increase of Ag-specific CD8 T cells secreting IL-2 (Figure 5.3D) Importantly, a 
significant number of the E7-specific CD8 T cells were polyfunctional, with ISG15-
immunized groups eliciting significantly higher frequencies of CD8 T cells producing 
either IFNγ alone or dual IFNγ+TNFα+ in the spleens 7 days post vaccinations (Figure 
5.3E). There was also a modest increase in the triple-positive IFNγ+TNFα+IL-2+ CD8 
secreting cells in the ISG15-treated groups. Since ISG15 can have an effect on NK cells, 
we monitored vaccine-induced NK responses, but no significant changes were seen 
after vaccination with ISG15 (Figure 5.4A) (9). Furthermore, the administration of ISG15 
did not increase vaccine-induced CD4 T cell responses as measured by ex vivo E7 
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pooled peptide stimulation (Figure 5.4B).  
 Given that cytotoxic CD8 T lymphocytes (CTL) are critical components in 
protection (1,5,24,25), we assessed the cytolytic properties of the adjuvant-induced CTL 
responses to undergo degranulation and secrete effector cytokines simultaneously 
(Figure 5.5). The groups vaccinated with immunoadjuvant ISG15 showed higher 
percentages of the degranulation marker, CD107a (wtISG15, 2.4%; mutISG15, 3.1%), 
compared with HPV16-alone group (Figure 5.5A). More interestingly, the ISG15-
adjuvanted vaccines elicited substantially higher frequencies of polyfunctional CTLs, with 
a substantial representation of cells showing one, two, and three immunological 
functions (Figure 5.5B-C). Notably, compared to HPV16 administered alone, the ISG15-
treated groups showed significantly higher frequencies of CD8 T cells co-expressing 
CD107a+IFNγ+TNFα+ (wtISG15, 0.35%; mutISG15, 0.43%) (Figure 5.5C). Collectively, 
the high frequencies of effector cells secreting proinflammatory cytokines are indicative 
of the ISG15 cytokine-like properties and its adjuvant effects to enhance vaccine 
potency by diving potent functional effector CTL immunity. Overall, an important 
observation here was that a DNA plasmid expressing the mutISG15, incapable of 
conjugation, maintained the adjuvant effects displayed by wild-type form, suggesting that 
ISGylation is likely not required for immunomodulation of CD8 T cells.  
 
ISG15 adjuvant amplifies robust Ag-specific effector-memory CD8 T cell 
responses  
Since it has been demonstrated that magnitude and quality of E7-specific CD8 T 
cell responses correlates with the therapeutic efficacy of HPV vaccine against 
established tumors (24,26), we investigated the HPV tetramer-specific CD8 T responses 
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that may correlate with vaccine-induced HPV-associated tumor control. To this end, non-
tumor-bearing B6 mice were immunized with the aforementioned vaccination 
formulations and schedule in Figure 5.2A. One week after final immunization, the 
magnitude and subset differentiation of Ag-specific CD8 T cell responses were 
examined using the CD8 epitope specificity of HPV16 E749-57 H2-Db-RAHYNIVTF 
tetramer in the spleen and blood (Figure 5.6). Both wtISG15 and mutISG15 constructs 
were able to significantly increase the DbE7 tetramer-specific CD8 T cell responses in 
the spleen compared to HPV16 group alone (Figure 5.6A and B). In addition, the 
delivery of both ISG15 plasmids also significantly amplified the number of DbE7 
tetramer-specific CD8 T cells in the peripheral blood, suggesting trafficking of tumor 
target-specific CTL’s into the periphery (Figure 5.6E) (26). The frequency of E7-tetramer 
T cells in the blood within the wtISG15 and mutISG15 groups were 4 and 5.5-fold higher 
compared with the nonadjuvanted group, respectively. This data confirmed that 
immunoadjuvant ISG15 could amplify the Ag-specific CD8 T cells.  
It has been suggested that effector-memory CD8 T cells are optimal subsets for 
protective immunity and may predict therapeutic efficacy against tumors (4,5,27,28). 
Effector memory T cells are the focus of cancer vaccines as they can initiate rapid 
effector function and migrate quickly to the infected- or tumor-site (1,29-31). In this 
study, we measured the DbE7 MHC class I tetramer vaccine-induced effector/effector-
memory CD8 T cell subset based on expression marker of KLRG1 (effector memory - 
Teff) (5,14,27) (Figure 5.6). The administration of wtISG15 resulted in a ~3-fold increase 
in the percentages of Teff cells in the spleen, compared with the HPV16-only vaccinated 
group (Figure 5.6C and D). Similarly, the inclusion of mutISG15 also significantly 
enhanced the Teff responses in the spleen (Figure 5.6D). In addition, as shown in Figure 
5.6F, the percentages of Teff cells in the blood were significantly higher in the adjuvant 
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groups. These data suggest that immunoadjuvant ISG15 can enhance the magnitude 
and quality of E7-specific CD8 T cell responses.    
 
ISG15 acted as an effective CD8 T cell immunoadjuvant inducing antitumor 
immunity 
We next determined the therapeutic efficacy of ISG15 in a TC-1 tumor-bearing 
mice model. Naïve recipient B6 mice (n = 10/group) were first inoculated subcutaneously 
with TC-1 tumor (5x104) cells followed by HPV16, HPV16/wtISG15, HPV16/mutISG15 or 
pVAX1 vaccination four days after tumor implantation (tumors had reached an average 
size of 2 mm), followed with three boosts at 1-week intervals (Figure 5.7A). Tumors in 
mice immunized with the mixture of HPV16/wtISG15 grew significantly slower than 
HPV16 vaccinated group alone (Figure 5.7B). In contrast, pVAX1 control group failed to 
show any therapeutic effect with all mice dying by day 35. Interestingly, mice given the 
HPV16/mutISG15 had significantly better tumor control than mice given 
HPV16/wtISG15, likely due to greater induction of tumor-specific CTL responses. In 
addition, compared to HPV16/wtISG15, the HPV16/mutISG15 combination rapidly 
induced regression of more established TC-1 tumors (Figure 5.8). At day 42 post tumor 
implantation, 6/10 mice in the HPV16-mutISG15 were tumor free, compared with either 
HPV16 (1/10) or HPV16-wtISG15 (2/10) (Figure 5.8). Taken together, the adjuvant 
properties of ISG15 demonstrated effective control and therapeutic cure of HPV-
associated tumor-bearing mice.  
Given ISG15 adjuvant properties to enhance E7-specific-CTL responses that are 
essential to target established preexisting HPV infections (22,23), we investigated the 
role of ISG15-elicited CD8 T cells for HPV-associated tumor elimination. Therefore, in a 
therapeutic setting, CD8 T cells were depleted by intraperitoneal injection of anti-CD8 
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antibody, beginning 1 day post-tumor inoculation and repeated every three days 
subsequently (Figure 5.7C). Our results revealed that CD8 depletion significantly 
abrogates the therapeutic effects of ISG15 adjuvancy as no mice survived to 30 days 
post-implantation (Figure 5.7D). To confirm these findings, we performed CD8 T cell 
adoptive transfer experiments in T cell immunodeficient B6 Rag1 KO mice (32). 4 x 106 
CD8 T cells purified from splenocytes of HPV16, HPV16/wtISG15, and 
HPV16/mutISG15 immunized mice (Figure 5.2A) were injected intravenously 4 days 
post-inoculation of TC-1 cells (Figure 5.7E). As compared to HPV16 and naive controls, 
mice that received either wtISG15 or mutISG15 vaccine-induced CD8 T cells had 
significantly slower tumor growth (Figure 5.7F), likely owing to their functional CTL 
phenotype (Figure 5.3 and 5.5). Taken together, the results suggest that ISG15-elicited 
CD8 T cells are essential to prolonging survival and controlling tumor growth in the TC-1 
therapeutic tumor model. 
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FIGURES 
 
Figure 5.1. Generation and expression of ISG15 encoding DNA vaccine plasmids. 
(A) Schematic illustration of ISG15 protein and the amino acid sequences of wild-type 
ISG15 (wtISG15) and mutated ISG15 (mutISG15). The IgE leader sequences are 
underlined. The C-terminal ubiquitin-like conjugation site is bold and underlined. The 
mutation sites introduced into the conjugation motif for mutISG15 (unconjugated form) 
are in red. (B) map of ISG15 constructs. (C) Expression of ISG15 constructs examined 
by Western blot analysis. The lowest band represents free ISG15. (D) Detection of 
secreted wtISG15 and mutISG15 from transfected RD cells were confirmed via ELISA. 
Data represents the means with SEM for two replicate assays.  
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Figure 5.2. Co-delivery of ISG15 DNA vaccination promoted E7-specific CD8 T cell 
immune responses secreting IFNγ production. (A) Immunization schedule for DNA 
vaccine adjuvant study. C57BL/6 mice (n = 4-5/group) were immunized twice at two-
week intervals with HPV16 construct with or without wtISG15 or mutISG15 adjuvant 
constructs via IM/EP delivery. One week after last vaccination, spleens were harvested 
to analyze the Ag-specific CD8 T cell responses. (B) The frequency of E7-specific IFNγ 
(spot forming cells/106 splenocytes) responses induced after each vaccination was 
determined by IFNγ ELISpot assay in response to E7 pooled peptide containing the 
specific CD8 HPV16 E7 epitope (RAHYNIVTF). Data represent 2 independent 
experiments with 4-5 mice per group. *, P < 0.05; **, P < 0.01. Error bars indicate SEM.  
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Figure 5.3. ISG15 induces polyfunctional HPV16 E7-specific CD8 T cells. (A) 
Schematic diagram of gating strategy used to identify Ag-specific CD8 T cell 
populations. (B-D). Column graphs show the percentages of HPV16 E7-specific CD8 T 
cells releasing total cytokines IFNγ (B), TNFα (C), and IL-2 (D) after stimulation with 
DbE749-57-specific peptide. (E) Column chart show polyfunctional subpopulations of 
single-, double-, or triple-positive CD8 T cells releasing effector cytokines: IFNγ, TNFα, 
and IL-2 to E749-57-specific stimulation. Pie charts represent proportion of each cytokine 
population. Experiments were performed at least two times with similar results with 4-5 
mice per group. *, P < 0.05 compared with HPV16 group. Error bars indicate SEM.  
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Figure 5.4. ISG15 had no profound influence on the NK or CD4 T cells. (A) Dot plot 
graphs show the percentages of NK cells in the spleens 1 week after final immunization 
with HPV16, HPV16/wtISG15 or HPV16/mutISG15 groups. (B) Dot graphs show HPV 
E7-specific CD4 T cells releasing IFNγ in response to ex vivo E7 pooled peptide 
stimulation in the spleens. Data was not significant. Experiments were performed at least 
two times (N = 4-5 mice/group). *, P < 0.05; **, P < 0.01. Error bars indicate SEM. 
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Figure 5.5. ISG15 induces HPV16 E7-specific CD8 T cells undergoing cytotoxic 
degranulation following immunization. E7-specific CD8 T cell responses measured 
by intracellular cytokine and CD107a staining after stimulation of splenocytes with 
DbE749-57 restricted (CD8) peptide were examined in all groups of animals 1 wk after final 
immunization. (A) Ag-specific cytolytic degranulation of CD8 T cells measured by 
staining for degranulation marker expression, CD107a. (B and C) Column graph shows 
the frequency of cytolytic CD8 T cells simultaneously expressing only IFNγ (B) or the 
frequency of polyfunctional cytokine producing and/or CD107a expressing CD8 T cells 
(C). Experiments were performed at least twice with similar results with 4-5 mice per 
group. *, P < 0.05; **, P < 0.01 compared with HPV16 group. Error bars indicate SEM 
 
 
 
 
 
 
145 
 
 
Figure 5.6. ISG15 augments the formation of the effector-memory E7-specific CD8 
T cell population. Groups B6 mice (n = 4-5) were immunized twice with HPV16, 
HPV16/wtISG15 or HPV16/mutISG15 at two-week intervals. One week after last 
immunization, both splenocytes and peripheral blood mononuclear cells were strained 
for CD8, DbE749-57 tetramer, and the effector memory KLRG1 marker. (A) Representative 
flow plot showing H2-Db-RAHYNIVTF-restrticted HPV16 E7-specific CD8 T cells in the 
spleen one week after final immunization, or (B) in data represented as a scatter plot 
graph. (C-D) Representative dot plots (C) and compiled data of the percentages of E7 
tetramer-specific KLRG1+CD8+ effector memory phenotype population in the spleen 
(D). (E-F) The percentages of total DbE749-57 tetramer-binding CD8 T cells from the 
peripheral blood (E) and tetramer-specific effector memory CD8 T cells (F). Data is 
representative of at least 2 experiments. *, P < 0.05; **, P < 0.01. Error bars indicate 
SEM.  
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Figure 5.7. The therapeutic effects induced by ISG15 in tumor-bearing mice. (A) 
Schematic representation for therapeutic study. (B) Tumor growth measurement 
after therapeutic DNA/EP vaccination (n = 10). (C) Schematic representation for CD8 T 
cell depletion with therapeutic vaccination. (D) Tumor growth curve of vaccinated groups 
(n = 5) without CD8 T cells. (E and F) schematic representation for T cell adoptive 
transfer study (E). Approximately 4 x 106 CD8 T cells from vaccinated mice were purified 
from splenocytes and adoptively transferred into tumor-bearing T cell immunodeficient 
B6 Rag1 KO mice (n = 5) and assessed for tumor growth (F). All tumor-bearing mice 
were injected subcutaneously with 5x104 TC-1 cells. *, P < 0.05; **, P < 0.01; ***, P < 
0.001. Error bars indicate SEM.  
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Figure 5.8. Inclusion of ISG15 as a vaccine adjuvant improves both tumor control 
and regression in tumor-bearing mice. Groups of C57Bl/6 mice (n = 10/group) were 
injected subcutaneously with 5x104 TC-1 cells. Starting on day 4 after tumor 
implantation, all groups of mice were immunized followed with three boosts at weekly 
intervals. Immunization with ISG15 constructs delayed tumor growth or led to tumor 
regression in tumor-bearing mice. Tumor measurements (average values for each 
individual mice) for each time point are shown only for surviving mice. Mice were 
sacrificed when tumor diameter reached approximately 18-20 mm. Images are 
representative examples of tumor size at day 42 after tumor implantation.  
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DISCUSSION 
ISG15 is known to play a major role in antiviral defense. In addition, it has also 
been reported to function as an immunoregulatory molecule (6). The existence of a 
secreted unconjugated form of ISG15 has been reported to have cytokine-like activity, 
with evidence supporting its ability to induce IFNγ responses (9-13). Thus, this study 
builds on these findings and extends ISG15 research in a therapeutic tumor model 
system.  
Herein, we first report the therapeutic efficacy of ISG15 immunoadjuvant 
properties to augment Ag-specific CD8 T cell tumor immunity. We used a well-
established preclinical HPV therapeutic challenge model to test the adjuvant effects of 
ISG15 in a DNA vaccine setting. The main results of this study are that inclusion of 
ISG15 can (i) increase the polyfunctional Ag-specific CTL responses; (ii) induce effector-
like memory CD8 T cell subset differentiation; (iii) have antitumor therapeutic effects; 
and (iv) elicit vaccine-induced protective immunity independent of conjugation, further 
establishing free ISG15 immunomodulatory properties.  
In this study, we report that the inclusion of ISG15-induced robust Ag-specific 
IFNγ responses. We find this in accordance with previous studies indicating that ISG15 
can induce IFNγ secretion by lymphocytes (7-10). However, we include new evidence 
that ISG15 delivered as a separate molecule in an adjuvant function, can drive CD8 T 
cells to enhance their secretion of IFNγ and TNFα, further adding to the pool of 
information regarding ISG15 immunomodulatory properties on T cells. It is noteworthy to 
report that in this model or approach, ISG15 was not involved in induction of NK cells, as 
previously shown (8). Furthermore, given that CTL functionality represents an important 
correlate of protective capacity against HPV16 established tumors (24,25,33), we report 
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that ISG15 promoted the expansion and Ag-specific cytolytic function of CD8 T cells by 
augmenting the expression of IFNγ, TNFα and the degranulation maker CD107a in 
various combinations. We also demonstrated that ISG15 delivered as an vaccine 
adjuvant, amplified E7 tetramer-specific CD8 vaccine-induced T cell responses.  The 
reasons behind ISG15 ability to enhance the frequency of Ag-specific CD8 T cell 
responses are unknown. However, an study by Casanova and colleagues have shown 
that ISG15 may work in synergy with IL-12, suggesting that ISG15 likely promoted 
enhanced CD8 T cells induction and expansion synergistically with IL-12 (10). In 
addition, the ability of ISG15 to induce IFNγ secretion by lymphocytes, may also suggest 
that ISG15 might bind to a cell surface receptor to modulate immune responses (6). The 
identity of a cell surface receptor for ISG15 has yet to be discovered. Further studies will 
be needed to elucidate the mechanism(s) underlying the adjuvant effects of ISG15 
including soluble ISG15. 
The administration of immunoadjuvants in vaccines has long been a studied as 
an important method of improving their efficacy, or potency. Here we explored the 
antitumor role of ISG15. Prior work in the TC-1 tumor challenge model, has 
demonstrated that this model is CD8 T cell dependent for protection (12,33-35). As 
expected, the results revealed that accordant with the enhance polyfunctional CTL 
responses, administration of ISG15 led to strong inhibition of tumor growth, regression 
and prolonged survival. Moreover, depletion of CD8 T cells in mice nullified the antitumor 
effects of ISG15 and supported the tumors to grow larger compared to the non-treated 
CD8 mAb HPV16 group. These data support that the antitumor activity of ISG15 was 
dependent on CD8 T cells.  Subsequently, as demonstrated in our adoptive transfer 
experiments, CD8 T cells alone can reduce tumor volume, suggesting that the ISG15 
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vaccine-induced CD8 T cell responses must be more functional at clearing HPV-infected 
cells. In this experiment setting, the enhanced induction of E7-specific effector memory-
like T cells may have correlated with the therapeutic efficacy of ISG15-treated groups 
against established tumors. This notion is supported by the enhanced CTL activity 
(Figure 5.4) and E7 tetramer-positive Teff cells in both the spleen and blood of mice 
vaccinated with ISG15 (Figure 5.5). Notably, there were more detectable CD8 Teff cells 
responses in the periphery, suggesting trafficking of target specific CD8 T cells to the 
site of malignancy and initiating immediate effector function (26,31). Our studies appear 
to be supportive of previous work demonstrating that vaccines eliciting higher Teff 
correlated with superior protective immunity against inhibiting tumor growth (1,5,14). 
Therefore, the magnitude and quality of E7-specific CD8 T cell memory population 
correlated with the efficacy of ISG15 treated groups to control or resolve tumors during 
the first 3 weeks of treatment. These potential correlates of immunity may represent a 
major tool for continued development of future tumor vaccines. Consistent with this is 
recent reports indicating that vaccine-induced effector memory may be the best 
prognostic factor for therapeutic vaccines targeting established tumors or latently 
infected pathogens (1,5,27,28). Central memory CD8 T cells elicited by ISG15 may have 
also been important, as central memory T cells are essential features by which vaccines 
can mediate protective immunity (29-31,36). This is an area of further investigation. 
Overall, on the basis of these findings, the improved therapeutic effect by ISG15 is 
associated with Ag-specific CTL responses. 
In the same experimental setting, a highlight of this study was demonstrating that 
the protection afforded by ISG15 was most likely not dependent on its conjugated form, 
but rather on free ISG15. Our results indicated that mutISG15 was able to induce a 
similar trend of robust Ag-specific antitumor T cell responses compared to wtISG15, 
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suggesting that this activity was independent of ISGylation. The immunomodulatory 
property of soluble free ISG15 is in agreement with several studies suggesting that 
ISG15 acts as an immune activating cytokine (37). Both ISG15 constructs did not differ 
enormously in their effectiveness at eliciting E7-specific tumor immunity. Thus, given that 
both forms of the ISG15 constructs exerted similar immunostimulatory effects, the 
phenotypes in CD8 T cells were not dependent on the motif (38). Interestingly, 
mutISG15 was significantly better able to control the progression of established tumors 
compared to wtISG15-adjuvanted treated mice. As more mutant-ISG15 is secreted from 
transfected cells in our experiments (Figure 5.1D), it may orchestrate a more effective 
adaptive response; thus, leading to better control of tumor growth and pathogen 
clearance. However, the manner in which unconjugated secreted form of ISG15 
(mutISG15) is able to induce better antitumor responses compared to wtISG15 is still not 
yet clear. Nevertheless, the ability of the mutISG15 form to induce superior antitumor 
responses highlights its potential to serve as an alternative potent ISG15 adjuvant. In 
addition, it emphasizes that developing new ways to increase the levels of free ISG15 
may be a novel approach to treat cancer and other infectious diseases.  
In summary, the results of the current preclinical study provide more insight into 
the immunomodulatory properties of free ISG15 and its potential to serve as a promising 
vaccine adjuvant in cancer immunotherapy. The results also confirm the notion that 
ISG15 can function as an immunomodulatory molecule. Moreover, the evidence that 
ISG15 can be an effective adjuvant to drive potent CD8 T cell responses, support future 
studies to evaluate its application in TB- or HIV-infection models.  
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CHAPTER 6 
 
ISG15 IS AN INFLAMMATORY MEDIATOR AND IMMUNOADJUVANT FOR 
INFECTIOUS DISEASE 
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ABSTRACT 
 
The significance of the ubiquitin-like protein, interferon-stimulated gene 15 (ISG15), in 
human disease has gained considerably with studies that found ISG15 deficiency 
increases susceptibility to mycobacterial infection among other pathologies.  However, 
the role of ISG15 in the cellular response to intracellular bacterial pathogens and the 
translation of its immunomodulatory properties to novel immunotherapies have not yet 
been explored.  To accomplish this task, we employed the use of ISG15-deficient mice 
and in vivo expression vector to augment expression of murine ISG15 in wild-type mice.  
As with mycobacteria, ISG15-/- mice are highly susceptible to infection with the model 
pathogen, Listeria monocytogenes (LM), and display significantly reduced production of 
IFNγ.  Tissue-specific defects in adaptive immunity to LM were also observed in ISG15-/- 
mice along with impaired dendritic cell maturation suggesting a possible role for ISG15 
in T cell activation and memory formation.  In fact, use of ISG15 as an immunoadjuvant 
enhances virus-specific CD8 T cells responses and provides protective immunity against 
lethal intracranial lymphocytic choriomeningitis virus (LCMV) challenge infection. This 
work elucidates the role of ISG15 as a critical mediator of innate anti-bacterial immunity 
and a potent activator of adaptive immunity, a finding with significant implications in 
immunotherapy development. 
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INTRODUCTION 
Ubiquitin and ubiquitin-like proteins (UBLs) have essential roles in the 
development of functional immune responses (1).  One ubiquitin-like protein, in 
particular, Interferon-stimulated gene 15 (ISG15), is gaining prominence due to its 
specific induction during infection and relevance in human disease (2,3).  ISG15 is highly 
induced during viral infection and mediates protection against influenza, HIV, and 
Sindbis virus infection among others (4,5). Type I Interferon produced during an infection 
induces expression of ISG15, leading to its secretion and, like ubiquitin, conjugation to 
intracellular substrates through the action of a unique enzymatic cascade (6,7). While 
the molecular consequences of ISGylation are yet to be fully elucidated, it can inhibit 
protein ubiquitylation and, therefore, block viral particle release (8-15). 
Recent studies, however, expand the scope of ISG15 function beyond innate 
antiviral defense (16,17).  Bogunovic, et al. discovered that individuals with mutations in 
Isg15 are more susceptible to infection by the intracellular bacterium Mycobacterium 
tuberculosis (Mtb). The increased susceptibility due to ISG15 deficiency in these patients 
correlated with impaired induction of pro-inflammatory cytokines by leukocytes (16,18).  
Interestingly, these data agree with in vitro studies previously performed over twenty 
years ago (19,20). In these studies, recombinant human ISG15 was found to activate 
leukocytes in vitro when added to culture media and induce production of 
proinflammatory cytokines (19). The use of a soluble form of ISG15 to induce these 
immune activating effects is relevant as several studies suggest that ISG15 may have 
immunomodulatory properties in its secreted form (18). Therefore, questions remain 
regarding the immunological functions of ISG15 beyond innate anti-viral immunity. This 
study endeavors to further elucidate this expanded role for ISG15 in immunity and 
translate its immunomodulatory properties to a novel therapeutic strategy.  
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METHODS 
Mice  
ISG15-/- mice and their syngeneic wild-type strain C57BL/6J were obtained from 
Jackson Laboratory (Bar Harbor, ME) and bred and housed in the University of 
Pennsylvania Hill Pavilion Animal Facility and in the TTUHSC Abilene LARC.  Mice were 
kept on a 12-hour light/dark cycle with sterile water and UV-treated or autoclaved 
standard rodent diet. All mouse experiments were performed in accordance with the 
regulations of the Institutional Animal Care and Use Committee of the TTUHSC and 
University of Pennsylvania according to the guidelines of the National Institute of Health. 
 
Bacterial strains 
LM strains were cultured in BHI (Brain-heart infusion, CM1135, Oxoid LTD, Hampshire, 
England) media supplemented with 50 ug/mL of streptomycin, harvested at mid-log 
growth phase (0.6-0.8 at O.D. 600), aliquots flash-frozen in liquid N2, and stored at -
80oC.  LM stock titers were determined by serial dilution of a thawed stock vial, plating of 
dilutions onto BHI-streptomycin agar plates, and counting the colony-forming units 
(CFUs) after 18-24 hrs. at 37oC.  For each infection experiment, a frozen stock vial was 
freshly thawed, bacteria pelleted by centrifugation, and the pellet washed twice with 1X 
phosphate-buffered saline (PBS). 
 
In vitro LM Infection 
Infection of bone marrow-derived macrophage (BMM) was performed as described 
previously (61). For mRNA analysis, BMMs were seeded onto tissue culture-treated 
dishes, incubated overnight, and infected with LM at a multiplicity of infection (MOI) of 
10.  The infected cells were washed, gentamicin was added 30 min after infection, and 
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cells processed for RNA isolation using the RNeasy Mini kit (QIAGEN) according to the 
manufacturer's instructions.  
 
In vivo LM Infection 
For primary infection studies to determine cytokine responses by qPCR and ELISA, 6-8 
week old C57BL/6 and ISG15-/- mice were euthanized three days after intraperitoneal 
(i.p.) injection with 105 CFU of LM in 200μl of sterile 1x PBS.  To determine the role of 
ISG15 in poly(I:C)-exacerbated listeriosis, C57BL/6J and ISG15-/- mice were infected 
i.p. with 104 CFUs of LM alone or administered 150μg of poly(I:C) i.p. two days after LM 
infection. All mice were euthanized on day 4 post-infection and spleens extracted.  
Spleens were processed into single-cell suspensions, serially diluted, plated onto BHI-
agar plates supplemented with 50ug/mL streptomycin and colony-forming units counted 
after overnight growth at 37oC.  For longitudinal infection studies, 6-8 week old C57BL/6J 
and ISG15-/- mice were i.p. injected with 104 CFUs of LM in 200μl of sterile 1x PBS.  At 
experiment end, mice were euthanized and processed for bacterial load.  LM CFUs in 
the spleen and liver were determined as described previously (61).  In Figure 6.1, mice 
were injected with 103, 104, and 105 CFU LM in 200µl of 1x PBS i.p. and euthanized at 
day 4-post infection. Spleens and livers of the infected mice were harvested and LM 
bacterial load determined by serial dilution of single cell suspensions and colony-forming 
units counted after overnight growth on BHI-agar supplemented with 50ug/mL 
streptomycin.  In Figure 6.2, 6-8 week old C57BL/6 and ISG15-/- mice were infected 
with 103 CFU of the attenuated Δacta LM strain, DPL-4029 or virulent LM.  These mice 
along with naïve WT and ISG15-/- mice were subsequently challenged with 
intraperitoneal injection of 105 CFUs LM.  Five days after challenge, mice were 
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euthanized and organs processed for flow cytometric analyses and bacterial load 
determination. 
 
Quantitative PCR 
RNA was isolated from splenocytes and bone marrow-derived macrophages using an 
RNeasy plus mini kit (Qiagen). RNA was quantified using a Nanodrop 
spectrophotometer and 1ug of RNA was converted to cDNA using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). The Step One Plus Real Time 
system from Life Technologies was used for qPCR analysis in combination with FAST 
SYBR Green (Applied Biosystems). To determine relative quantity of target genes 
between groups,18S rRNA was used as a reference. 
 
ELISA 
In Figure 6.1, serum was collected by post-euthanasia heart puncture bleeds and blood 
clots removed after incubation at 4°C for 30 minutes followed by centrifugation.  Serum 
samples were diluted 1:40 and assayed for levels of IFN-γ using the mouse ELISA 
Ready-SET-Go! kit (eBiosciences, San Diego, CA, USA) according to the manufacturer's 
instructions. In Figure 6.2, splenocytes were stimulated with 5 ug/mL of H2-Kb-restricted 
LLO epitope peptide (62), MHC Class I-restricted HIV gag epitope peptide (63), or plate-
bound anti-CD3/CD28 along with 50 U/mL of rhIL-2 overnight and media collected the 
following day. Undiluted conditioned media was assessed for IFNγ and TNFα using the 
mouse ELISA Ready-SET-Go! kit.  Results were obtained at O.D. 450 using a Micro-
plate reader (SynergyHT, BioTek) and analyzed on Gen5 (Ver1.08). 
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Flow cytometric analysis 
In Figure 6.1-6.2, spleens were extracted from mice and placed in 5 mL complete media 
(Corning Cellgro; DMEM 1X; Cat no. 15-013-CM).  Spleens were mechanically 
macerated and passed through 40 um cell strainers (Fisher, Cat no. 22363549, 
22363547) to produce single-cell suspensions.  Cells were treated with ACK lysis buffer 
for 3-5 minutes at room temperature and washed three times in 1x PBS.  Cells were 
suspended in complete media and cell counts determined using a Beckman Coulter Vi-
Cell XR.  For T cell stimulation, 2 x 106 cells were plated in 96-well round-bottom plates 
and stimulated with 5ug/mL of MHC Class II-restricted LLO epitope peptide 
(NEKYAQAYPNVS) (64), MHC Class II-restricted E7 epitope peptide (DRAHYNI) (65), 
or PMA/ionomycin for 6 hours at 37°C, 5% CO2 in the presence of monensin and 50 
U/mL of rhIL-2.  For cell surface staining, splenocytes were stained for various cell 
surface markers after Fc-blockade with anti-CD16/CD32(Clone 93; 14-0161-85) using 
fluorochrome-labeled mAbs (Supplementary information). All samples were acquired on 
an LSRII or LSRFortessa flow cytometer (Becton Dickinson Biosciences, San Jose, 
CA,USA), and data was analyzed using FlowJo software (v10, Tree Star).  In Figure 6.3, 
splenocytes were added to a 96-well plate (1x106/well) and were stimulated with the 
immunodominant LCMV CTL epitope (NP396-404) (66) (Invitrogen) for 5-6 hours at 
37C/5% CO2 in the presence of Protein Transport Inhibitor Cocktail (Brefeldin A and 
Monensin) (eBioscience) according to the manufacturer’s instructions. The Cell 
Stimulation Cocktail (plus protein transport inhibitors) (phorbol 12- myristate 13-acetate 
(PMA), ionomycin, brefeldin A and monensin) (eBioscience) was used as a positive 
control and R10 media as negative control. All cells were then stained for surface and 
intracellular proteins as described by the manufacturer’s instructions (BD, San Diego, 
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CA). Briefly, the cells were washed in FACS buffer (PBS containing 0.1% sodium azide 
and 1% FCS) before surface staining with flourochrome-conjugated antibodies. Cells 
were washed with FACS buffer, fixed and permeabilized using the BD Cytofix/Cytoperm 
TM (BD, San Diego, CA, USA) according to the manufacturer’s protocol followed by 
intracellular staining. Antibodies and reagents for staining are listed in Supplementary 
information.  All data was collected using a LSRII flow cytometer (BD Biosciences) and 
analyzed using FlowJo software (Tree Star, Ashland, OR) and SPICE v5.2 (free 
available from http://exon.niaid.nih.gov/spice/). Boolean gating was performed using 
FlowJo software to examine the polyfunctionality of the T cells from vaccinated animals. 
Dead cells were removed by gating on a LIVE/DEAD fixable violet dead cell stain kit 
(Invitrogen) versus forward scatter (FSC-A). 
 
Plasmid construction 
The GenBank accession no. Q64339.4 for mouse ISG15 was used to synthesize the 
ISG15 plasmid DNA construct. The ISG15 plasmid DNA construct has a highly efficient 
immunoglobulin E (IgE) leader sequence inserted at the 5′end of the gene. The construct 
was commercially synthesized and genetically optimized (codon- and RNA-optimization) 
for expression in mice and then subcloned (all by GenScript, Piscataway, NJ) into a 
modified pVAX1 mammalian expression vector (Invitrogen, Carlsbad, CA).  Plasmid 
expressing pLCMV-NP (NP) was prepared as previously described (34).  
 
Transfection and expression of plasmids 
In vitro ISG15 was confirmed by western blot (WB) analysis. 293T cells were cultured in 
a 6-well plate and transfected with construct using Neofectin transfection reagent 
(NeoBiolab) following manufacture’s protocol. Forty-eight hours later, cells were lysed 
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using modified cell lysis buffer (Cell Signaling) with complete protease inhibitor cocktail 
tablets (Roche) and cell lysate was collected. WB analysis was performed with an anti-
ISG15 antibody (Cell Signaling) and visualized with IRDye 800CW goat anti-rabbit 
antibody (Li-Cor) using the Odyssey imagining system (Li-Cor). β-actin served as a 
loading control and visualized with IRDye 680 goat anti-mouse antibody (Li-Cor). In 
addition, an indirect immunofluorescence microscopy assay was also executed to 
confirm expression of ISG15 DNA construct. Rhabdomyosarcoma (RD) cells were plated 
on two-well chamber slides (BD Biosciences) and grown to 70% confluence overnight in 
a 37oC incubator with 5% CO2. The cells were transfected with 1 μg of ISG15 constructs 
and the control plasmid pVAX (1 μg/well) using TurboFectinTM8.0 Transfection Reagent 
(OriGene) according to the manufacturer’s instructions. Forty-eight hours later the cells 
were fixed on slides using ice cold methanol for 10 min. The cells were stained with anti-
ISG15 mouse monoclonal antibody (Cell Signaling) and subsequently incubated with 
Alexa 555-conjugated anti-rat secondary antibody (Cell Signaling). Slides were mounted 
using Fluoromount G with DAPI (Southern Biotechnology). Images were analyzed by 
florescence microscopy (Leica DM4000B, Leica Microsystems Inc, USA) and 
quantification was conducted using SPOT Advanced software program (SPOTTM 
Diagnostic Instruments, Inc). Secretion of ISG15 was examined by using a CircuLex 
mouse ISG15 ELISA kit (MBL International), according to manufacturer’s protocol. 
 
Vaccinations and LCMV challenge 
Mice were immunized once intramuscularly (i.m.) in the tibialis anterior muscle as 
previously described (29,67). In vivo electroporation was delivered, with the 
CELLECTRA adaptive constant current electroporation device (Inovio Pharmaceuticals), 
at the same site immediately following vaccination as described (67). The mice (n = 5) 
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were immunized with either 10 μg pVAX1 or 10 μg pLCMV-NP with or without 11 μg of 
ISG15 construct. All studies were repeated at least three times. For lethal challenge 
studies, mice were challenged i.c. with 40xLD50 of LCMV Armstrong as previously 
described [34] in 30 μl of virus diluent (PBS with 20% FBS and 1X Anti-Anti (Invitrogen, 
Carlsbad,CA). All mice LCMV challenged were housed in a BSL-2 facility and were 
observed daily for 21 days.  
 
ELISpot assays 
Spleens were harvested 21 days following immunization to monitor vaccine-induced 
responses as previously described (29,67). After spleens were harvested and 
processed, IFNγ ELISpot assays were performed to determine the antigen-specific 
cytokine secretion from immunized mice as described previously (29,67). The LCMV-
specific T cell responses were assessed by stimulating splenocytes with the 
immunodominant H2-Db LCMV CTL epitope (NP396-404 ) (66). 
 
Statistical analysis 
The one-tailed student t test was applied for comparison of the quantitative data of the 
cellular immune responses induced by infection or vaccination. Statistically significant 
outliers were removed from datasets by the ROUT method.  All error bars indicate SEM 
and all tests were performed using the Prism Software (La Jolla, CA) (*, P < 0.05; **, P < 
0.01; ***, P < 0.001). Survival curves were analyzed by log-rank (Mantel-Cox) test.  
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RESULTS 
To determine the relevance of ISG15 in the innate immune response to the 
model pathogen, Listeria monocytogenes (LM), ISG15 gene expression was inspected 
after LM infection in wild-type C57/BL6 mice.  Isg15 mRNA expression was significantly 
induced at the peak of infection on day 3, with 100-fold higher expression of Isg15 in the 
spleen, a major site of infection, compared to uninfected control mice (Figure 6.1A). 
Infection of bone marrow-derived macrophages (BMM) with LM also resulted in a time-
dependent induction of Isg15 and the gene encoding the ISG15 E1 conjugating enzyme, 
Ube1L (Figure 6.1B).  Furthermore, secreted ISG15 protein could be detected in the 
serum of infected WT mice at the peak of LM infection but not in ISG15-/- controls 
(Figure 6.1C). Expression of Isg15 during LM infection was Type I IFN-dependent as 
antibody-mediated blockade of IFN-β significantly blunted the Isg15 induction in LM-
infected BMMs (Figure 6.1D). These data suggest the ISG15 pathway is induced during 
LM infection and is dependent on production of Type I IFN.  In contrast to viral infection, 
Type I IFN exacerbates certain bacterial infections including listeriosis by impairing both 
innate and adaptive responses to LM (21-23).   
To determine if ISG15 mediates Type I IFN exacerbation of listeriosis, WT and 
ISG15-/- mice were infected with LM and Type I IFN was induced by administering a 
dsRNA mimetic molecule, poly (I:C) (21,24). Surprisingly, ISG15 is not necessary for 
Type I IFN-mediated exacerbation of listeriosis and two independent experiments 
suggested that ISG15-/- mice may even be more susceptible to LM infection (Figure 
6.1E).  The role of ISG15 in innate immunity to LM was further explored with a time-
course infection.  On day 1 post-infection, ISG15-/- mice were more resistant to acute 
infection with LM as evidenced by significantly reduced bacterial burden (Figure 6.1F). 
However, bacterial burden was significantly elevated in ISG15-/- mice at the peak of 
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infection on day 3 and continued to rise subsequently in contrast to their wild-type 
counterparts.   We next sought to determine if this result was only relevant at the initial 
infection dose, 104 CFUs, as previous studies have shown dose-dependent susceptibility 
to LM (25). WT and ISG15-/- mice were infected with a log range of infection doses from 
103 CFUs to 105 CFUs of LM. In the spleens of WT mice receiving the lowest dose of LM 
(103 CFUs), only 40% of mice had evidence of listeriosis (Figure 6.1G).  However, 80% 
of ISG15-/- mice had detectable levels of LM in their spleen (Figure 6.1G). Similar 
results were observed in the livers of WT and ISG15-/- mice after receiving the lowest 
dose with 20% and 100% of mice demonstrating listeriosis, respectively (Figure 6.1H). 
Significantly increased listeriosis was also observed at higher starting doses in both the 
spleens and livers of ISG15-/- mice (Figures 6.1G-H).  While NK cell numbers were 
similar (Figure 6.1I), the increased susceptibility to acute LM infection in ISG15-/- mice 
did correlate with significantly reduced expression of splenic ifng and serum levels of 
IFNγ (Figure 6.1J-K), an essential proinflammatory cytokine in the clearance of LM 
infection (26,27).  
As LM virulence has previously been reported to inversely correlate with adaptive 
immunity to LM (23), we sought to determine if ISG15 deficiency also compromised 
adaptive immune responses to LM. After prior vaccination with an attenuated strain of 
LM (DPL-4029), with reduced ability to undergo ActA mediated cell-to-cell spread, WT 
and ISG15-/- mice were challenged with the virulent 10403S strain of LM and 
development of adaptive immunity assessed on day 5 post-infection (Figure 6.2A). Both 
WT and ISG15-/- demonstrated similar induction of LM-specific CD8 T cell immunity in 
the spleen as evidenced by specific production of IFNγ and TNFα after H2-Kb LLO-
epitope296-304 peptide stimulation (Figure 6.2B). In addition, ISG15-/- mice generated 
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similar numbers of LLO-specific splenic CD4 T cells after LM challenge and stimulation 
with LLO190-201 epitope peptide (Figure 6.2C). Furthermore, no deficiencies were 
observed in overall splenic CD4 and CD8 T cell populations of ISG15-/- mice during 
primary and secondary responses to LM (Figure 6.2D-E).  As expected, splenic LM 
bacterial load in previously infected mice was comparable between ISG15-/- and WT 
mice (Figure 6.2F).  However, liver bacterial load in previously infected ISG15-/- mice 
was approximately 100-fold greater than in previously infected WT mice (Figure 6.2G).  
Similar liver-specific defects in adaptive immunity were observed when WT and ISG15-/- 
mice were first infected with a low dose of virulent LM (103 CFUs) prior to high-dose 
challenge (Figure 6.2H-J).  While these results suggest ISG15 may be involved in liver 
immune-privilege (28), the altered adaptive immune response to LM may be due to 
defects in the myeloid compartment. In fact, greater numbers of myeloid cells were 
observed in the spleens of ISG15-/- mice during LM infection, but there were significantly 
fewer conventional dendritic cells to facilitate induction of a robust T cell response to 
control infection in the liver (Figure 6.2K-M).  Furthermore, stimulation of splenic 
dendritic cells with LPS revealed that ISG15 deficiency impairs dendritic cell maturation 
as evidenced by reduced surface levels of costimulatory molecules CD80 and CD86 
(Figure 6.2N-P). Collectively, these results would suggest that ISGylation facilitates T 
cell priming, a function that has not yet been attributed to it. Therefore, ISG15 may be 
important in fostering cell-mediated adaptive immunity by augmenting antigen-
presenting cell number and function.  
The observed results, that ISG15 deficiency impairs IFNγ responses during LM 
infection, led us to determine if these observed immunoregulatory properties of ISG15 
could be leveraged to enhance responses to immune-privileged sites. Therefore, we 
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induced overproduction of ISG15 in wild-type mice by delivering it as a DNA vaccine 
adjuvant to augment T cell-mediated immunity. This in vivo mammalian ISG15 
expression DNA plasmid was developed as previously described (29) (Figure 6.3A).  
Briefly, the mouse ISG15 gene was cloned into the pVAX mammalian expression vector 
under the control of a CMV promoter and with an IgE leader sequence to allow for 
secretion (Figure 6.3A). After transfection of 293T cells with pVAX-mISG15, cells 
proficiently expressed intracellular murine ISG15 as determined by Western Blot 
analysis and fluorescent microscopy (Figures 6.3B and 6.3C, respectively). As shown in 
Figure 6.3C, ISG15 expression was found in the cytoplasm as determined by 
colocalization with the nuclear stain, DAPI (30,31) (Figure 6.3C).  Due to the inclusion of 
an IgE leader sequence, transfection with pVAX-mISG15 also resulted in proficient 
secretion of soluble mouse ISG15 into the culture supernatants from pVAX-mISG15 
transfected 3T3 cells in comparison to empty vector transfected cells (Figure 6.3D). To 
determine if ISG15 could augment CD8 T cell-mediated immunity in vivo, further studies 
were performed with an infection model in which ISG15 is not relevant, the intracranial 
(i.c.) lymphocytic choriomeningitis virus (LMCV) infection model (32,33). The LCMV 
infection model is an established model to study CD8 T cell responses to the brain of 
infected mice (34). Therefore, to characterize the CD8 T cell responses driven by ISG15, 
groups of mice were intramuscularly administered plasmid expressing LCMV structural 
protein, NP, with or without plasmid expressing mISG15. Mice receiving the NP vaccine 
administered with mISG15 generated significantly more DbNP396-40 (NP396)-specific IFN-
γ spot-forming cells (SFCs) than mice receiving pVAX-NP or empty pVAX plasmid alone 
(Figure 6.3E). Furthermore, the NP vaccine administered with mISG15 induced 
significantly higher percentages of NP-specific polyfunctional CD8 T cells compared to 
mice receiving vector expressing antigen alone (Figure 6.3F). To determine if the 
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observed adjuvant effect of mISG15 impacted survival, mice were challenged 21 days 
after vaccination with a lethal intracranial dose (40xLD50) of the LCMV Armstrong strain 
(34). Dramatically increased survival to lethal LCMV infection was observed in the 
mISG15 and NP vaccine group compared to the group-receiving NP antigen alone 
(Figure 6.3G). Taken together, these data demonstrate that mISG15 can act as an 
immunoadjuvant to activate highly effective antigen-specific CD8+ T-cell responses to 
even immune-privileged sites. 
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FIGURES 
FIGURE 6.1 
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FIGURE 6.1 CONT. 
 
Figure 6.1. ISG15 deficiency impairs innate immune responses to LM  (A) Mice (n=3/group) were infected with 105 
LM CFUs and euthanized at the peak of infection on day 3 along with a group of uninfected mice.  Spleens were excised, 
processed into a single-cell suspension, and RNA extracted.  After conversion to cDNA, spleens were assessed for 
expression of Isg15 by qPCR analysis.  Bar graphs depict induction of Isg15 expression after LM infection.  (B) Bone 
marrow-derived macrophage (BMM) were differentiated with M-CSF and infected with LM (n=3/group).  BMM were lysed 
after 8 and 16 hours post-infection along with uninfected controls and processed for RNA extraction.  After cDNA 
conversion, BMMs were assessed for Isg15 gene expression along with the gene for its E1-activating enzyme, Ube1l.  (C) 
WT (n=4) and ISG15-/- mice (n=5) infected with 105 LM CFUs were euthanized on day 3 post-infection and serum 
collected to assess levels of secreted ISG15 protein by ISG15 ELISA.  (D) BMMs were infected with LM followed by 
treatment with isotype control or IFN-beta blockading antibody one hour post-infection (n=3/group).  At experiment end, 
BMMs were lysed, mRNA extracted, converted to cDNA, and Isg15 gene expression assessed by qPCR analysis. (E) WT 
(n=4) and ISG15-/- (n=5) mice were infected i.p. with 104 CFUs of LM alone or administered 150μg of poly(I:C) i.p. two 
days after LM infection (n=3/group).  All mice were euthanized on day 4 post-infection and spleens excised and 
processed into single-cell suspensions.  Suspensions were serially diluted and plated out on BHI-streptomycin agar plates 
in order to determine colony-forming units (CFUs) per spleen. (F) WT and ISG15-/- mice (n=3/group) were infected i.p. 
with 104 CFUs of LM and euthanized on day 1, 3, and 5 post-infection.  Spleens and livers from infected mice were 
excised and processed into single-cell suspensions.  Suspensions were serially diluted and plated out on BHI-
streptomycin agar plates in order to determine colony-forming units (CFUs) per organ.  Total bacterial load was 
determined by adding LM CFUs from the spleen and liver of each mouse.  In order to determine if susceptibility to LM 
infection is dose-dependent, WT and ISG15-/- mice (n=5/group) were infected i.p. with a log range of doses of LM CFUs.  
At day 4 post-infection, spleens and livers were extracted, processed into single-cell suspensions, serially diluted, and 
plated out on BHI-streptomycin agar plates.  (G) Scatter plots depicting LM CFUs in the spleens of WT and ISG15-/- after 
infection with a log range of doses.  (H) Scatter plots depicting LM CFUs in the livers of WT and ISG15-/- after infection 
with a log range of doses.  (I) Scatter plot depicting NK1.1+ splenocytes in WT and USP18-/- mice during primary LM 
infection with 105 CFUs.  (J) WT (n=5/group) and ISG15-/- mice (n=3/group) were infected i.p. with 105 CFUs of LM and 
euthanized at the peak of infection on day 3 post-infection.  Spleens were excised, processed into single-cell 
suspensions, and RNA extracted.  After conversion to cDNA, spleens were assessed for expression of the 
proinflammatory cytokine gene Ifng.  (K) Production and secretion of IFN-γ was confirmed by ELISA analysis of serum 
from WT and ISG15-/- mice (n=5/group) infected with 105 CFUs LM at peak of infection on day 3 post-infection.  Amount 
of IFN-γ protein in serum was calculated with a protein standard. *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
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FIGURE 6.2 CONT. 
 
Figure 6.2.  ISG15 deficiency alters adaptive immune response to LM and impairs 
DC maturation.  (A), Schematic depicting the experimental procedure to determine the 
role of ISG15 in adaptive immunity to LM.  Briefly, WT and ISG15-/- mice were infected 
i.p. with 105 CFUs of LM with or without prior infection with 103 CFUs of the attenuated 
LM strain, DPL-4029 (B), Production of IFNγ and TNFα by LLO-specific CD8+ T cells 
after stimulation with MHC Class I-restricted LLO epitope peptide, control peptide, or 
anti-CD3/CD28 as measured by ELISA after prior infection with DPL-4029 and challenge 
with LM.  (C), LLO-specific IFNγ-producing splenic CD4+ T cells from LM-infected WT 
and ISG15-/- mice with stimulation by phorbol 12-myristate 13-acetate (PMA) (50ng/mL) 
and ionomycin (800ng/mL), control peptide or MHC Class II-restricted LLO epitope 
peptide. (D), Splenic CD8+ T cell and (E), splenic CD4+ T cell percentages during innate 
and adaptive response to LM.  (F), LM bacterial burden in the spleen and (G), liver of 
WT and ISG15-/- mice. (H), Schematic depicting alternate experimental procedure to 
determine the role of ISG15 in adaptive immunity to LM.  Briefly, WT and ISG15-/- mice 
were infected i.p. with 105 CFUs of LM with or without prior infection with 103 CFUs of 
the virulent LM strain, 10403S.  (I) LM bacterial burden in the spleen and (J), liver of WT 
and ISG15-/- mice from experiment depicted in H.  (K), Splenic myeloid cells during 
innate and adaptive response to LM from experiment depicted in Fig. 2A.  (I), 
Percentage of myeloid cells that are CD11chi and (J), overall percentage of splenocytes 
that are conventional DCs during LM infection.  (K), WT and ISG15-/- spleens were 
stimulated with 1ug of LPS for 6 hrs. and surface expression of markers associated with 
DC maturation were assessed by flow cytometry for expression of CD86, (L), CD80 and 
(M), co-expression of CD80 and CD86. *, P < 0.05; **, P < 0.01; ***, P < 0.001, ****, P < 
0.0001. 
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FIGURE 6.3 
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FIGURE 6.3 CONT. 
 
Figure 6.3. Elevated ISG15 expression augments virus-specific CD8 T cell 
responses and increases survival against lethal LCMV challenge. (A), Depiction of 
ISG15 protein adjuvant constructs. (B), expression of ISG15 in 293 T cells as examined 
by Western blot analysis. Labeled panels show protein detected by anti-ISG15 mAb. (C), 
Detection of expression of ISG15 via immunofluorescence microscopy. (D), secretion of 
ISG15 after transfection of empty pVAX and pVAX-mISG15 in 3T3 cells (n=3/group) was 
confirmed via ELISA of conditioned media. (E), B6 mice (n=5/group) where immunized 
once with or without ISG15 and 21 days later mice where sacrificed and spleens where 
processed to monitor the vaccine induced immune responses. IFNγ ELISpot was 
performed to detect antigen specific immune responses to the LCMV DbNP396-404 
antigen (NP396) in combination with ISG15 when used in IM immunization via 
electroporation. (F) Multiparameter flow cytometry was used to determine the 
percentages of polyfunctional CD8+ T cell cytokine profile. The bar chart shows the 
percentage of NP-specific CD8+ T cells displayed as triple, double of single positive 
CD8+ T cells secreting cytokines. (G) Mice (n=10/group) were immunized one time IM 
using EP with 10ug of empty vector control plasmid (pVAX) or 10ug of LCMV-NP with or 
without ISG15 adjuvant. At day 21 post-vaccination, mice were challenged intracranial 
with 40xLD50 LCMV and animal survival is displayed in the graph. Experiments were 
performed at least three times in independent experiments and data are representative 
of the results. *, P < 0.05; **, P < 0.01, ****, P < 0.0001. 
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DISCUSSION 
ISG15 has a well-established role in innate antiviral responses, but recent 
studies have shed light on further functions in immunity for this small ubiquitin-like 
protein (3,16,17).  Our studies support this expanded role of ISG15 in immunity, as we 
find it is essential for innate immunity to the bacterial pathogen, LM (Figure 6.1). 
Furthermore, while ISG15 deficiency does not hinder formation of splenic LM-specific T 
cell responses, protective adaptive immunity is not evident in the liver of ISG15-/- mice 
after subsequent LM challenge (Figure 6.2).  Additionally, splenic DCs from ISG15-/- 
mice have reduced expression of maturation markers and overexpression of ISG15 by 
WT mice was able to augment pathogen-specific CD8 T cell responses and increase 
survival to lethal intracranial LCMV challenge (Figure 6.3). These results confirm a 
growing consensus that the role of ISG15 is likely more pleiotropic than just directing 
anti-viral innate immunity and prompt further questions regarding its mechanisms in 
immunity and promise in immunotherapy development (18).    
In regard to innate defense against LM infection, previous studies suggest ISG15 
may impact several stages of the bacterium’s lifecycle. Once LM invades a phagocytic 
cell, autophagy activates and facilitates clearance and processing of the pathogen 
(35,36). ISG15 deficiency has previously been reported to impair autophagy and, 
therefore, may exacerbate listeriosis and hinder presentation of LM-derived epitopes 
(37).  However, LM has evolved strategies to evade autophagic destruction and escape 
into the host cell cytosol (38-40). Once LM invades the cytosol of an infected cell, it 
rapidly polymerizes actin and propels itself into the cell membrane, forming protrusions 
into surrounding cells and propagating the infection (41-44). ISG15 may also hinder this 
process as it covalently binds actin and regulates its polymerization, possibly hindering 
LM virulence at this stage (45,46).  Lastly, protrusion formation by LM, a necessary step 
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in its cell-to-cell spread, is carried out through exploitation of the ezrin/radixin/moesin 
(ERM) complex, an interface between the cytoskeleton and the cell membrane (47,48). 
ISG15 conjugates components of the ERM complex and, while the consequence of this 
ISGylation is unclear, it may hinder its usefulness for LM cell-to-cell spread (30).  
More broadly, our findings in ISG15-/- mice provide support for recent studies 
demonstrating that individuals with mutations in Isg15 are at increased risk for 
intracellular facultative bacterial infection (16,49).  This susceptibility is likely due, in part, 
to reduced IFNγ production in ISG15-/- mice and leukocytes from ISG15-deficient 
patients leading to impaired macrophage activation (16).  In fact, reduced activation of 
ISG15-/- macrophage has previously been reported in the context of viral infection (50).  
One possible explanation for the role of ISG15 in IFNγ production could be that it 
contains alarmin-like activity (51). Over two decades ago, a pair of studies found that 
recombinant ISG15 alone, when added to culture with PBMCs, could stimulate IFNγ 
production (19,20). Further credence to this alarmin hypothesis is that ISG15 is 
expressed and secreted to a high degree during disease states such as infection and 
cancer (10,52-56). Alternatively, recent studies suggest that ISG15 may augment the 
ability of a cell to produce IFNγ in response to stimulus (16,17). This may be the 
consequence of a recently proposed mechanism for ISG15, stabilization of the negative 
regulator of Type I IFN signaling, USP18 (17). In response to intracellular bacterial 
infection, USP18 facilitates robust STAT4-dependent IFNγ production and bacterial 
clearance (17,57). Interestingly, mutation of the LRGG repeat in ISG15 did not impair 
ISG15-mediated stabilization of USP18 suggesting conjugation is not necessary for 
some ISG15 functions (17). Further studies to inspect the dependence of ISG15 
immunomodulation on USP18 status and conjugation potential are ongoing. 
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In addition to an expanded role in innate anti-bacterial immunity, our study also 
provides evidence for a novel role for ISG15 as a powerful immunoadjuvant for T-cell 
mediated immunity (Figure 6.2-6.3).  While ISG15 deficiency appeared to have a limited 
impact on T-cell responses to LM, overexpression of ISG15 significantly augmented 
polyfunctional LCMV-specific CD8 T cell responses, which are essential to survival 
against LCMV challenge (58). An explanation for this discrepancy could be that 
endogenous ISG15 is not essential for intrinsic T cell function, as there could be 
redundancy within the Type I IFN-induced responses. Thus, there could be other 
mechanisms by which the T cells are still able to get activated even if it is to a lesser 
extent. This needs to be further investigated. On the contrary, in the case of the LCMV 
model, ISG15 clearly had an effect on augmenting CD8 T cells when delivered as an 
immunoadjuvant. This suggested that CD8 T cells, on the other hand, could respond to 
soluble ISG15. We find this in accordance with previous data demonstrating that free 
soluble ISG15 can induce lymphocytes to induce IFNγ responses (16,17). However, 
evidence is still lacking as to whether ISG15 binds a receptor to mediate these 
immunomodulatory CD8 T cell effects or if intracellular uptake and conjugation is 
required. Further work is required to elucidate the mechanism of action between 
secreted vs. non-secreted ISG15. We are currently investigating this approach. 
Alternatively, our results provide strong evidence that ISG15 may facilitate or orchestrate 
the adaptive responses through enhanced dendritic cell maturation (Figure 6.2). One 
possible hypothesis is that ISG15 is acting as a DAMP much like HMGB1 that binds a 
pattern-recognition receptor (PRR) to induce inflammation (59,60). A previous study by 
Padovan, et al. in 2002 suggested a similar DC stimulatory property for ISG15 secreted 
from melanoma cells (54).  More recently, ISG15 was found to synergize with IL-12 to 
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enhance activation of Mtb-specific T cell responses (16). The summation of this 
evidence suggests that ISG15 is a powerful immunoadjuvant for CTL-mediated 
immunotherapy.  Therefore, further studies are warranted to determine the possibly 
broad applicability of ISG15 as an immunoadjuvant for other diseases and to explore the 
relevance of ISG15 conjugation and secretion in this novel role. 
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CHAPTER 7 
 
DISCUSSION, IMPLICATIONS, AND FUTURE STUDIES 
 
“The reward for work well done is the opportunity to do more.” 
                                                                         – Jonas Salk 
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Vaccines represent one of the greatest medical interventions against diseases. 
However, there is still a great need for effective vaccines against cancers and many 
chronic infectious such as HIV, tuberculosis and malaria. For these pathogens, it is 
known that CD4 T helper 1 (TH1) and CD8 T cell-mediated immunity is critical in 
preventing or controlling the onset of disease (1). These challenging diseases have 
shifted vaccine focus in generating T cell-mediated immune responses and adjuvants 
that specifically drive this preferred effects (1). Adjuvants are critical components of most 
clinical vaccines which are used to shape the quantity and quality of immune responses. 
Currently available U.S. Food and Drug Administration (FDA)–licensed adjuvants are 
poor inducers of TH1 and even worse at treating CD8 T-cell responses (2,3). Therefore, 
it is important to identify a new generation of potent vaccine adjuvant(s) that can induce 
potent and durable T cell immunity.  
Different vaccine platforms have been studied, but the development of DNA-
based vaccines in conjunction with molecular adjuvants has emerged as particularly 
promising for enhancing effective T cell induced viral and tumor immunity (4). It is 
becoming increasingly well recognized that the administration of immunostimulatory 
molecules, such as cytokines or cytokine-like molecules, to modulate immune responses 
has great potential in medicine (4,5). Thus, by harnessing the power of our own immune 
system, cytokines are promising vaccine adjuvants for enhancing the immune responses 
against an array of infectious diseases. Several studies into the biology of IL-33 and 
ISG15 suggest that they might serve as effective vaccine adjuvants (6,7). In this thesis, 
we show for the first time the efficacy of both IL-33 and ISG15 as DNA vaccine 
adjuvants in varies models of infection. We show new insight into the biological 
properties of both IL-33 and ISG15, and highlight their potential as new promising 
adjuvants at improving the magnitude and function of effector CD8 T cell responses. 
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Therefore, both IL-33 and ISG15 are new players in the immunoadjuvant arena, with the 
potential to improve effectiveness of future immunotherapies for cancer and chronic 
diseases. Collectively, our results provide strong evidence for their future role as potent 
novel adjuvants in vaccines designed to boost CD8 T cell immunity 
 
IL-33 as a Vaccine Adjuvant 
IL-33, a member of the IL-1 cytokine family is released by necrotic cells or by 
activated innate immune cells during tissue damage or infection (6,8). It is considered to 
serve as the first line of defense against pathogens, in other words, to serve as an 
alarmin, by providing an endogenous danger signal that triggers inflammation and 
promotes cell-mediated immune response. For many years IL-33 has been studied in 
the context of T helper type 2 (TH2)-driven inflammatory disorders (9). Interestingly, IL-33 
has now emerged as a cytokine with a plethora of pleiotropic properties. Depending on 
the immune cells targeted by IL-33, it is reported to not only promote TH2 immunity, but 
evidence has begun to unveil IL-33’s unappreciated role to induce both TH1 and CD8 T 
cell–mediated immunity (6,10). Therefore, in this study we investigated the potential role 
of IL-33 to act as an immunoadjuvant to elicit effective CD8 T cell-mediated tumor and 
viral immunity.  
Herein, we first demonstrate that both biologically active forms of IL-33, full-
length (proIL-33) and mature IL-33 (mtrIL-33) when combined with a HPV16 E6/E7 
encoded DNA vaccine, enhanced the Ag-specific effector memory CD8 T cell immune 
responses. Their adjuvant activities skewed toward the TH1 axis, and not to the TH2 axis. 
We reported that both isoforms drove IFNγ responses, but neither form drove high 
secretion of IL-4 or any elevation of IgE levels as previously reported (11,12). Finally, 
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both proIL-33 and mtrIL-33 adjuvants induced potent anti-tumor CD8 T cell immunity 
which facilitated successful tumor regression of established TC-1 tumor-bearing mice. 
Given these significant findings that IL-33 can augment bonafide Ag-specific CD8 
protective tumor immunity, we expanded the scope of these studies to access its 
efficacy in a LCMV viral challenge model. The LCMV model is known to require CD8 T 
cell responses for protective immunity (13-18). For these studies I utilized mtrIL-33, 
instead of proIL-33, given proIL-33 alternative action as a nuclear transcription factor 
which still needs to be further elucidated (6,8,9). Thus, I only focused on IL-33’s cytokine 
activity and noted that mtrIL-33 delivered as an adjuvant significantly enhanced the 
LCMV-specific antiviral immunity and provided complete or significant protection against 
a high-dose lethal LCMV intracranial challenge. Collectively, these studies validated IL-
33’s role as a potent vaccine adjuvant for future T cell vaccine studies.    
 The specific role in the protective responses against HPV-associated cancers 
and LCMV infection have been attributed to CD8+ T cell immune responses, and 
therefore, are the focus for achieving effective immunity against such diseases (13-21). 
Our results showed that the cytokine secreting T cell responses induced by proIL-33 and 
mtrIL-33 were mainly mediated by polyfunctional Ag-specific CD8 T populations 
secreting IFNγ+TNFα+IL-2+, IFNγ+TNFα+ and IFNγ+, while a large proportion of CD8 T 
cells having a cytolytic phenotype. Although we found this data in accordance with 
Bonilla et al. demonstrating that IL-33 can drive plurifunctional CD8 T cell responses in a 
viral infection model (10), we further demonstrated that the delivery of IL-33 isoforms as 
immunoadjuvants can indeed enhance plurifunctional CD8 T cell responses, further 
expanding the pool of information we now know about IL-33. In addition, we reported 
that both IL-33 isoforms could significantly amplify and increase the magnitude of 
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tetramer-specific effector CD8 T cell responses in the periphery in a vaccine setting, 
which correlated with superior viral protection and tumor regression (Chapters 2 & 3). 
The reasons behind the role of IL-33 to expand the frequency of CD8 T cells are not yet 
entirely clear (10,22,23). Recently, Luzina et al. demonstrated in a vaccine delivery 
approach that mtrIL-33’s effect is ST2-dependent (11). Moreover, substantial research 
has shown (i) that activated CD8 T cells can express ST2 receptor and (ii) that ST2 is 
important for IL-33 action, as mice deficient in ST2 are entirely unresponsive to IL-33 
(24). Therefore, the ability of ST2+CD8 T cells to respond to immunoadjuvant proIL-33 
and mtrIL-33 is a possible explanation for the vaccine-induced augmentation (10,22). On 
the other hand, although one might assume that proIL-33 should induce similar effects to 
mtrIL-33 because they bind to the same ST2 receptor, Luzina et al. also reported that 
they have differences in their specific activities. Luzina et al. demonstrated that proIL-33 
promotes inflammation differently from mtrIL-33 in an ST2-independent fashion (11). 
Additional studies that involve IL-33 receptor knockout mice will help confirm whether 
our proIL-33 TH1 adjuvant properties are dependent or independent of ST2 receptor. We 
are currently pursuing these studies. These data demonstrate the overall superiority of 
immunoadjuvant IL-33 in enhancing the Ag-specific CD8+ T cells in a DNA vaccine 
setting. 
Another mechanism behind IL-33’s potential to drive the formation and 
differentiation of effector memory CD8+ T cells is likely due to its ability to significantly 
increase T-bet expression in CD8+ T cells in vivo (Chapters 2 & 3). Joshi and colleagues 
have shown that overexpression of T-bet is enough to induce the formation of KLRG1+ 
effector cells and that CD8+ T cells lacking T-bet are impaired in forming these cytolytic 
effector cells (25). Therefore, my data presented in this thesis supports the notion that 
an increase in T-bet is associated with effector CD8+ T cell differentiation and their ability 
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to have CTL phenotype. This finding also supports previous data showing by Yang et al. 
demonstrating that CD8 T cells treated with IL-33 in the presence of IL-12 result in T-bet-
dependent expression of ST2 in vivo (22). Furthermore, it is also possible that our 
selected vaccine antigens, which are potent TH1 antigens, may have facilitated the 
induction of TH1 cytokines IL-12 and IFNγ secretion by APCs. Therefore, this induced 
favored TH1 cytokine milieu perpetuated by our selected antigen may have induced a 
favorable immune environment that allowed IL-33 to foster a greater TH1 cell-mediated 
immune response. Further studies are needed to understand exactly how IL-33 induces 
TH1 IFNγ responses in the context of an in vivo immune setting.  
Overall, my studies conclude that IL-33 can act as an immunoadjuvant to 
increase the potency of DNA vaccines. We established that some of the preclinical 
beneficial effects of IL-33 as an adjuvant are: (i) IL-33 can increase the seroconversion 
rate; (ii) facilitate the use of smaller doses of antigen to induce protective immunity; (iii) 
reduce the number of doses required to achieve protection; (iv) provide an appropriate 
desired immune response (TH1 and CD8 T cells); (v) increase the generation of effector 
memory T cells; and (vi) increase the speed of initial response. In the future, we hope to 
determine if IL-33 can also improve weak immune responses, where it will be beneficial 
for the elderly or immunocompromised individuals. Taken together, the improved 
efficacy of our DNA vaccines offered by IL-33 in this thesis highlights its potential utility 
as a future vaccine adjuvant in the treatment of a variety of chronic diseases, including in 
the context of cancer vaccine therapies. 
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IL-33: TH2 vs TH1 Route of Immunization 
Although IL-33 originally has been associated with TH2 immunity, our IL-33 
studies report that IL-33 delivered as a vaccine adjuvant could modulate immune 
responses toward a TH1/CD8+ T cell response. Under different conditions it appears that 
IL-33 can have different functions either associated in driving TH2- or TH1-immune 
responses when delivered in vivo (10,11,26,27). How one method elicits TH2 responses 
and another TH1 response is unclear. The reasons for the differences may be attributed 
to variations in the routes of immunization in which the surrounding microenvironment 
(targeting cells and cytokine network) potentiate different outcomes. For instance, 
delivery into the mucosal sites which is normally rich with TH2-driven cells (T regulatory 
cells, mast cells, basophils, eosinophils and innate lymphoid cells) may favor a TH2 
response, while it is likely that residential and local immune cells in the muscle may favor 
a TH1 response during DNA vaccination. However, the key cell types in the muscle site 
that could be expressing ST2 and responsible for mediating the vaccine-induced 
responses have not been investigated. Furthermore, the TH1-driven nature of the 
adjuvant properties could have also been perpetuated because of the selected vaccine 
target antigen activating APCs to trigger IL-12, which will support IL-33’s IFNγ-inducing 
activity (22), and without it, a TH1 response will dominate. Therefore, further testing is 
needed to determine if IL-33 is dependent on IL-12 to favor a TH1 response in vivo. 
Overall, this supports the theory that the immunomodulatory functions of IL-33 might 
actually be more complex than initially assumed. Therefore, the route of delivery should 
be carefully studied to maximize the desired T cell phenotype in a particular immune 
setting to better target a particular disease 
 
193 
 
IL-33 Isoforms as Future Vaccine Adjuvants 
Along with all the different established cytokines, there has recently been an 
appreciation for alternative splicing or processing of cytokine genes (eg. IL-1, IL-2, IL-7, 
IL-18), which result in multiple cytokine isoforms with different functional activities (28). 
Cytokine isoforms can provide additional diversity to their complex biological effects that 
participate in control and protection against different foreign pathogens. Indeed, IL-33 
has emerged as a cytokine containing several different isoforms that can play a role in 
facilitating protective immunity (11,27-31). Tsuda et al. demonstrated the existence of 
multiple splice variants of IL-33 dependent on the cell type expressing IL-33 (30). 
Furthermore, Lefrancais et al. reported that neutrophil-specific proteases in neutrophils 
could cleave full-length human IL-33 to generate several mature processed variants with 
enhanced biological activity (tenfold) compared with proIL-33 (28). They also 
demonstrated that murine IL-33 can be similarly cleaved by these same neutrophil 
proteases (cathepsin G and elastase), generating two isoforms of mtrIL-33 (28). In our 
studies, in chapter 3, two bands of IL-33 were detected after transfection with proIL-33 in 
human rhabdomyosarcoma cells (27). Therefore, the observed humoral responses 
elicited by our proIL-33 adjuvant, may not have been driven solely by proIL-33, but also 
by either spliced variants of proIL-33 or processed forms of proIL-33 (aka mtrIL-33), as 
processing of the adjuvant did occur in vitro. These alternatively spliced or processed IL-
33 cytokine isoforms represent attractive candidates for further study as possible 
vaccine adjuvants or immune modulating therapeutics. For future studies we plan to 
compare the immune modulation induced by these different identified isoforms of proIL-
33 (splice variants) and mtrIL-33 (processed forms). This will provide insight into their 
potential to be properly utilized for different vaccination systems. Thus, fully 
understanding the IL-33 signaling system, especially its cytokine contributions as a 
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nuclear modulator versus extracellular molecule, will open new chapters on how to 
harness the power of all IL-33 isoforms in future vaccines and cancer therapies. The 
accessibility and continued study of both ST2 and IL-33 knockout mice will help enhance 
our understanding of IL-33’s ability to influence adoptive immunity and its power to 
protect against disease. 
 
ISG15 as a Vaccine Adjuvant 
Given our success with IL-33 as vaccine molecular adjuvant to induce potent T 
cell immunity, we decided to continue this successful approach to identify additional 
adjuvants capable of amplifying CD8 T cell antitumor and antiviral immunity. I therefore, 
employed a DNA vaccination approach to investigate the inclusion of ISG15 to also 
enhance Ag-specific CD8 T cell responses.  
ISG15 is an ubiquitin-like protein induced by type I interferon and is associated 
with antiviral activity (32). For decades, free ISG15 has been implicated in the production 
of IFNγ, thus functioning as an immunomodulatory molecule (33-35). More recently, a 
study by Casanova and colleagues confirmed this cytokine-like role for ISG15 by 
demonstrating that ISG15-deficiency was associated with a loss of IFNγ, which in turn 
led to increased susceptibility to mycobacterial disease in both mice and humans (36). 
However, ISG15’s role to influence CD8 T cell responses and act as a vaccine adjuvant 
has not yet been explored. In this study, we showed for the first time the efficacy of 
ISG15 as a molecular adjuvant to augment Ag-specific CD8 T cell viral and tumor 
immunity. We used the well-established preclinical LCMV intracranial and HPV-
associated therapeutic challenge models to test the adjuvant effects of ISG15 in a DNA 
vaccine setting. The main results of this study are that inclusion of ISG15 can (i) 
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increase the polyfunctional Ag-specific CTL responses secreting IFNγ+TNFα+IL-2+; (ii) 
induce effector-like memory CD8 T cell differentiation; (iii) have antitumor therapeutic 
effects; (iv) induce significant LCMV protective immunity; (v) elicit vaccine-induced 
protective immunity independent of conjugation, further establishing free ISG15 perhaps 
functions as a cytokine; (vi) increase the magnitude and phenotype of tetramer-specific 
CD8 T cell responses, which correlated with tumor regression; and finally that (vii) CD8 
T cell depletion and adoptive transfer experiments revealed that ISG15 protective 
efficacy was CD8 T cell-mediated. Collectively, my work provides more insight into the 
immunomodulatory properties of ISG15 and its potential to serve as an effective CD8 T 
cell vaccine adjuvant in a therapeutic tumor or infectious setting. 
The reasons behind ISG15 ability to enhance the frequency of Ag-specific CD8 T 
cell responses are unknown. However, a recent study by Casanova and colleagues 
have shown that ISG15 may work in synergy with IL-12, suggesting that ISG15 likely 
promoted enhanced CD8 T cells synergistically with IL-12 (36). In addition, the ability of 
ISG15 to induce IFNγ secretion by lymphocytes, may also suggest that ISG15 might bind 
to a cell surface receptor to modulate immune responses (32). The identity of a cell 
surface receptor for ISG15 has yet to be discovered. Nevertheless, the actions of 
extracellular ISG15 have been most clearly tied to the induction of IFNγ secretion by 
lymphocytes (31-35). Our findings in Chapter 6, demonstrated that susceptibility to acute 
LM infection in ISG15-/- mice correlated with the significantly reduced expression of IFNγ 
responses both in the spleen and in the blood. Although ISG15 deficient mice seemed to 
have limited impact of T cell responses to LM overtime, we did see that delivery of 
ISG15 as an adjuvant augmented LCMV-specific CD8 T cell protective immunity. We 
find this in accordance with previous data demonstrating that free soluble ISG15 can 
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induce lymphocytes to induce IFNγ responses (31-35). An explanation for this 
discrepancy could be that endogenous ISG15 is not essential for intrinsic T cell function, 
as there could be redundancy within the Type I IFN-induced responses. Therefore, by 
other unknown mechanisms the T cells are still able to get activated even if it is to a 
lesser extent. Alternatively, by using ISG15 deficient mice, our results provided evidence 
that ISG15 may facilitate or orchestrate the adaptive responses through enhanced 
dendritic cell maturation. Therefore, ISG15 may not only modulate T cells directly as a 
“cytokine-like” molecule, but may also foster cell-mediated adaptive immune response 
by augmenting APC functions. Further studies will be needed to elucidate the 
mechanism(s) underlying the adjuvant effects of ISG15. The evidence that ISG15 can be 
an effective adjuvant to drive potent CD8 T cell responses, support future studies to test 
its application in other infection models that require T cell immunity.  
A major highlight of our study in Chapter 5 was demonstrating that ISG15 
delivered as an immunoadjuvant generates responses independent of conjugation as an 
LRLRGG-mutant ISG15 also induced potent CD8 T cell responses. This suggested that 
the protection afforded by ISG15 was most likely not dependent on its conjugated form, 
but rather on free ISG15. However, we cannot exclude the functional properties of 
intracellular free ISG15 or conjugated ISG15 as it has been shown to also be biologically 
functional (32,37). We are currently pursuing their different association with modulating 
immunogenicity. Overall, the ability of free ISG15 (mutISG15) to induce superior 
antitumor responses (Chapter 5) highlights its potential to serve as an alternative potent 
ISG15 adjuvant. In addition, it emphasizes that developing new ways to increase the 
levels of free ISG15 may be a novel approach to treat cancer and other infectious 
diseases.  
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Free ISG15 
To date, there are two mechanisms of action by which ISG15 contributes to the 
host response to infection: (i) conjugation dependent actions of ISG15 and (ii) the 
biological properties of ISG15 that are mediated by free ISG15. In this thesis, we 
demonstrate that the protection afforded by ISG15 can be independent on its conjugated 
form, free ISG15, supporting the notion that ISG15 perhaps functions as a cytokine. 
However, while this study provides the first in vivo evidence that free ISG15 delivered as 
an adjuvant contributes to host response during a tumor therapeutic or viral challenge 
model, it does not distinguish between the actions of extracellular and intracellular free 
ISG15. Therefore, further testing is needed to distinguish between the activity of 
intracellular and extracellular free ISG15. The identification of an ISG15 receptor(s) and 
in vivo blocking antibodies for ISG15 would be essential tools in defining whether the 
protection mediated by ISG15 in any infectious or tumor model is through the action of 
extracellular free ISG15. The availability of recombinant mouse ISG15 would also be a 
valuable tool to further establish a proof of concept. Overall, fully understanding the 
biological function of free ISG15 would allow us to fully harness its power to treat a 
variety of infectious diseases and cancers.  
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IL-33’s and ISG15’s Role on CD8 T Cell Memory Subsets 
The establishment of immunological memory means that the immune system is 
able to respond with greater strength upon re-encounter with a same pathogen and is 
the basis for effective vaccination (38). The CD8 memory T cell population is 
heterogeneous, but perhaps the best characterized CD8 memory T cell subsets is the 
paradigm of central and effector memory cells (39-42). Central memory T (Tcm) cells 
localize to the lymphoid tissues and are capable of robust recall proliferation, whereas 
effector-memory T (Tem) cells, are predominately located in the peripheral sites and can 
quickly become cytolytic, but with limited proliferative capacity. There is still a 
controversy about which subset of memory CD8 T cells are most optimal for protective 
immunity. However, from a therapeutic point of view, the goal of successful vaccination 
might best be the induction of effector-like memory CD8 T cells to rapidly control 
infection and/or tumor growth. Recently, reports have begun to show that the effector-
memory KLRG1+CD8+ T cell population can mediate potent protective immunity against 
certain pathogens (43-45) and might be optimal for immediate regression of established 
subcutaneous (s.c.) tumors (46). Our results showed that mice immunized with IL-33 
and/or ISG15 induced robust expansion of Ag-specific effector memory CD8 T cells in 
the periphery, suggesting trafficking of activated CD8 T cells to the site of Ag stimulation. 
The high frequency of Ag-specific effector-memory cells in the periphery is consistent 
with the observation that effector-memory T cells can migrate to the site of infection and 
initiate immediate effector function (39). Our findings support the concept that vaccine-
induced effector-memory CD8 T cell responses might be important memory CD8 T cell 
subsets for an effective therapeutic vaccine against tumors and other chronic infections 
(46). Furthermore, the quantity and quality of the effector memory T cells amplified by 
both our molecular adjuvants (IL-33 and ISG15) seemed to correlate with their efficacy in 
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the tumor or viral challenge models. Therefore, these potential correlates of immunity 
may suggest a different focus for vaccination strategies.  
We are currently investigating the ability of IL-33 and ISG15 to generate Tcm 
immunity, since Tcm cells are important subsets that also mediate optimal protective 
immunity against pathogens and constitute the basis for vaccination (39-42,47,48). 
However, given that Murali-krishna et al. have reported that the initial magnitude (burst 
size or peak) of the CD8 effector T cell responses correlates to the long-term memory 
responses, suggest that IL-33 and ISG15 most likely can induce long-term immunity 
(49). Moreover, because preventative vaccines should induce long-lasting Ag-specific 
responses, we are further investigating the efficacy of these immunostimulatory 
adjuvants in the context of prophylactic vaccines and its establishment of long-lasting 
memory responses. Overall, understanding the mechanism of action by which either 
both IL-33 and/or ISG15 influences the expansion, or development of heterogeneous 
CD8 T cell populations in vaccines is an important area for further investigation. 
 
IL-33’s and ISG15’s Role on the Humoral Responses 
Antibodies are an important part of the host immune system to identify and 
neutralize infectious agents and have been the correlate of immunity for all currently 
successful licensed vaccines. Although CD8 T cells responses were important in our IL-
33 study, we also examined the effects of IL-33 on B cell responses. The major 
significant difference between proIL-33 and mtrIL-33 was that proIL-33 was able to 
increase the HPV E7-antigen specific IgG binding levels. Full length IL-33’s dual function 
property, to act not only as a cytokine, but also as a nuclear transcription factor, may 
explain the increase in antibody responses by proIL-33. Its nuclear localization may have 
effects on modulating the humoral immune responses. Thus, the specific transcriptional 
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targets of nuclear IL-33 are still unknown and must be further investigated. Another 
possibility for this outcome could have been due to the ability of proIL-33 to modulate the 
immune responses independent of its cognate ST2 receptor (11). We are currently 
pursuing understanding full-lengths association with modulating immunogenicity using 
ST2 knockout mice. Moreover, just recently published, Zhao et al. demonstrated that IL-
33 promoted humoral responses to HBV during the pathogenic progress (48). They 
reported that IL-33 activated humoral immunity against HBV in vivo and in vitro by 
activating T follicular helper cells. This recent report confirms our findings that IL-33 can 
modulate humoral immune responses. Although the importance of our findings are not 
yet clear, these data suggests that IL-33 could also be useful in vaccine strategies 
aiming to achieve enhanced antibody responses and cellular immunity. In regards to 
ISG15, to the best of our knowledge, ISG15’s role on the effect of antibody responses 
has never been examined and is an area of further investigation. In the future, in parallel 
with IL-33, we hope to study their immunoadjuvant properties on humoral responses 
using an influenza challenge model, a model which antibodies are known to be essential 
for protection.  
 
IL-33’s and ISG15’s Effects Other Immune Cells (DCs, NK and CD4 T Cells)  
It is well known that antigen presented by activated DCs and the type of 
production of polarizing cytokines they secrete can promote different fates on T cell 
development (50). First, we demonstrated that IL-33 could induce DC maturation by 
assessing the up-regulation of certain surface expression markers and their induction of 
proinflammatory cytokines, all of which may influence adaptive immunity. Mouse bone 
marrow derived dendritic cells (BMDCs) in vitro incubated with recombinant IL-33 up-
regulated the DC maturation markers, CD80, CD86 and CD83 and secreted pro-
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inflammatory TH1 cytokines.  The ability of IL-33 to induce phenotypic maturation of DCs 
in vitro, may explain IL-33’s functional role on the impact of CD8 T cells observed in our 
study, recruiting the right type of immune cell infiltration necessary to facilitate both 
effective viral and tumor immunity. Regarding ISG15’s effects on DC maturation, we 
observed that in ISG15-/- mice, their DCs were impaired and unable to undergo DC 
maturation, suggesting a possible role for ISG15 in T cell activation and memory 
formation. Therefore, we are currently investigating both IL-33 and ISG15 roles on DC 
maturation and function during vaccination in vivo. 
Considering that CD4 T cells play an important role in facilitating an effective 
adaptive immune response, by helping the activity of other immune cells (e.g. B cell 
antibody class switching, maximizing bactericidal and cytotoxic T cell activity) by 
releasing cytokines, we evaluated if our adjuvants can augment CD4 TH1 cell responses. 
While ISG15 did not enhance Ag-specific CD4 T cells responses, IL-33, however did 
significantly increase the TH1 CD4 T cell responses against HPV, HIV, and TB (Chapters 
2,3,4). Although for years it was assumed that IL-33 mainly played a role in CD4 TH2 
immunity (given the early findings of the selective expression of ST2 by TH2 but not Th1 
cells) (6), our results intimated that mtrIL-33 in vivo might directly enhance TH1 CD4 T 
cell responses. IL-33 as a DNA adjuvant can broadly expand T cell responses. An 
explanation for this could most likely be that only activated TH1 CD4 T cells can express 
ST2 receptor, and in synergy with IL-12, local IL-33 will significantly augment a TH1 
response (22). This aspect requires further study. Taken together, our data shows that 
IL-33 can be both an effective CD4 and CD8 T cell vaccine adjuvant, while ISG15 seems 
to only enhance CD8 T cell-mediated responses. Nevertheless, it still needs to be 
completely determined whether ISG15 can modulate CD4 T cell responses, given that 
the models I used are mainly CD8 T cell-mediated. We plan to test ISG15 CD4 T effects 
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using other pathogen targets such as TB, where CD4 TH1 responses are known to be 
critical for protective immunity. Although CD4 T cell help is not crucial for CD8 T cell 
priming, it is believed to be essential in the expansion of secondary responses of 
memory CD8 T cells (39,51,52). Thus, we are currently determining if IL-33 or ISG15 
can induce effective CD8 T cell responses independent of CD4 responses during the 
course of homologous prime-boost vaccination.  
Finally, it is likely that other immune cells may have accounted for the observed 
enhancement in TH1 immunity. For instance, both IL-33 and ISG15 have been shown to 
activate Natural Killer (NK) cells to secrete IFNγ (8,23). Nevertheless, further studies will 
be needed to elucidate under what conditions both IL-33 and ISG15 promotes TH1 and 
CD8 T cell immunity; to determine their regulatory networks bridging the innate with the 
adaptive immune responses. 
 
IL-33’s and ISG15’s Application for Other Disease Targets and Cancer 
Given these significant findings, we went on to observe in a preclinical setting, 
that IL-33 would also increase the Ag-specific CD4 and CD8 T cell responses when co-
delivered with a DNA vaccine encoding either a HIV, flu, malaria or TB target antigens 
(Chapters 2,3,4 and unpublished data). We are currently examining the efficacy of IL-33 
in a malaria, influenza, and TB challenge models. On the other hand, we reported that 
ISG15-/- mice are highly susceptible to infection with the model pathogen, Listeria 
monocytogenes (LM), and display significantly reduced production of IFNγ. Therefore, 
with the recent finding observed by Bogunovic et al, that individuals with mutations in 
Isg15 are more susceptible to infection by the intracellular bacterium Mycobacterium 
tuberculosis (Mtb) (36), we are next evaluating ISG15’s application in a TB-infection 
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model. Overall, these findings significantly highlight the important role for both IL-33 and 
ISG15 as effective adjuvants to be incorporated into future vaccines targeting an array of 
microbial infections.  
 The important roles IL-33 and ISG15 may play in cancer is only beginning to 
surface. For instance, three recent studies have highlighted the important role of IL-33 in 
human cancer and tumor mouse models (Lung, melanoma, cervical, breast and 
carcinoma) and have shown that IL-33 can drive antitumor CD8 T cell responses (27,53-
58). For ISG15, its role in protective tumor immunity has only begun to be appreciated 
(57). In accordance with our data, Burks et al just recently demonstrated that free ISG15 
could induce an antitumor immune response in vivo and in vitro against breast cancer 
(58). They reported that extracellular free ISG15 suppresses breast tumor growth and 
increased NK cell infiltration into xenografted breast tumors in nude mice. Clearly, my 
studies provided stronger evidence for IL-33’s and ISG15’s beneficial role in tumor 
immunity and their utility to be used as cancer immunotherapies. My studies showed that 
a HPV DNA vaccine plus our adjuvant combinations (IL-33 and/or ISG15) induced great 
control or complete tumor regression in a therapeutic HPV-associated murine tumor 
challenge model. More studies using ISG15-/-, UBE1L-/-, ST2-/- and IL-33-/- mice will 
help further elucidate the significant roles ISG15 and IL-33 play in the host antitumor 
responses. Given the recent studies (as mentioned above) showing that IL-33 and 
ISG15 as immunoadjuvants can augment Ag-specific TH1 and CD8 T cell immune 
responses, its role in enhancing tumor surveillance and antitumor immunity is worth 
continued investigation. In the future, we plan to study both IL-33’s and ISG15’s specific 
role in the tumor microenvironment and surveillance process.  
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Similarities and Differences Between IL-33 and ISG15 Adjuvant Properties 
Both IL-33 and ISG15 delivered as vaccine adjuvants enhanced potent Ag-
specific polyfunctional CD8 T cell tumor and viral immunity. Both adjuvants induced high 
frequencies of effector CD8 T cells responses compared to the non-treated adjuvant 
DNA vaccine groups. In contrast to IL-33, ISG15 did not significantly enhance the CD4 T 
cell responses. Therefore, IL-33 is capable of augmenting broader T cell responses. 
However, given ISG15’s ability to modulate the adaptive responses (increasing vaccine-
induced IFNγ responses), suggests that ISG15 can potentially function like a cytokine 
similar to IL-33. In addition, besides their effects on CD8 T cells, our results may 
propose that the adjuvants effects of IL-33 and ISG15 may also be through DC 
activation and maturation. Further studies are warranted to determine how IL-33 and 
ISG15 orchestrate the adaptive responses through enhanced DC maturation. Overall, I 
have provided evidence of their potential relevance for the design of future T-cell based 
vaccines against cancers and infections requiring such desired responses. Since both 
IL-33 and ISG15 adjuvants can affect the immune responses in different ways, such as 
eliciting a broad range of immunological responses (humoral vs. cellular immunity or 
both), it is important to choose a candidate adjuvant for future specific vaccine 
formulations. The results of the similarities and differences between IL-33 and ISG15 are 
summarized in Table 7.1. 
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Combination of Adjuvants  
Adjuvants are critical components of many vaccines and will continue to be 
essential components for the development of future vaccines for the treatment of 
infectious diseases and cancers. However, deciding how to select to the best vaccine 
adjuvant for enhancing protective immunity will depend on the disease in question. 
Consequently, no single adjuvant is capable of stimulating broad and robust protective 
immune responses required to fight chronic infectious diseases and cancers. Therefore, 
it is believe that a future design of vaccines will focus on incorporating multiple adjuvants 
as a way to enhance multiple immunological parameters and improve vaccine efficacy. 
Recent studies have shown that using multiple adjuvants in combination can 
synergistically enhance or improve the immune responses to vaccines. For example, the 
combination of toll-like receptor agonists can enhance DC function, the induction of CD8 
T cell responses, and antibody responses (59,60). The literature has even shown 
evidence of combination adjuvants containing cytokines like IL-12, IL-2 and GM-CSF 
increasing specific CTL and IFNγ-secreting T cell responses (4,59-61). Therefore, with 
this knowledge, in the future, we hope to coadminister IL-33 and ISG15 in combination 
or simultaneously in a vaccine setting. We also plan to compare their efficacy individually 
or in combination to other TH1 inducing cytokines, such as IL-12 and IL-18. In addition, 
we plan to test both IL-33 and ISG15 in combination with other licensed adjuvants (alum, 
ASO4, or MF59) as a goal to enhance effective antibody and cellular responses required 
to induce protective immunity in each particular disease.  
 Although the combination of adjuvants may be the way forward in vaccine design 
to elicit robust and broad protective immune responses, such an approach might not be 
enough to treat cancer or chronically infected patients, where overcoming the well-
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established immunosuppressive environment can be challenging. Therefore, an 
alternative, will be to administer vaccines in combination with other therapeutic 
interventions (e.g. immunotherapy), such as monoclonal antibody immune checkpoint 
inhibitors (e.g. PD1, PDL1, LAG-3, and/or TIM-3). Identifying the appropriate 
combination of adjuvants (double combination therapy) plus therapeutic treatments 
(triple combination therapy) may offer tremendous opportunities for improving the 
efficacy of future vaccines to treat against complex chronic diseases and cancer.  
 
Clinical Application 
It may be an investing effort into harnessing the power of IL-33 and ISG15 in the 
clinical setting. For instance, a recent study examining the expression of IL-33 in cervical 
tissue of patients with different stages of HPV cervical disease showed that lower levels 
of IL-33 in cervical tissue were associated with more severe stages of HPV-induced 
dysplastic change (55). Furthermore, an important study by Casanova and colleagues, 
have shown that humans lacking ISG15 develop mycobacterial diseases (35). 
Therefore, it is conceivable to suggest that delivery of IL-33 or ISG15, like other 
cytokines IL-2 or IFNγ, could be used to help fight viral and bacterial infections, as well 
as cancer in the general population. However, this hypothesis remains to be tested. In 
order to move these adjuvants into clinical studies, their immunogenicity and efficacy 
must be tested in other animal models. In the future, we to hope to immunize non-human 
primates with our adjuvants along with selected target antigens (e.g. HPV or HIV) study 
to determine immunogenicity. 
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Closing Remarks 
In this thesis, I exclusively show for the first time that IL-33 and ISG15 can be 
promising molecular adjuvants at improving CD8 T cell immunity in a vaccine setting. 
The exciting evidence that IL-33 and ISG15 can induce protective immunity in both 
infectious and cancer models, supports their development as immunoadjuvant 
candidates for enhancing the potency of both prophylactic and therapeutic DNA 
vaccines (Figure 7.1). This knowledge opens new avenues for harnessing the power of 
IL-33 and ISG15 as immunostimulatory adjuvants for future novel vaccines against 
diseases that require TH1/CD8 T cell protective immunity such as TB, malaria, HIV, and 
even cancers. In the end, although the immune system may never win the war against 
disease, but with effective adjuvants like IL-33 and ISG15, it might just avoid some 
mortal battles.  
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FIGURES 
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Figure 7.1. The potential biological mechanisms of the adjuvant properties of IL-33 and ISG15 on immune cells to 
induce viral, bacterial, and tumor immunity. These observed effects are determined by the specific cells targeted and 
the associated cytokine network. (a) IL-33 as a cytokine has dual-function: acting as a cytokine and localizing in the 
nucleus which functions are unclear. The administration of both full-length IL-33 (proIL-33) and mature IL-33 (mtrIL-33) 
can have cellular activities on NK/NKT, CD4 and effector CD8 T cells which produce Th1-associated protective immunity.   
Also potentially accompanying, APCs produce and secrete IL-12, which then induces expression of ST2 on NK/NKT cells 
and CD8+ T cells, permitting IL-33 to induce Th1-associated cytokine production. It is unclear whether Th1 CD4+ T cells 
are able to upregulate ST2, however, IFNγ production by other activated immune cells likely leads to their amplification 
which then can help activate antiviral and tumoricidal immunity. Interestingly, recent evidence hints at a new activity for 
proIL-33 to activate cells independent of the ST2 receptor. Does proIL-33 bind to another unknown receptor? Or is proIL-
33 taken up by cells by apoptotic bodies caused from necrotic cells, which in turn, allows proIL-33 to migrate into the 
nucleus of the new cell and facilitating an immune response? These mechanisms are unknown. Moreover, data has 
demonstrated that proIL-33 can elicit antigen-specific antibodies, yet its role in protection against infectious pathogens 
remains to be determined. (b) Type I IFNs stimulates the production of ISG15 usually after infection or by tissue damage.  
Normally, ISG15 conjugates to target proteins by a method known as ISGylation to control viral infection. However, ISG15 
can also exist into other forms: free intracellular ISG15 and free extracellular ISG15 which are depicted here. Little is still 
known about the properties of conjugated ISG15 form, but even less is known about the free forms of ISG15. 
Interestingly, recent evidence (along with what is presented in this thesis) highlights that free extracellular ISG15 may 
potentially act as a cytokine and induce Th1 immune responses. Free soluble ISG15 has now been described as having 
cellular activities (adjuvant properties) on NK cells and CD8 T cells. ISG15’s immunological properties suggest it might 
have a receptor, however, no ISG15 receptor has been discovered. It is believe that in synergy with IL-12, ISG15 can 
further augment Th1 immunity. It is unclear if ISG15 works as a DAMP-associated molecule (increasing DC function or 
maturation) or if it is engulfed by the cells through unknown process to modulate adaptive immune responses. It is known 
that free intracellular ISG15 has immunomodulatory properties, but the molecular mechanisms behind it are still unknown. 
Notes: DAMP, damaged-associated molecular pattern molecule; NK, natural killer cells; INF, interferon; Alt, alternative; 
Rc, receptor; Teff, effector memory CD8 T cells; Tfh, CD4 T follicular helper cells 
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